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Thrombin is the key protease that regulates hemostasis; the delicate balance 
between procoagulation and anticoagulation of blood. In clotting disorders, like deep vein 
thrombosis or pulmonary embolism, procoagulation is up-regulated, but propagation of 
clotting can be inhibited with drugs targeting the proteases involved, like thrombin. Such 
drugs however, have serious side effects (e.g., excessive bleeding) and some require 
monitoring during the course of treatment. The reason for these side effects is the 
mechanism by which the drugs’ act. The two major mechanisms are direct orthosteric and 




we sought an alternative mechanism called allosteric, partial inhibition, that has shown 
promise to truly regulate coagulation. Partial inhibition through allosteric mechanisms are 
well described for membrane-bound and oligomeric proteins. However proteases, 
specifically monomeric proteases (i.e., thrombin), have not shown this phenomenon until 
now. A small library of coumarin-based sulfated allosteric modulators (CSAMs) was 
synthesized to target a surface region called exosite 2; mainly composed of highly 
positively charged residues surrounded by hydrophobic patches. Studies revealed a non-
competitive mechanism of binding with a range of IC50s between 0.2-58 µM combined 
with inhibitory efficacies (ΔY) between 22-73%; indicative of allosteric, partial inhibition. 
The KD was determined for the most potent compound (3g; IC50 = 0.2 µM, ΔY = 47%) at 
0.15 µM. 3g was observed to bind at exosite 2 through unfractionated heparin competition 
and thrombin mutant studies. Additional computational studies were in agreement with the 
mutant and competition studies, showing the sulfate of 3g binding within a pocket 
containing R126 and R233. Fluorescence quenching and antithrombin inactivation rate 
studies described a conformational change to thrombin’s active site in the presence of 3g, 
supporting reduction of thrombin’s catalytic efficiency, without complete inhibition of 
thrombin’s proteolytic activities. Coupled enzyme assays and gel electrophoresis showed 
that in the presence of 3g, hydrolysis of fibrinogen (IC50 = 0.51 µM, ΔY = 94%) and 
protein C activation (IC50 = 1.7 µM, ΔY = 91%) is fully inhibited. Alternatively, FXIII 
activation was shown to be only partially inhibited by the presence of 3g, and FXI 
activation did not show any significant activation or inhibition. 3g was also shown to be 




induce an anticoagulant effect. Mice studies looking at the effects of 3g in vivo showed that 
even at high concentrations, showed no abnormal bleeding or any other irregularities. This 
work highlights a novel occurrence regarding thrombin’s allosteric functionality against 
multiple endogenous substrates. This library of compounds may be useful in the future 
development of allosteric inhibitors and probes that pose little to no risk of bleeding events 
by inducing partial inhibition. 
 
Key Words: Partial inhibition, thrombin, glycosaminoglycan mimetics, protease, exosite, 























Biological systems rely heavily on enzymatic processes to function through a 
number of catalytic pathways1. Of those, hydrolysis of peptide bonds through use of 
proteases (also known as proteinases and peptidases) play major roles in homeostatic 
regulation (e.g., immune response, blood coagulation, apoptosis, etc.)1,2, as well as in 
disease (e.g., cancer, viral/bacterial infection, cardiovascular disease, etc.)3–6. The 
translation of proteases must be well regulated due to their highly efficient nature of 
catalysis. If up or down regulation of specific proteases is not maintained, several degrees 
of dysfunction could result from degradation of non-ideal substrates or buildup of 
substrates that could be potentially harmful. In the human genome alone 2-4% of the DNA 
is made up of genes encoding for proteases; with an estimated number of 550 protease 
genes known to date1. Proteases can be further categorized by traits relating to their 
mechanism of action; and are done so in the following order of prevalence in humans. Of 
the > 550 proteases, 34% make up the metalloproteases, 31% serine proteases, 26% 
cysteine proteases, 5% threonine proteases, and 4% aspartic proteases1,2. These distinctions 




selective treatments may be developed to augment their effects if over produced in a 
system. 
1.1.1 Types and Mechanisms 
Metalloproteases are named so because of their one or more cationic transition 
metals located within their active (orthosteric) site. The most prevalent metal found in 
metalloproteases (MPs) is zinc (Zn2+)7,8, but in some circumstances cobalt (Co2+) and 
manganese (Mn2+) have also been found7,8. The transition metal within the active site is 
typically held in place by coordination with two histidine residues and a glutamate residue 
(three histidines may also be present)9,10. With regards to MP’s catalytic mechanism, there 
are currently two theories on how the active site facilitates hydrolysis. The first is that 
upon hydrolysis of a peptidyl bond, a water molecule coordinated with the Zn2+ is 
activated by a secondary glutamate. In turn the Zn2+ also coordinates with the carbonyl 
oxygen from the substrate and facilitates the hydrolysis of the substrate by the nucleophilic 
water molecule9–11. The other theory suggests that the secondary glutamate acts as the 
nucleophile instead of a water molecule, and forms an acyl intermediate with the substrate 
carbonyl and the zinc. The theory suggests that a water molecule then behaves as a 
nucleophile, but attacks the carboxylate of the secondary glutamate, causing deacylation 
and hydrolysis product formation11.     
The second most abundant class, serine proteases, catalyze numerous hydrolytic 
reactions with high rates and efficiency for a multitude of endogenous macromolecules. 
These proteases contain a serine residue in their active site and is coupled to a histidine 




nucleophile, an acid, and a base reside in close proximity to facilitate hydrolysis of a 
peptide12,13. When a substrate enters the catalytic triad, the aspartate stabilizes the histidine 
while it hydrogen bonds with the proton of the hydroxyl nucleophile of the serine14. The 
hydroxyl then attacks the carbonyl forming a tetrahedral intermediate and the subsequent 
electron movement hydrolyzes the amide bond producing an amine terminus and is 
exported from the active site. As a water molecule enters the active site, the nitrogen of the 
histidine again hydrogen bonds the one of the water’s protons, making the water 
nucleophilic, where it attacks the in situ ester and forms an acyl intermediate. This then 
causes a collapse of electrons back onto other half of the substrate forming the carboxy 
terminus, regenerating the serine as the second product is released from the active site12–14. 
Serine proteases also contain a small pocket within their active site known as an oxyanion 
hole, which uses backbone hydrogens from the amide bonds (from the serine and an 
adjacent amino acid, usually glycine) to stabilize the negatively charged intermediates15.  
Cysteine proteases, as their name suggests, utilize a thiol containing cysteine 
residue at the center of their active sites. Although cysteine proteases are similar to the 
serine proteases, the pKa of the thiol (normally ~8.3) is significantly lower; hovering near 
3.3216,17. This has been shown to be due to the thiolate-imidazolium (or thiolate-
imidazolium-asparagine) ion pair that exists in the reactive site17. Thus depending on the 
environment of the active site and the family of cysteine protease, a catalytic triad or a 
catalytic dyad may exist18. With a cysteine protease’s catalytic triad, the same mechanism 
as the serine protease can be observed, except the intermediary ester that is formed is now 




Cys-His16–18. In the catalytic dyad, typically the same type of mechanism exists, in the 
absence of the Asn, and instead is stabilized by electrostatic effects from ionizable groups 
within 20 Å of the Cys-His; resulting in a nucleophilic attack from the thiolate on the 
peptidyl substrate17. The mechanism proceeds with the thioester intermediate, releasing the 
N-terminus product, addition of nucleophilic water to restore the cysteine thiol and release 
the C-terminus product.  
Threonine proteases are unique in that they utilize a secondary alcohol for their 
nucleophile, rather than a primary nucleophile like the serine’s and cysteine’s. Due to the 
secondary alcohol present, the γ-methyl group sterically blocks basic residues (i.e., 
histidine) responsible for deprotonating the alcohol. To remedy this, nature has constructed 
threonine proteases to having the threonine be the N-terminal amino acid19. With this, the 
γ’-hydroxyl faces the N-terminal amine, allowing the amine to behave as a base20. The 
presence of a water molecule allows the amine to abstract a proton, and in turn the newly 
formed hydroxyl deprotonates the γ-hydroxyl of threonine21. The threonine then attacks the 
carbonyl of the substrate present in the active site, forming a tetrahedral intermediate, 
which goes on to hydrolyzing the amide bond. The threonine is restored when the water 
molecule stabilized by the N-terminal amine hydrolyzes the intermediary ester, releasing 
the C-terminal product. 
Lastly, the aspartic proteases utilize two aspartic acid residues existing with one as 
the acid and the other as the conjugate base, aspartate. This class represents a small number 
of the total protease presence in the human genome; only 15 of the 21 identified so far 




mammalian proteases from viral, fungal, and parasitic sources (composed of >20 
individual aspartic proteases)1. The mechanism is very simple in that the conjugate base 
activates a water molecule, which in turn attacks the peptide bond of the substrate22–24. The 
electrons transferred to the oxygen of the carbonyl in the tetrahedral intermediate, abstract 
the proton of the second aspartic acid22–25. The hydrolysis of the substrate is then 
completed by the second aspartate removing a proton of the tetrahedral intermediate 
hydroxyl, causing the electrons to resonate back through the amide bond, forming a 
carboxy terminus and an amine terminus. The resonance restores the aspartic dyad for 
another substrate to be hydrolyzed.  
1.1.2 Serine Protease Recognition Sequences 
Comprehending the different protease mechanisms is an important aspect in 
understanding how the individual proteases behave. However for this work, serine 
proteases are the focal point. While their hydrolysis mechanism is straight forward, the 
serine protease’s recognition of substrates is seemingly of more interest. Serine proteases 
are unique in that they are highly plastic enzymes and able to adopt numerous structural 
conformations to accommodate their substrate(s)13,26. This means that a protease can 
hydrolyze multiple, structurally dissimilar proteins or peptide networks with similar kinetic 
rates13,27–32. Although the specificity of substrate is very broad with the different families 
of serine proteases, sequence selectivity is usually conserved within each family13,33,34. In 





For example, trypsin, is considered to be fairly promiscuous, and is most widely 
known for its use in biochemical laboratories for digestion of other proteins. Trypsin’s 
proteolytic mechanism involves hydrolyzing the C-terminus of a peptidyl linkage when the 
position, P1 residue, is an arginine (R) or lysine (K). However, the residues proceeding and 
preceding the P1 position directly affect the recognition and affinity. For most cases, 
proline blocks cleavage if it is at the P1’ position, a caveat though is that if the positional 
sequence, P4-P3-P2-P1-P1’-P2’, is XXWKPX or XXMRPX (where X is any amino acid), 
the proline has no blocking capabilities35,36. Likewise, if the positional sequence is 
XXC/DKDX, XXCKH/YX, XXCRKX, or XXRRH/RX, the hydrolysis is blocked35. The 
understanding of this specificity and selectivity is critical when investigating active site 
inhibitors of proteases for drug development. However, these competitive inhibitors simply 
bind within the orthosteric pocket with a greater binding affinity (> KD), outcompeting 
endogenous substrates. This route of inactivating a protease’s activity has been studied for 
decades. 
Another key example is the chymotrypsin-like protease, thrombin. It is broadly 
used in vitro for biochemical assays and is the key protease in blood coagulation, which 
will be discussed later, as the main topic of this work. Like trypsin, thrombin’s proteolytic 
activity is at the C-terminal of arginine residues at P1 within a peptidyl sequence35,37. 
Additional optimal conditions include when arginines are flanked by glycines at the P2 and 
P1’ positions. Other favorable conditions are when the P4 and P3 positions are occupied by 
hydrophobic residues, proline occupies P2, and for P1’ and P2’ to lack acidic residues35,37. 




P1 revealed several interesting observations. At P4, long chain, hydrophobic residues (e.g., 
isoleucine, leucine, norleucine, phenylalanine and to some extent tryptophan) were ideal 
substitutions38. Most likely owing to thrombin’s S4 pocket being considerably 
hydrophobic; containing isoleucine, methionine, leucine, and tryptophan. The P3 position 
was shown to be non-discriminatory; with the exception of glutamate, which produced 
little catalytic activity from thrombin39. Lastly at the P2 position, proline dominated 
showing no other residues capable of producing comparable catalytic efficiency35,37–39. 
This information is important in understanding thrombin’s natural substrate sequence 
specificity, and how changes in thrombin’s substrates can have remarkably different 
catalytic rates.  
1.2 Venous and Arterial Thromboembolism 
 The relationship between protease activity and cardiovascular disease (CVD) is 
strongly correlated. Both genetic and environmental factors have been shown to be key 
activators of CVD40. Notably, there are two common types of CVD: venous 
thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary 
embolism (PE); and arterial thromboembolism (ATE), which includes ischemic stroke and 
myocardial ischemia, leading to myocardial infarction40,41. Two simple distinctions 
between the two diseases are the locations of a thrombus (blood clot) formed, which in 
turn causes an embolism (occlusion) in either a vein or an artery, and the clinical 
symptoms each disease articulates40. Although these diseases are classified as separate 
entities, they share many common traits, risk factors, and have been shown be more related 




proteases within the coagulation system, while ATE has been understood to be directly 
caused by activated platelets45,46. However as more investigations ensue, they suggest a 
relationship between the two diseases40,42–44. 
 Distinctions and symptoms relating to venous thromboembolism as stated involves 
thrombus formation within a vein resulting in occluded blood flow, swelling and pain. 
DVT presents itself mostly in the “deep veins” including the femoral vein, pelvic vein, and 
in some instances the cerebral veins43,47. PE blood clots are actually fragments of DVT 
clots, which break off and travel to the lungs. This results in partial or full occlusion of the 
pulmonary arteries which can be detrimental to the lung tissue containing the clot. It is 
important to note that although PE blood clots occur in arteries, they are included in the 
VTE description because they are caused directly by DVT clots.  
 Arterial thromboembolism generally considered to be more dangerous, due to their 
location of formation. ATE’s typically form around areas that have experienced an arterial 
rupture called an atheroma. This is usually caused by the buildup of plaques within the 
arterial wall called atherosclerosis within the heart or brain45,46. Once the plaques induce an 
atheroma, thrombosis ensues forming an occlusion that partially or fully blocks blood flow 
to the specific area affected48. The result in the case of a blockage to heart is a myocardial 
ischemia and to the brain is an ischemic stroke. The tissue suffers from loss of blood flow, 
thus loss of oxygen, causing an infarction. 
1.2.1 Prevalence 
VTE and ATE have significant epidemiological impacts on world populations. It is 




>250,000 incidence cases annually49. Concurrently, ~30% of patients have at least one 
recurring episode within a 10-year period following initial diagnosis49. The mortality rate 
varies year-to-year, but typically ranges from 60,000-100,000 deaths/year49. According to a 
report by the American Heart Association, ischemic strokes brought on by ATE, result in > 
675,000 incidence cases/year in the US alone, with about 170,000 of those being 
reoccurrences49. Nearly 25% of those cases result in death each year. Looking at the world 
population, > 39 million identified cases/year from ischemic stroke, owing to 11.13% of 
deaths worldwide50. The same report goes on to stating that 735,000 Americans experience 
myocardial infarctions each year, with 210,000 of those being repeated episodes49,50. This 
results in ~370,000 deaths/year in the US. For myocardial infarctions worldwide, > 7.2 
million deaths occur each year; making it the leading cause of death49. These unsettling 
statistics highlight the fact that although cardiovascular diseases have been relentlessly 
studied, available treatments are not enough in providing long-term stasis of patients.  
1.2.2 Serine Proteases of the Coagulation Cascade 
The end goal for many scientists interested in preventing or combating CVDs is to 
develop new, more effective treatments, or to identify new mechanisms that are able to be 
targeted. However before understanding the various pharmacological treatments, one must 
understand the concept behind one of the main driving forces for VTE and ATE, the 
coagulation cascade. Under normal conditions, endothelial cells, which coat the interior of 
blood vessels, produce prostacyclin (prostaglandin I2 or PGI2) and nitric oxide (NO) and 
excrete them into blood flow. Combined, these two molecules act as vasodilators; while 




exposed and tissue factor is released52. The glycoprotein von Willebrand factor (vWF), 
binds to the collagen and mediates the binding of platelets to exposed collagen, which 
induces initial activation of platelets53. The activated platelets undergo major structural 
changes, becoming dendritic, and release granules containing a multitude of coagulation 
factors, adhesion molecules, polyphosphates, adenosine diphosphate (ADP), calcium 
(Ca2+), and thromboxane A2 (TXA2). ADP and TXA2 induce platelet recruitment, 
activation, and aggregation; while the calcium is essential for several of the coagulation 
factors to bind platelets53,54. The activated platelets expose phosphatidylserine on their 
extracellular surface, as well as release polyphosphates, giving way to the two coagulation 
pathways53,55. 
The first coagulation pathway is called the intrinsic or “contact-activation” 
pathway. The pathway is given that term because the protease cascade that ensues, is a 
result of polyanionic interactions with the surface of the protease, factor XII55. Upon the 
activation of platelets, small amounts of FXII come in contact with the phosphatidylserine 
or the polyphosphates released by the platelets, inducing a conformational change, 
activating FXII. The little FXIIa produced then activates kallikrein from prekallikrein. At 
the same time, high molecular weight kininogen (HMWK) binds to the negatively charged 
surface of the injured endothelium and the activated platelets, acting as a cofactor for more 
kallikrein and FXIIa generation55,56. FXIIa in turn, activates factor XI in the presence of 
calcium, initiating the intrinsic pathway55. As seen in Figure 1, FXIa goes on to activating 
factor IX in the presence of calcium57. At this point, the cascade enters the common 




calcium, and phosphatidylserine activate small levels of thrombin from prothrombin, the 
key protease of the coagulation cascade57–59. 
To get to the same common pathway, the extrinsic pathway or “tissue factor” 
pathway, is initiated by the actual trauma of the damaged blood vessel. Damage to the 
endothelial cells exposes the subendothelium, which expresses high levels of 
thromboplastin (tissue factor; TF). The TF forms a complex with plasma factor VII, 
activating it, which subsequently activates both FIX and FX, completing the loop for the 
common pathway59,60. As stated above, the extrinsic and intrinsic pathway generate low 
levels of thrombin, which then goes on to performing multiple functions, including 
amplifying its own production. Thrombin behaves as a procoagulant by activating factor 
VIIIa, FIXa cofactor61; as well as activating factor V, a FXa cofactor61. As these cofactors 




thrombin is greatly accelerated. When thrombin levels are sufficient, thrombin goes on to 
hydrolyzing its main substrate, fibrinogen, into insoluble fibrin monomers. Thrombin 
concurrently will activate factor XIII, a transglutaminase responsible for cross-linking the 
fibrin monomers, forming the initial fibrin mesh that holds the activated platelets together 
around the site of injury62. Thrombin can also recruit more activated platelets to the injury 
site by binding with glycoprotein 1bα (GP1bα) and cleaving the protease-activated 
receptors (PAR) 1 and 4 on the platelet surface63,64. Binding of thrombin to GP1bα (or 
polyphosphates) also induces a feedback loop of thrombin activation by independently 
activing more FXIa (see Figure 1)65,66. 
1.2.3 Hypercoagulation: Current Treatments, Mechanisms, and Side Effects 
As insinuated above, the concentration of zymogen and active proteases released by 
platelets or that are free flowing in plasma play a critical role in contributing to blood 
clotting, as well as disorders like hypercoagulation. Hypercoagulable states 
(thrombophilia) are defined as when a patient has a higher tendency to form abnormal 
blood clots due to several factors including genetics, medical conditions, or medication 
being taken67. Predominantly, inherited factors are the most concerning, due to a patient 
being unaware that they are predisposed. The most common type of thrombophilia is factor 
V Leiden, a genetic mutation of the F5 gene, where factor V is translated68. The mutation 
causes a sequence alteration at the codon for Arg506 at the activated protein C cleavage 
site and substitutes with glutamine69. This mutation results in FVa:FXa complex remaining 
active for 10-fold longer, producing considerably more thrombin. There is also support that 




allows FXa generation to be accelerated for longer periods of time69. Combined, these 
would produce an abnormal acceleration of clot formation.  
 The second most common type of thrombophilia is the prothrombin gene mutation 
(G20210A mutation) on the F2 gene. This single nucleotide mutation is part of the 
noncoding region of the prothrombin gene, and thus does not cause any mutation to the 
prothrombin itself. However, the mutation does cause an up-regulation of prothrombin 
produced69,70. Statistical analysis of people with the G20210A mutation showed a 2-3-fold 
increase in having a clotting event69,70, with those odds increasing if combined with other 
risk factors, especially cancer.  
 In order to combat these thrombotic events, whether the source is congenital or 
acquired, anticoagulant drugs have been used and continue to be in development for 
treatment of DVT, PE, and arterial thrombosis. These drugs act in one of two ways, direct 
or indirect. One of the first and most widely used anticoagulants is warfarin. Warfarin is a 
coumarin-based small molecule that acts as an indirect anticoagulant. The mechanism by 
which warfarin proceeds through targets the coagulation proteases requiring calcium, for 
binding platelet surfaces71. Better known as a vitamin K antagonist, warfarin inhibits 
vitamin K epoxide reductase, and effectively reduces the amount of vitamin K available as 
a cofactor for γ-glutamylcarboxylase71–73. The γ-glutamylcarboxylase adds a γ-carboxylic 
acid to glutamic acids on thrombin, FVII, FIX, FX, and protein C; called the Gla-domain, 
responsible for binding calcium73. The warfarin in turn, causes production of coagulation 
proteases that lack the Gla-domain, which renders them incapable to bind to platelets71. 




coagulation include glycosaminoglycans and their derivatives, which will be explained in 
greater detail in Chapter 1 Section 3. 
 Although warfarin and its derivatives function very well to inhibit coagulation, 
extensive monitoring of the drug per individual patient is required due to the complications 
associated with warfarin therapy74. The main issue relating to warfarin is the high risk of 
excessive bleeding events (hemorrhaging), even when taken as prescribed. Accidental 
overdose greatly increases the risk for hemorrhages and induction of hemophilia-like 
symptoms, with the only immediate reversal agent (antidote) being fresh frozen plasma75. 
Vitamin K can be introduced, but takes 4-6 hours before liver production of natural 
coagulation factors containing the Gla-domain will be synthesized75.  
 Due to this potentially severe complication, researchers began investigating 
alternative anticoagulants. These direct anticoagulants, bind directly to a protease’s active 
site, rendering them incapable of catalyzing hydrolytic reactions76. To date, there are two 
types of direct orthosteric anticoagulants available in the clinic, with more being 
investigated for alternative targets. The two types include thrombin-specific and FXa-
specific inhibitors. For thrombin-specific there are also two subtypes, univalent and 
bivalent. The most notable univalent direct thrombin inhibitors (DTIs) are argatroban and 
dabigatran. Argatroban is an injectable small molecule that has been approved for the 
treatment of thrombosis and for patients experiencing heparin-induced thrombocytopenia 
(HIT); a immunological condition brought on by the anticoagulant heparin, causing a 
reduction in platelet concentrations77. The drug reversibly binds to thrombin’s orthosteric 




(IC50) of ~10 nM against platelet aggregation for free thrombin and ~20 nM for clot-bound 
thrombin77,78. Dabigatran is an orally bioavailable small molecule that reversibly inhibits 
thrombin’s orthosteric site with a KI of 4.5 nM79, as well as acts on thrombin in the clot-
bound state with an IC50 of 10 nM79. It is dosed as a prodrug, dabigatran etexilate, which 
additionally contains an ethyl ester and hexyloxycarbonyl carbamide, to increase 
hydrophobicity and membrane absorption80.  
 The bivalent DTIs indeed interact with the active site of thrombin, but also with a 
secondary site called exosite 1. Exosite 1 is an allosteric site on thrombin adjacent to the 
orthosteric site, and will be discussed in greater detail in Chapter 1 Section 4. The first 
bivalent DTI to be discovered was hirudin. Hirudin, a 65 amino acid peptide found the in 
the salivary glands of leeches, has an interesting mechanism of action81. It first recognizes 
thrombin by binding to exosite 1 through mainly electrostatic and hydrophobic interactions 
using its last 17 residues at the C-terminus81. Then the peptide chain, mainly through its 
hydrophobic residues of the N-terminus binds within the active site pocket of thrombin, 
occupying the S1-S4 pocket81. This discovery was a novel mechanism, both in the exosite 
binding and the way it binds to thrombin’s active site pocket. 
 The direct FXa inhibitors (DXIs), like apixaban and rivaroxaban, act by targeting 
FXa’s orthosteric site. The compounds are selective and do not inhibit thrombin or other 
coagulation proteases, which subsequently do not have any direct effects on platelet 
aggregation82. However, these two small molecules do inhibit both free and clot-bound 




for treatment of DVT and PE. Apixaban boasts a KI of 0.08 nM83 and rivaroxaban has a 0.4 
nM KI84.  
 A large drawback of all of these anticoagulants is the risk of excessive and severe 
bleeding. Although the DTIs and DXIs effectively treat thrombotic complications better 
than warfarin, some side effects are more prevalent than compared to warfarin. 
Argatroban, dabigatran, and rivaroxaban have been shown to have almost a 2-fold increase 
in major gastrointestinal bleeding85. Argatroban also showed with >10% of patients in trial 
experiencing minor bleeding in urinary organs, coupled with increased events of low 
hemoglobin85. Hirudin clinical trials showed 2-10-fold increases in bleeding from injury 
sites, drops in hemoglobin, and non-threatening bleeding (i.e., nose bleeds)85. Until 
recently, none of these treatments had an approved, reliable emergency antidote. In 2015 
however, idarucizumab was discovered to be a fast-acting antidote for dabigatran and its 
anticoagulant effects86.  
1.3 Glycosaminoglycans 
 An alternative treatment to the anticoagulants discussed above, along with the 
oldest anticoagulant known, heparin and its many derivatives form a group of compounds 
known as glycosaminoglycans (GAGs). GAGs as they exist in nature, are linear, complex, 
carbohydrate structures composed of repeating, disaccharide units87. The type of 
monomeric sugars that make up the disaccharides contain at least one amine in each 
disaccharide. GAGs are biosynthesized in virtually all mammalian cells and are usually 
attached to a protein or lipid, dubbed a proteoglycan or glycolipid87. Thus, GAGs are found 




cells87. GAGs are one of the most unique biomolecules synthesized by cells because they 
are non-template-based and can have variable modifications through epimerization, 
sulfation, and acetylation.  
 GAGs can be broken down into five major classes: hyaluronan (HA), chondroitin 
sulfate (CS), dermatan sulfate (DS), keratin sulfate (KS), and heparin/heparin sulfate 
(H/HS). HA is the only non-sulfated GAG, composed of the disaccharide repeating units of 
N-acetylglucosamine and glucuronic acid, which contains glycosidic linkages that 
alternative between the anomeric carbons β1-4 and β1-3 (GlcNAcβ1-4GlcAβ1-3)87. CS is a 
variably O-sulfated GAG made up of N-acetylgalactosamine and glucuronic acid. The CS 
is linked through glycosidic bonds at the β anomeric carbons, 1-4 and 1-3 (GalNAcβ1-
4GlcAβ1-3) with a sulfation pattern typically composed of the 4- and 6- position of the 
GalNAc and the 2-position of GlcA87; although analysis has shown that some 
disaccharides remain desulfated88. DS is very similar to CS and was once considered a 
derivative of chondroitin sulfate, but the GlcA is isomerized, giving way to iduronic acid 
(IdoA)87. Thus DS contains the GlcNAcβ1-4IdoAβ1-3 disaccharide linkage. KS is another 
variably O-sulfated GAG consisting of galactose and N-acetylglucosamine (Galβ1-
4GlcNAcβ1-3), but interestingly can be part of a branched glycan system through mannose 
linking89. It can also be capped at the non-reducing end with fucoses or N-acetylneuraminic 
acid89.   
 Lastly and more importantly for this work, heparin/heparan sulfate is a variably O-
sulfated and N-sulfonated GAG composed of α-glucosamine and β-glucuronic or α-




disaccharide unit87. Variability of acetylation or sulfonation at the C-2 amine, as well as 
isomerization within disaccharide units causing the anomeric carbon to change between α 
and β, makes H/HS the most complex GAG sequence90. Heparin and heparin sulfate are 
collective in grouping because their backbone disaccharides and sulfation/acetylation 
patterns are generally the same, however heparin has been shown to be more sulfated than 
HS; heparin contains ~2.7 sulfates per disaccharide versus HS having ≥ 1 sulfate per 
disaccharide87. In humans, free heparin only consists of ~5% of the total H/HS, with HS 
dominating in the proteoglycan form. Additionally, heparin is produced mainly in mast 
cells, only being excreted under affliction87.  
 GAGs have a role in almost every biochemical mechanism in the body, with H/HS 
most notably being involved within blood coagulation91. H/HS are indirect anticoagulants 
that act as cofactors for endogenous serine protease inhibitors (serpins). These serpins, 
such as antithrombin and heparin cofactor II, act to covalently inactivate the serine 
protease by insertion of an inactivation loop into the active site of the protease. The serpin 
initially interacts with the protease non-covalently, through a Michaelis-like complex, 
similar to that of normal substrate interactions92. However, when the protease attempts to 
hydrolyze the inactivation loop, the hydrolysis reaction is halted when the serine 
covalently cleaves the C-terminal arginine within the inactivation loop92. Once the covalent 
linkage occurs, the protease-bound serpin undergoes a conformational change, irreversibly 
augmenting the active site pocket, disrupting the catalytic triad92. H/HS accelerates this 
reaction by binding tightly to a distal site on the serpin (KD = low nM) and weakly binding 




dynamic interaction with the H/HS, allowing it to “walk” along the H/HS chain until it can 
begin interacting with the serpin to form the initial Michaelis-like complex92,94. This 
acceleration by H/HS increases the rate of the inactivation by 2000-4000-fold95,96. 
In clinically relevant situations, exogenous heparin extracted from bovine or 
porcine sources is used for anticoagulant treatment. The heparin derived in this fashion 
must meet strict federal guidelines pertaining to the molecular weight, degree of sulfate, 
and animal source97. Because full length heparin is not yet possible to chemically 
synthesize, a number of enzymatic, chemoenzymatic, and synthetic steps have been taken 
to create heparin derivatives like low-molecular weight heparin (LMWH; enoxaparin)98, 
ultra-low-molecular weight heparin (ULMWH)99, and fondaparinux (pentasaccharide)100. 
These heparins show lower 
affinity towards plasma 
proteins and as they 
decrease in size, show less 
effects accelerating serpin-
thrombin interactions, but focus mainly on facilitating antithrombin (AT)-FXa interactions; 
with fondaparinux exclusively targeting AT-FXa (see Figure 2). The reasoning behind 
making smaller heparin analogs is to combat heparin-induced thrombocytopenia (HIT), 
mentioned earlier. In some patients, heparin triggers the formation of antibodies, that act 
by activating platelets101. The activated platelets form microaggregates that lowers the free 
platelet count in blood, but also can cause occlusions to blood capillaries101. Lower 




Unfortunately the drawbacks besides HIT as seen with other anticoagulants, 
include major bleeding complications with heparin, LMWH, and fondaparinux. Although 
LMWH and fondaparinux have reduced the risk for HIT, both showed higher prevalence of 
major and minor bleeding after surgery, but overall equivalent or less bleeding for 
treatment of DVT and PE compared to heparin102. This information suggests that although 
there are downfalls for every type of anticoagulant, immense progress has been made 
regarding safety of the drugs. However the notion of an “ideal” anticoagulant, which 
would instill hemostasis to predisposed and afflicted patients, still looms. 
1.4  Allostery and Conformational Change 
  Arguably one of the most important phenomenon that occurs with proteins and 
within the study of enzymology, is the concept of allosterism.  Allostery can be defined as 
a distal interaction that induces a functional change to a protein (or enzyme), thereby 
altering the primary site’s binding capability or catalytic efficiency103. Two major theories 
have been at the forefront when describing allostery. The first was introduced by the 
discovery of hemoglobin’s quaternary structure104. The theory suggested that structural 
alterations of the protein’s conformation, induced by allosteric effectors, changed a 
substrate’s binding affinity to the protein. This brought about the common explanation of 
oxygen binding and the effect of 2,3-biphosphoglycerate (BPG) binding to hemoglobin 
and how it effects the tense (T) and relaxed (R) states. It stated that hemoglobin in the 
deoxy form (deoxyHb) has a low affinity for oxygen (T-state), but once an oxygen binds to 
one of the four subunits, cooperativity takes over. This cooperativity induces 




oxygen, transitioning to oxyhemoglobin (oxyHb) or R-state105. When BPG binds to the 
allosteric site of Hb, it stabilizes the T-state, in turn reducing the affinity for oxygen. 
 An alternative to this theory is the idea that an allosteric effector can broaden or 
narrow the free energy within a protein’s conformational space106,107. This theory implies 
that entropic events within the conformational space of the protein actually affects the 
thermodynamics and the conformational dynamics, thus speeding up or slowing down the 
motions of the protein itself106,107. Simply put, a distinct structural change does not need to 
occur for a protein to respond to an allosteric effector108. Therefore when looking at 
allosteric effects as a whole, one must take into consideration that if the no structural 
change can be identified, then dynamic allostery must be taking precedence.  
 Allostery is a significant aspect of the coagulation cascade in that thrombin, the key 
regulatory protease of the system, is highly regulated by allosteric interactions109,110. 
Structurally, thrombin is a 37 kDa monomeric, serine protease with two distinct allosteric 




and exosite 2 (residues include: R93, R97, R101, R126, R233, K235, K236, and K240); as 
seen in Figure 3, using PDB ID: 3EQ0. This is in addition to the typical serine protease 
catalytic triad composed of S195, H56, and D102. These exosites are highly cationic in 
nature, owing to their ability to bind with anionic species like the sulfates of GAGs, the 
tyrosine sulfates of many cofactors and peptides, and 
D/E residues found in repeat sequences of many of 
the same cofactors and peptides109. Additionally, the 
exosites contain many hydrophobic pockets that aid 
in ligand specificity and recognition109,111.  
In conjunction with the active site and exosite 
recognition, thrombin is known to have high degrees 
of conformational plasticity112, allowing it to sample 
a number of conformational states at any time; shown in Figure 4. Thrombin is thus 
considered to have a large conformational space. Because of this flexibility, thrombin is 
able to recognize and hydrolyze multiple substrates with only three recognition sites 
(active site, exosite 1 and 2)112. Therefore, it is reasonable to assume that allosteric 
effectors can induce either conformational or dynamic allostery. For example, when 
heparin binds to exosite 2, no significant structural change is observed in crystallographic 
studies113 or by using fluorescence techniques114. However, other endogenous ligands like 
γ’-fibrinogen115 and GP1bα116 induce significant alterations to thrombin’s structure through 
exosite 2-mediated interactions; sharing similar binding modes and residues to heparin. It 




concentration of sodium in solution117. Na+ has been shown to bind with the backbone 
carbonyl oxygens of thrombin’s Y184, R221 and K224, as well as with four water 
molecules117. The binding of sodium coordinates the residues properly to give functional 
geometry to the S1 pocket, allowing it to recognize the arginine residue of substrates117. 
Thus, low sodium concentrations or blocking of this region would yield impaired 
recognition of the substrate and reduced catalytic activity. 
1.5  Glycosaminoglycan Mimetics 
 Having recognized that the exosites of thrombin can be selective for specific 
sequences, to which the extent of these can be altered by the hydrophobicity of the ligand 
(i.e., increasing the non-ionic binding energy), it was apparent that the design of synthetic 
compounds could result in allostery-induced dysfunction of the catalytic site. Initial 
development and studies used chemoenzymatically-derived sulfated, low molecular weight 
lignins (LMWLs)118–120, which were purposed to mimic heparin binding. The difference 
however was that backbone scaffold was significantly more hydrophobic by use of 
phenoxypropanoic acid and dihydrobenzofuran repeat units instead of GlcN and 
GluA/IdoA repeats118. Also the sulfation in the LMWLs was O-phenolic, replacing the 
GAGs alkyl O-/N-sulfonation118.  
Using chromogenic substrate hydrolysis assays, the LMWLs were shown to inhibit 
thrombin’s activity by direct interaction of the heparin binding site (HBS), shown through 
heparin competition and Michaelis-Menten kinetic studies with low nanomolar IC50s118,120. 
These were confirmed as non-saccharide glycosaminoglycan mimetics (NSGMs) by means 




reduced as the concentration of sodium was increased, suggesting that the multivalent 
interaction of the sulfates was taking place, as seen with heparin119. The mutant studies 
revealed that like heparin, R93 and R175 had significant impacts in binding with the 
LMWLs showing a 7-8-fold reduction in inhibition when mutated121. Additional 
electrostatic interactions included R101, K233, K235, and K240, which form the heparin 
binding site121. However the notable difference is that although the LMWLs and heparin 
bind at the same site, the LMWL induce allosteric inhibition of thrombin, while heparin 
does not. Thus, the inhibition aspect must arise from the hydrophobic interactions of the 
backbone scaffold. 
Although the LMWLs displayed impressive inhibition concentrations, they were 
not selective. Along with inhibiting thrombin, they also inhibited plasmin, FIXa, FXa, 
FXIa, neutrophil elastase, and cathepsin G120. The LMWLs were also polydisperse, 
variably sulfated, and had non-uniform linkages118. To combat some of these issues, a 
synthetic polymer known as SbO4L was developed. Being SbO4L was fully synthetic and 
the chemistry restrictive to one linkage being formed by a phenolic SN2 reaction, the 
polymer formed was linked uniformly122. The polydispersity and average sulfation 
presence were also uniform as compared to unfractionated heparin and LMWH used in the 
clinics. Significant advances over the LMWLs was SbO4L’s log10-fold selectivity towards 
thrombin and its ability to inhibit both thrombin and thrombin’s binding affinity to GP1bα 
on platelets, effectively acting as an antithrombotic and antiplatelet agent122,123. 
Stemming from the LMWL discoveries and concurrently with the SbO4L work was 




closely resembled small molecule-based inhibitors, rather than polymeric ligands. The 
initial SAMs included sulfated monomeric, dimeric, trimeric, and tetrameric 
benzofurans124–126. The synthesis of these molecules was to eliminate polydispersity, while 
increase the non-ionic contributions to LMWL scaffold. As mentioned previously, the 
LMWLs contained dihydrobenzofuran cores, which were easily attainable through the 
cyclization of 1,2-dihydroxybenzene and acetoacetate124,125. This gave the benzofuran 
heterocycle that was variously oligomerized in multiple reports and contained various 
sulfation patterns, as well as a variety of protected and deprotected scaffolds124–126. The 
general pattern of inhibition was that as the scaffolds elongated through oligomerization, 
the inhibition became more potent. Additionally, the BFs showed much better inhibition 
containing only one phenolic sulfate, and opening up the ester present in the structure to a 
carboxylate, did not increase the potency124,125. Suggesting that the BFs act through mainly 
hydrophobic interactions, while the sulfate is simply needed to “steer” the benzofuran to 
the exosite127. Using the same techniques as for the LMWL, the BF family of compounds 
showed that they bind to exosite 2 and specifically, the most potent BF dimer (IC50 = 5 
µM) was shown to bind at R173128, while the benzofuran trimer (IC50 = 0.67 µM) was 
shown to bind at the R233 residue of thrombin125. Modeling studies showed two distinctly 
different binding sites for the dimer and trimer, and the tetramer did not have high 
potency125. Overall this suggested that the inhibition of thrombin by the BFs was size 
dependent and relied on hydrophobic interactions as well as the thrombin residues 
donating hydrogen bonds to the H-bond acceptors of the BF molecules. It is important to 




equipotent IC50s (0.8 µM for FXIa versus 0.67 µM for thrombin), by binding to FXIa’s 
HBS129. 
Other SAMs produced included quinazolinone, flavone, and tetrahydroisoquinoline 
scaffolds. These compounds were structurally different from the BFs and so were their 
specificity towards coagulation proteins. The quinazolinones/flavones (QAOs) were 
synthesized as monomers or as dimers (homodimers or heterodimers with a flavone 
moiety), which were linked by alkyl chains connected by 1,2,3-triazole(s), or by just alkyl 
chains of varying lengths. The compounds were shown to be selective toward FXIa, over 
thrombin, FXa, trypsin, and chymotrypsin127. The most potent QAO was a bisulfated 
homodimer with a 1,2,3-triazole containing a 5 carbon alkyl linker, possessing an IC50 of 
59 µM127. Alteration of the linkage from the 1- and 4-position to the 1,2,3-triazole to 1- 
and 5-position led to ~2-fold drop in potency, suggesting that the triazole geometry plays a 
significant role in binding to FXIa127. Alternatively, the tetrahydroisoquinolines (THIQs) 
were found to be antithrombin accelerators for FXa inactivation. The THIQs accelerated 
the inactivation of FXa by ~79-fold, but doing so with low potency130. However, an 
interesting point to take away is that the relatively similar scaffolds have remarkably 
different specificities and induce very different effects. Some act as direct, allosteric 
inhibitors, that bind to the HBSs of proteases, while others bind to the HBSs and act as 
heparin does in acceleration of AT inactivation.  
1.6 Partial Inhibition 
 One aspect of allosteric inhibition that has been hinted at by previous data, was the 




inhibition of thrombin. In lay terms, 
even at saturation of the ligand, the 
protease remains active and able to 
hydrolyze substrate. In graphical terms 
(dose-response profiles), partial 
inhibition is identified by the ΔY 
(efficacy of inhibition) where the ΔY > 
20% and < 80% (Figure 5). What is of 
interest is the principle that while the ligand is inhibiting the protease, it remains partially 
active towards the small substrate. This phenomenon could translate into multiple 
downstream effects. For instance, if there is an alteration to thrombin’s pocket, endogenous 
substrate may not be as recognizable or there may be activation when there is typically 
inhibition131. Another possibility is that the catalytic efficiency is reduced, thereby slowing 
the enzyme’s hydrolysis rate due to dysfunction of the S1 pocket or catalytic triad132. 
Furthermore, partial inhibition is a rare event in enzymes, especially with thrombin being a 
monomeric protein. The typical proteins or enzymes that experience partial inhibition are 
multimeric proteins such as receptors/membrane-bound proteins or multimeric proteins.  
 There are a multitude of examples for allosteric inhibitors inducing partial 
inhibition of receptor/membrane-bound proteins. Likewise, the examples include not only 
the typical structural conformational changes, but also conformational dynamic changes. 
Recently, two examples of partial agonism explained by conformational dynamics have 




The first report used crystallography and computational simulations which compared 
agonist, partial agonist and antagonist ligand volumes bound to the binding site with 
calculated free energy surfaces. The study showed that increasing the ligand size, lowered 
the agonist efficacy; meaning that the free energy’s minima narrowed, reduced, or a 
combination of the two133. This was indicative of small ligands being agonists, and as their 
size increased, they became partial agonists or antagonists. Thus, the free energy diagrams 
for each ligand may be used to predict if a ligand would act as a partial agonist or not. 
Furthermore, the curvature of the free energy graphs may be correlated with the energies 
relating to the glutamate channel’s opening or closing in response to a ligand, but with a 
caveat that the simulations were performed using a monomer of the receptor and not the 
full tetrameric structure133.  
The second report takes this notion a step further where they investigated the 
glutamate receptors using a partial agonist and monitoring the FRET changes at the dimer 
interface of the ligand binding domain. They successfully demonstrated that the partial 
agonist, DCG-IV, did not induce full occupancy of the low FRET state, even at saturating 
levels; unlike the full agonist, which occupied the high FRET or active state134. 
Additionally, saturating concentrations of DCG-IV was able to keep dynamics near the 
basal state of the receptor. This was also compared to full agonist, which showed that its 
induced dynamics were dramatically slower, in looking at FRET traces134. The last major 
aspect described that mutations made at conserved sequences of transmembrane (TM) 
domains, positive allosteric modulators (PAMs) that bind at those TM domains drastically 




domains are directly linked to the ligand binding domain, an important feature the first 
report hypothesized.  
A caveat regarding this partial agonism is that these reports indeed showed partial 
inhibition through conformational dynamics, but did not use allostery. This is an important 
aspect to take into consideration because again, receptors are multimeric proteins, but not 
enzymes. Therefore, their mechanisms of action are vastly different and are difficult to 
make comparisons to. Although many allosteric agonists exist, they do not all directly 
cause partial inhibition in receptors135. They can however enhance or modulate the partial 
agonist, as seen in the example of DCG-IV and the PAM of the TM domains134. An 
example however of an allosteric partial antagonist examines the structure activity 
relationship of the 5-(phenylethynyl)pyrimidine scaffold. They showed that by varying 
small structural changes to the scaffold, it changed the allosteric activity from partial 
antagonist (71% response) to full antagonist (99% response)136. They concluded from this 
study that the allosteric partial antagonism is not conserved to the general scaffold because 
of the large variations in the activity of the inhibitor on the receptor136. This demonstrates 
the high sensitivity of an allosteric site and that minor changes can have dramatic effects 
on the outcome, most likely due to dynamics. To look at more classical examples of 
allosteric partial inhibition, one must turn to a recently discovered inhibitor of a 
phosphodiesterase, which is most relevant to this work.  
 The study on phosphodiesterase 4 (PDE4) examines the notion of an allosteric 
partial inhibitor in order to aid in the prevention of side effects from patient using 




Their evidence suggests that the PDE4 acts a dimer with negative cooperativity and can be 
within multiple conformations; so as in saying only one of the two binding sites may be 
open or closed at any time. Their lead designed compound was shown to be 1000-fold 
more selective for the PDE4 isoform137. The study had observed that their lead compound 
acted by shifting the binding of two key hydrophobic residues at the active site and 
predicted interactions with the residues involved in binding the Zn2+ metal137; which is 
linked to conformational allostery. The overall partial inhibition was > 50% with an IC50 of 
2 nM, while also decreasing the kcat/KM of one of the active sites137. Additionally, the 
cAMP levels in the cell cultures were not shown to be elevated, insinuating that the 
allosteric partial inhibitor was indeed perform its enzymatic duties137.   
 The work described herein provides several details of partial inhibition by allosteric 
and non-allosteric structural conformational changes and conformational dynamics. 
Convincingly, there is a plethora of information regarding partial inhibition, but only with 
regard to higher multimeric proteins, with the last study involving a dimer. One important 
factor that separates oligomeric proteins with enzymes is that the for enzymes, only 
allosteric effectors can induce partial inhibition135. With the receptors, the partial inhibition 
can be induced by an allosteric modulator or by a ligand within the main ligand binding 
domain, because the receptors act through channel opening and closing. If a ligand binds to 
the enzyme active site, there is an all-or-none phenomenon where partial inhibition 
fundamentally cannot occur. However, allostery offers up that accessibility if the ligand 
induces a specific change to the structure or to the dynamics of the enzyme. The following 




monomeric enzyme, thrombin, its mechanism of inhibition, as well as a number of 

















Over the past decade, our lab has presented multiple works on the development of 
non-saccharide glycosaminoglycan mimetics (NSGMs). These NSGMs began as 
chemoenzymatically and fully synthetically produced , lignin-based polymers presenting 
diverse arrangements of O-sulfates and carboxylates114. The first generation of NSGMs 
were plagued with difficult characterization and separation; resulting in heterogeneous 
mixtures and diverse conformational sequences122. Stemming from these polymers came 
small molecules composed of heterocyclic cores, some mimicking the lignins, decorated 
with O-sulfates synthesized from phenolic moieties. These heterocyclic cores included 
benzofurans, quinazolinones, and flavones that were analyzed from monomeric cores to 
tetrameric cores, in some instances. The addition of heterocyclic cores to produce 
monomers through tetramers was done in two manners, direct conjugation or with varying 
linkers. To this, the development of more than 150 diverse sulfated allosteric modulators 




coagulation124,125,127,129,130,138 and inhibition of cancer stem cell proliferation and 
differentiation139.  
We chose to expand the diversity and functionality of the SAM libraries, which led 
us to study coumarins as the heterocyclic scaffold of choice for several reasons. A number 
of coumarins are commercially available with diverse, synthetically accessible handles, 
which greatly reduces the number of steps involved with synthesis. Coumarins are 
pharmacologically relevant; the best and most relevant example of this is the vitamin K 
antagonist, warfarin, which utilizes a coumarin backbone71. The coumarin scaffold offers a 
structurally diverse core compared to the other heterocycles in the library, like the flavones 
and quinazolinones.  
 We chose to focus on the coagulation cascade to examine whether these coumarin-
based sulfated allosteric modulators (CSAMs) were efficacious against any of the 
pharmacologically relevant proteases involved. Our earlier work on designing/discovering 
allosteric modulators of thrombin showed that the sulfated scaffolds exhibited allosteric, 
full inhibition (ΔY = 80–100%) at saturation124–127. However, an interesting observation 
made with the lignin SbO4L and one of the benzofuran trimers was that at saturating 
concentrations of the inhibitors, thrombin remained partially active (ΔY = 20-79%)122,124. 





2.1. Synthesis of First and Second Generation CSAMs 
Sulfated coumarins were synthesized using either a protection–deprotection 
strategy or a selective reaction strategy, which enabled the generation of the desired 
number of free O-phenolic groups that could then be sulfated in a final step using sulfur 
trioxide–trimethylamine complex140,141. Initially, O-methylated analogs are deprotected 
using boron tribromide (BBr3) producing the free hydroxycoumarin scaffolds. The 
hydroxycoumarins were then sulfated using microwave assisted sulfation (MWAS), 
requiring sulfur trioxide trimethylamine complex (SO3.N(CH3)3), triethylamine (TEA) as a 
base, and acetonitrile (ACN) as the solvent. First and second generation dimeric species 
were also considered due to previous studies indicating that spanning a greater radius with 
larger compounds increased potency. The second generation dimers were chosen to 
represent the most promising compounds, with increased sulfation. For the first generation 
dimeric species, the hydroxycoumarins were alkylated selectively with either propargyl 
bromide, 1-bromo-3-chloropropane, or 1-bromo-4-chlorobutane. Subsequently, the 
chloropropane or chlorobutane was reacted with sodium azide, to produce the alkylazide. 
To form the dimeric compounds, the coumarin alkylazide and propyne groups were reacted 
through copper (I)-assisted azide-alkyne cycloaddition (CuAAC). The dimeric precursors 
were then sulfated using MWAS, resulting in a O-sulfate trimethylamine complex. The 
second generation CSAMs first had their catechol moieties selectively protected using the 
diphenylmethane (DPM) group, proceeded through the first alkylation steps, and was 
deprotected. This deprotection prior to azidation and CuAAC was selected due to the lack 




sulfated using the MWAS. For all sulfated compounds, an additional step using cation 
exchange chromatography ensured the alkylammonium sulfates were exchanged to sodium 
sulfates and lyophilized to produce the final compound.   
Collectively, the overall synthesis resulted in a 36 compound library of first 
generation CSAMs (Figure 9). Then followed by two second generation compounds, 
which contained higher degrees of sulfation of the two most promising molecules. Thus in 
total, a 38 compound library was successfully synthesized exploiting various sulfation 
patterns, substituent placement, and monomeric/dimeric species.   
2.1.1 Experimental Details 
For O-methylated coumarins, 50-100 mg of the starting material were suspended in 
5 mL of dry DCM and subjected to 1.5 eq. per oxygen atom of 1.0 M BBr3 solution at -78 
˚C under N2 atmosphere. The solutions were stirred for 5 h, allowed to reach room 
temperature (rt), following which the solutions were again cooled to 0 ˚C and 6 mL od 
water (or 1:1 water/methanol) were slowly added with stirring to quench the reaction over 
the course of 10 minutes. The biphasic solution was then condensed in vacuo and was 
taken up in 20 mL of ethyl acetate to which 15 mL of saturated ammonium chloride 
solution was sequentially added. The mixture was transferred to a separatory funnel where 
the organic phase was extracted and the aqueous phase was followed by two washes of 10-
20 mL of ethyl acetate. The organic layers were pooled, washed with brine, dried over 
anhydrous Na2SO4, and then condensed in vacuo. The residues were taken up in minimal 
DCM (~2 mL), dry-loaded onto silica gel and purified via normal phase flash 




demethylated products were pooled and condensed in vacuo to yield white or yellow solids 
in 87 – 98%; yielding precursors for products of 2w-2y (Figure 6).  
To prepare dimeric CSAMs 3a-3f (Figure 7), we began with 150 mg of O-methoxy 
coumarins, which were suspended in 5 mL of DCM in a round-bottom flask, brought down 
to -78 °C and 1.5 equivalence per oxygen atom of 1.0M BBr3 in DCM was added dropwise 
to the stirred solutions. The reactions proceeded for 5h as the temperature rose from -78 °C 
to room temperature. To quench the reactions, the round-bottom flasks were placed in ice 
baths to bring the reaction temperature to 0 °C. To the flask, 10 mL of 1:1 water:methanol 
was added to reactions, effectively demethylating the coumarins. The volatile components 
were condensed in vacuo and were taken up in 20 mL of ethyl acetate and 20 mL of 
saturated ammonium chloride solution. The solution was transferred to a separatory funnel, 
the organic layer was extracted and the aqueous phase was washed twice with 10 mL of 
ethyl acetate. The organic layers were pooled, washed with brine, and dried over 
anhydrous Na2SO4 and then concentrated in vacuo. The residues were taken up in minimal 
DCM (2-3 mL), dry-loaded onto silica and purified by normal phase flash chromatography 
(0-70% ethyl acetate:hexanes). The fractions containing the deprotected analogs were 




This yielded analogs containing two phenolic hydroxyl groups at the 7-position and 
the 3-(4’-phenyl)-position. These two phenols were predicted to have different pKa’s and 
thus by controlling the equivalence of base and electrophilic alkyl group, could selectively 
alkylate one hydroxyl over the other. These analogs were taken up in 5-10 mL of dry DMF 
and treated with 0.5-1.0 molar equivalence of Cs2CO3. The solution was stirred for 10 
minutes and 0.9-1.0 molar equivalence of 1-bromo-3-chloropropane or 1-bromo-4-
chlorobutane was added slowly to the solution over a period of 20 minutes. The reaction 
was allowed to continue stirring overnight (24 hours) at room temperature. Upon complete 
consumption of the starting material (monitored by TLC), the reaction was quenched with 
5 mL of 1.0 M HCl, 5 mL of water, and extracted with 20 mL of ethyl acetate. The 
aqueous phase was washed twice with 10 mL of ethyl acetate and discarded. The organic 
layers were pooled, washed with 20 mL brine, dried over anhydrous Na2SO4, and 
concentrated in vacuo. The residue was taken up in DCM, dry-loaded onto silica, and 
purified by normal phase flash chromatography. The separation yielded three major peaks 
that corresponded to three products; the first peak as the dialkyated species, the second and 
most prominent peak as the 7-alkylated species, and the third peak was the 3-(4’-
hydroxyphenyl) alkylation. The major peak, which contained 66-83% yield of products 
was chosen to move forward as the one half of the dimer and characterized by 1H-NMR to 
confirm structure and position of the alkyl group. 
Subsequently, the alkylchloride moiety was subjected to an azide substitution 
reaction to afford the alkylazide handle. To proceed with this, 1.5 equivalence of sodium 




of DMF within a 10 mL microwave tube. The tube was then moved a CEM Discover 




diluted with 3 washes of 10 mL ethyl acetate and separated with 30 mL of water. The 
organic layer was washed multiple times with 10 mL of water to remove excess DMF. The 
organic layer was then washed with brine, dried over anhydrous Na2SO4, and concentrated 
in vacuo. The residue was saved without further purification. The confirm the identity of 
the compound, 1H-NMR showed a distinct up-field shift of the adjacent CH2 and FT-IR 
was used to confirm the presence of the azide moiety ~2100 cm-1. 
Once the alkylazide was prepared, the alkyne handle needed for the cycloaddition 
was synthesized. The starting dihydroxy coumarin was transferred into a round bottom 
flask where 5 mL of dry DMF was added and stirred. To this, 0.5-1.0 molar equivalence of 
Cs2CO3 was added and stirred for 10 minutes. Following, 0.9-1.0 molar equivalence of 
80% propargyl bromide solution was slowly added to the stirred solution over the course 
of 10 minutes. The reaction was allowed to proceed overnight and monitored by TLC until 
all the starting material was consumed. The reaction was then quenched with 10 mL of 
1.0M HCl and diluted with water. 20 mL of ethyl acetate was added and the mixture was 
transferred to a separatory funnel. The organic layer was separated and the aqueous layer 
was washed twice with 10 mL of ethyl acetate to remove residual compound. The organic 
layers were pooled, washed with brine, dried over Na2SO4, and concentrated in vacuo. The 
residue was taken up in minimal DCM (2-3 mL) and dry-loaded onto silica gel for normal 
phase flash chromatography. The products, similarly to the alkylchloride, displayed three 
major peaks. The major second peak was identified by 1H-NMR to confirm positional 




Once both the azide and alkyne handle were produced, the coupling reaction could 
ensue. The coupling employed typical copper(I)-assisted azide alkyne cycloaddition 
(CuAAC) conditions where the azide and alkyne substituents were each dissolved in 1 mL 
of DMF mixed into a solution of 5 mL of 4:1 DMSO:DMF. After stirring for 10 minutes, 7 
mol% of sodium ascorbate solubilized in water was added to the solution and stirred for an 
additional 10 minutes. To this, a solution of 3 mol% of 10 mM 1:1 CuSO4∙5H2O:tris-[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]amine in 55% DMSO was added to the stirred 
solution and allowed to react overnight at room temperature. After the allotted time, the 
stirred solution was quenched by adding a few drops of 10% NH4OH (aq) and then flushed 
with 20 mL of water. A yellow to white precipitate formed and was filtered off. The 
precipitate was then taken up in 20 mL of ethyl acetate and washed with 5 mL of 1.0M 
HCl and 15 mL of water. The aqueous phase was discarded and the organic phase was 
washed with brine and dried over anhydrous Na2SO4. The organic phase was concentrated 
in vacuo and dry-loaded onto silica for normal phase flash chromatography. The desired 
product was isolated using 0-100 % ethyl acetate:hexanes, then 0-10 % methanol:DCM 
giving 72-94% yields and confirmed by 1H-NMR.  
 The last synthetic step involved microwave-assisted sulfation. The free 
hydroxycoumarins (demethylated monomers (2w-2y), free hydroxycoumarins (1a-1d; 2a-
2v) commercially obtained and synthetic dimers (3a-3g)) were taken up in 5 mL of 
acetonitrile (ACN), placed into a 10 mL microwave tube, and to it 6 molar equivalence of 
sulfur trioxide trimethylamine complex (SO3∙N(CH3)3) per OH was added and stirred. 




solution was allowed to stir for 10 minutes. At this point, there was a color change, 
indicating the hydroxyl groups were deprotonated. The reaction tubes were then placed 
inside the CEM microwave reactor and was allowed to react at 90-100 °C for 1 hour per 
OH being sulfated. Upon completion, the tubes and their contents were washed with DCM 
into a round bottom flask, spotted on TLC to confirm appearance of a sulfated species (10 
% methanol in DCM mobile phase; Rf between 15 and 30), and concentrated in vacuo. The 
residue was again taken up in minimal DCM and dry-loaded onto silica gel. Isolation of 
the sulfated compound utilized normal phase flash chromatography (0-30% 
methanol:DCM). Fractions containing the sulfated compound were concentrated in vacuo. 
The residue was taken up in minimal water >5 mL (or 3:1 water:methanol) and applied to a 
sephadex CM 25 sodium exchange column to produce a sodium sulfate salt from the 
alkylammonium sulfate salt. The fractions containing the compound were pooled, frozen at 
-80 °C, and lyophilized overnight. This produced a fine, off-white/yellow powder, which 
was analyzed by UPLC-MS, 1H-NMR, and 13C-NMR.  
The synthesis for the second generation CSAMs (3i and 3j) began by charging a 50 
mL round-bottom flask with 250 mg of 3-(3’,4’-dimethoxyphenyl)-7-methoxy-4-
phenylcoumarin in 5 mL of dry DCM. The flask was then put in -78 °C acetone bath. 
While stirring, 7.5 molar equivalence of 1.0M BBr3 in DCM was added dropwise to the 
stirred solution, flushed with nitrogen, and allowed to react to room temperature; over the 
course of 5 hours. Then, an ice bath replaced the acetone bath to bring the reaction to 0 °C 
and 10 mL of 1:1 methanol:water was slowly added to quench the reaction and allowed to 








ethyl acetate and washed with 15 mL of saturated ammonium chloride solution (aq.). The 
organic layer was separated and the aqueous phase was washed twice with 10 mL of ethyl 
acetate. The organic phases were pooled and washed with brine and dried over Na2SO4, 
filtered, and placed in a 250 mL round bottom flask to be condensed in vacuo. TLC (35% 
ethyl acetate:hexanes, Rf = 0.10) showed no starting material and a single spot, so the pale 
yellow residue obtained after concentration was used without any further purification; 
yield of 93% (206 mg, Figure 8, Step A). 
The now 3-(3’,4’-dihydroxyphenyl)-7-hydroxy-4-phenyl coumarin (200 mg) was 
placed in a two-neck round bottom flask and 14 mL of diphenylether was added. To this, 
1.5 molar equivalence of 1,1-dichloro-1,1-diphenylmethane was added and the flask was 
sealed and a reflux condenser was attached. The solution was littered with precipitant until 
refluxing conditions (175 °C) were reached in an oil bath for 5 hours, after which the 
homogenous solution cooled down to room temperature and crystals began forming. The 
crystals were filtered and washed with ice cold hexanes. The remaining crystals were 
transferred to a screw cap vial and dried in vacuo overnight, yielding 72% (219 mg, Figure 
8, Step B) of a diphenylmethyl (DPM) protected 3-(3’,4’-dihydroxyphenyl) moiety.  
The next step was to obtain the alkyne moiety for later usage in the cycloaddition. 
For 3i, the alkyne handle was the same as 3g. However for 3j, the alkyne handle contained 
the DPM protected 3-(3’,4’-dihydroxyphenyl) moiety, which was synthesized by adding 
1.2 molar equivalence of 80% propargyl bromide to a solution of 3 mL dry DMF, 103 mg 
of protected coumarin containing free 7-hydroxy, and 1.6 molar equivalence of Cs2CO3. 




and extracted and washed with ethyl acetate. The organic layer was washed with brine, 
dried over Na2SO4, concentrated, and dry loaded onto silica for flash chromatography (0-
60% ethyl acetate:hexanes). The fractions containing the desired product were pooled and 
concentrated in vacuo for further use (76 % yield, 97 mg, Figure 8, Step D).  
Subsequently, the free hydroxyl group on the 7-position of the DPM 3-(3’,4’-
dihydroxyphenyl) was also used with the electrophilic alkane chain. Thus, 1.2 molar 
equivalence of 1-bromo-4-chlorobutane was added to a stirred solution of the protected 
coumarin (103 mg) and 1.6 equivalence of Cs2CO3 in 3 mL dry DMF. The solution was 
allowed to react overnight and then quenched with 1.0 M HCl. 20 mL of ethyl acetate was 
added and the biphasic solution was put into a separatory funnel, where the organic layer 
was extracted. The aqueous layer was washed twice with 10 mL of ethyl acetate, after 
which the organic layers were pooled, washed with brine, dried over Na2SO4, filtered, and 
concentrated in vacuo. The remaining residue was taken up in ~5 mL of DCM and dry 
loaded onto silica gel. Flash chromatography was performed (0-60% ethyl acetate:hexanes) 
to isolate the protected, alkylated product. The fractions were pooled, concentrated, and 
dried under high vacuum overnight (89 % yield, 108 mg, Figure 8, Step C).  
The DPM protected butyl chloride coumarin and the DPM protected propargyl 
coumarin were both subjected to catechol deprotection by dissolving 108 mg and 97 mg, 
respectively in 10 mL of 80% acetic acid and refluxing for 3 hours produced the 
deprotected products, identified by TLC (70:30 hexanes:ethyl acetate, Rf 0.35 and 0.33 
respectively). The reaction mixture was cooled to room temperature and extracted with 25 




Na2SO4, filtered, and concentrated in vacuo. The residue was taken up in minimal DCM to 
be dry loaded onto silica gel and was purified by flash chromatography (0-100% ethyl 
acetate:hexanes). The fractions containing the product were pooled and concentrated in 
vacuo, and placed on high vacuum overnight yielding 88 % (69 mg) and 83 % (56 mg), 
respectively (Figure 8, Step E).  
The deprotected butyl chloride coumarin (69 mg) was dissolved in 3 mL of DMF 
and was reacted with 1.5 molar equivalence of NaN3. The reaction was heated at 70 °C for 
5 hours in a microwave tube. Once completed the reaction was diluted with 20 mL of ethyl 
acetate and washed several times with 10 mL of water to remove excess DMF. The organic 
layer was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. No 
further purification was performed for this compound. Confirmation of the alkylazide (97 
% yield, 68 mg) was done by FT-IR showing the N3 stretch (2100 cm-1) and the up-field 
shift of the adjacent CH2 triplet on 1H-NMR (Figure 8, Step F). 
Like previously used, the copper-assisted azide-alkyne cycloaddition was employed 
for dimerization of 3i precursor by dissolving 68 mg of deprotected butylazide in 1 mL of 
DMF. Then 97 mg of dichloro propargyl moiety of 3g was dissolved in 1 mL of DMF. The 
two were mixed together in 3 mL of DMSO and 7 mol% of sodium ascorbate dissolved in 
water was added to the stirred solution. After 10 minutes, 3 mol% of 1:1 
CuSO4∙5H2O:TBTA in a 55% DMSO solution was added to the reaction mixture and 
allowed to stir overnight. Upon completion, a few drops of 10% NH4OH was added, the 
solution turned blue and 20 mL of cold water was poured into the reaction tube, where a 




and kept for further use. The precipitate was taken up in 20 mL of ethyl acetate and 15 mL 
of 1.0M HCl was added. The biphasic solution was separated, the aqueous layer was 
washed twice with 10 mL of ethyl acetate, and the organic layers were pooled. The 
organics were then concentrated in vacuo, dry loaded onto silica gel, and the desired 
product was isolated by flash chromatography (0-100% ethyl acetate:hexanes to 0-10% 
methanol:DCM). The fractions containing the product were pooled and concentrated, 
yielding a yellow residue (65 % yield, 86 mg, Figure 8, Step G). 
Likewise for the 3j precursor, 77 mg (from a secondary batch) of the deprotected 
butylazide and 56 mg of the deprotected propargyl coumarin were each dissolved in 1 mL 
of DMF and mixed together in 3 mL of DMSO. Then, 7 mol% of sodium ascorbate was 
added to the stirred solution, where after 10 minutes, 3 mol % of 1:1 CuSO4∙5H2O:TBTA 
in a 55% DMSO solution was added to the reaction mixture and allowed to stir overnight. 
Upon completion, a few drops of 10% NH4OH was added, the solution turned blue and 20 
mL of cold water was poured into the reaction tube, where a yellow precipitate formed. 
After allowed to stir for 10 minutes, the precipitate was filtered and kept for further use. 
The precipitate was taken up in 20 mL of ethyl acetate and 15 mL of 1.0M HCl was added. 
The biphasic solution was separated, the aqueous layer was washed twice with 10 mL of 
ethyl acetate, and the organic layers were pooled. The organics were then concentrated in 
vacuo, dry loaded onto silica gel, and the desired product was isolated by flash 
chromatography (0-100% ethyl acetate:hexanes to 0-10% methanol:DCM). The fractions 
containing the product were pooled and concentrated, yielding an off-white residue (98 % 




The deprotected, coupled 3-(3’,4’-dihydroxylphenyl) coumarins were then sulfated 
using the same method mentioned above. The coumarins 86 mg (3i precursor) and 125 mg 
(3j precursor), respectively, were taken up in 3 mL of dry acetonitrile in a microwave tube 
with a stir bar. To that was added 12-24 molar equivalence of SO3∙N(CH3)3 and allowed to 
stir for several minutes, after which 20-40 molar equivalence of triethylamine was added. 
The solution stirred for another 10 minutes and the reaction tube was placed in a 
microwave and heated to 100 °C for 2 and 4 hours, respectively. Upon completion, the 








normal phase flash chromatography (0-30% methanol:DCM). The fractions containing the 
sulfated compound were pooled, concentrated in vacuo, and taken up in minimal water. 
The solution was then applied to a sephadex CM 25 column charged with sodium acetate, 
for sodium exchange of the amine salt. The fractions collected containing the sodium salt 
were pooled, frozen in a -80°C refrigerator, and lyophilized. This resulted in a light yellow 
powder (97 %, 103 mg, 3i) and an off-white powder (62%, 116 mg, 3j), respectively, 
which was stored at -20 °C for future use.  
2.2 CSAM Characterization 
 
 Characterization of the coumarin-based sulfated allosteric modulators utilized 
multiple techniques. 1H-NMR and 13C NMR characterizations was performed with a 400 
MHz Bruker NMR, IR measurements were done using a Varian FTIR, and MS data was 
obtained from a Waters Triple Quad Mass Spectrometer. 
3a1/3b1/3g1 – 1H NMR (Acetone-d6 400 MHz): 7.36 (m, 3H), 7.17 (dd, J = 8 Hz, 1.8 Hz, 
2H), 6.91 (d, J = 8 Hz, 2H), 6.88 (d, J = 8 Hz, 1H), 6.82 (d, J = 4 Hz, 1H), 6.74 (dd, J = 8 
Hz, 2.36 Hz, 1H), 6.54 (d, J = 8 Hz, 2H). 
3c1/3d1 – 1H NMR (Acetone-d6 400 MHz): 7.81 (s, 1H), 7.50 (d, J = 8 Hz, 2H), 7.44 (d, J 
= 8 Hz, 1H), 6.77 (d, J = 8 Hz, 2H), 6.74 (dd, J = 8 Hz, 2.32 Hz, 1H), 6.65 (d, J = 8 Hz, 
1H). 
3e1/3f1 – 1H NMR (Acetone-d6 400 MHz): 7.71 (d, J = 8 Hz, 1H), 7.21 (d, J = 8 Hz, 2H), 




3a2 – 1H NMR (Acetone-d6 400 MHz): 7.23 (m, 3H), 7.10 (dd, J = 8 Hz, 2.48 Hz, 2H), 
6.93 (m, 2H), 6.89 (d, J = 8 Hz, 2H), 6.80 (dd, J = 8 Hz, 2.54 Hz, 1H), 6.52 (d, J = 8 Hz, 
2H), 4.28 (t, J = 8 Hz, 2H), 4.02 (t, J = 8 Hz, 2H), 2.21 (quint, J = 8 Hz, 2H).  
3b2/3g2 – 1H NMR (Acetone-d6 400 MHz): 7.24 (m, 3H), 7.09 (dd, J = 8 Hz, 1.84 Hz, 
2H), 6.91 (m, 3H), 6.73 (dd, J = 8 Hz, 2.48 Hz, 1H), 6.50 (d, J = 8 Hz, 2H) 4.18 (t, J = 8 
Hz, 2H), 3.96 (t, J = 8 Hz, 2H), 1.81 (quint, J = 8 Hz, 2H), 1.72 (quint, J = 8 Hz, 2H).  
3c2 – 1H NMR (Acetone-d6 400 MHz): 7.98 (s, 1H), 7.69 (d, J = 8 Hz, 1H), 7.61 (d, J = 8 
Hz, 2H), 7.05 (s, 1H), 7.01 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.88 (d, J = 8 Hz, 2H), 4.32 (t, J = 
8 Hz, 2H), 4.08 (t, J = 8 Hz, 2H), 2.34 (quint, J = 8 Hz, 2H).  
3d2 – 1H NMR (Acetone-d6 400 MHz): 7.96 (s, 1H), 7.67 (d, J = 8 Hz, 1H), 7.58 (d, J = 8 
Hz, 2H), 7.02 (s, 1H), 6.99 (dd, J = 8 Hz, 2.36 Hz, 1H), 6.84 (d, J = 8 Hz, 2H), 4.15 (t, J = 
8 Hz, 2H), 3.92 (t, J = 8 Hz, 2H), 1.86 (quint, J = 8 Hz, 2H), 1.75 (quint, J = 8 Hz, 2H).  
3e2 – 1H NMR (Acetone-d6 400 MHz): 7.61 (d, J = 8 Hz, 1H), 7.05 (d, J = 8 Hz, 2H), 6.87 
(dd, J = 8 Hz, 2.52 Hz, 1H), 6.80 (d, J = 4 Hz, 1H), 6.79 (d, J = 8 Hz, 2H), 4.19 (t, J = 8 
Hz, 2H), 3.98 (t, J = 8 Hz, 2H), 2.31 (s, 3H), 2.21 (quint, J = 8 Hz, 2H), 2.18 (s, 3H).  
3f2 – 1H NMR (Acetone-d6 400 MHz): 7.73 (d, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, 2H), 6.98 
(dd, J = 8 Hz, 2.52 Hz, 1H), 6.93 (d, J = 8 Hz, 2H), 6.91 (d, J = 8 Hz, 1H), 4.22 (t, J = 8 
Hz, 2H), 4.01 (t, J = 8 Hz, 2H), 2.31 (s, 3H), 1.98 (quint, J = 8 Hz, 2H), 1.87 (quint, J = 8 
Hz, 2H).  
3a3 – 1H NMR (Acetone-d6 400 MHz): 7.23 (m, 3H), 7.10 (dd, J = 8 Hz, 2.48 Hz, 2H), 




2H), 4.28 (t, J = 8 Hz, 2H), 3.78 (t, J = 8 Hz, 2H), 2.21 (quint, J = 8 Hz, 2H). IR (neat): 
2102 cm-1. 
3b3/3g3 – 1H NMR (Acetone-d6 400 MHz): 7.24 (m, 3H), 7.09 (dd, J = 8 Hz, 1.84 Hz, 
2H), 6.91 (m, 3H), 6.73 (dd, J = 8 Hz, 2.48 Hz, 1H), 6.50 (d, J = 8 Hz, 2H) 4.08 (t, J = 8 
Hz, 2H), 3.34 (t, J = 8 Hz, 2H), 1.81 (quint, J = 8 Hz, 2H), 1.72 (quint, J = 8 Hz, 2H). IR 
(neat): 2098 cm-1. 
3c3 – 1H NMR (Acetone-d6 400 MHz): 7.98 (s, 1H), 7.69 (d, J = 8 Hz, 1H), 7.61 (d, J = 8 
Hz, 2H), 7.05 (s, 1H), 7.01 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.88 (d, J = 8 Hz, 2H), 4.32 (t, J = 
8 Hz, 2H), 3.81 (t, J = 8 Hz, 2H), 2.34 (quint, J = 8 Hz, 2H). IR (neat): 2119 cm-1. 
3d3 – 1H NMR (Acetone-d6 400 MHz): 7.96 (s, 1H), 7.67 (d, J = 8 Hz, 1H), 7.58 (d, J = 8 
Hz, 2H), 7.02 (s, 1H), 6.99 (dd, J = 8 Hz, 2.36 Hz, 1H), 6.84 (d, J = 8 Hz, 2H), 4.15 (t, J = 
8 Hz, 2H), 3.45 (t, J = 8 Hz, 2H), 1.86 (quint, J = 8 Hz, 2H), 1.75 (quint, J = 8 Hz, 2H). IR 
(neat): 2107 cm-1. 
3e3 – 1H NMR (Acetone-d6 400 MHz): 7.61 (d, J = 8 Hz, 1H), 7.05 (d, J = 8 Hz, 2H), 6.87 
(dd, J = 8 Hz, 2.52 Hz, 1H), 6.80 (d, J = 4 Hz, 1H), 6.79 (d, J = 8 Hz, 2H), 4.19 (t, J = 8 
Hz, 2H), 3.73 (t, J = 8 Hz, 2H), 2.31 (s, 3H), 2.21 (quint, J = 8 Hz, 2H), 2.18 (s, 3H). IR 
(neat): 2112 cm-1. 
3f3 – 1H NMR (Acetone-d6 400 MHz): 7.73 (d, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, 2H), 6.98 
(dd, J = 8 Hz, 2.52 Hz, 1H), 6.93 (d, J = 8 Hz, 2H), 6.91 (d, J = 8 Hz, 1H), 4.22 (t, J = 8 
Hz, 2H), 3.50 (t, J = 8 Hz, 2H), 2.31 (s, 3H), 1.98 (quint, J = 8 Hz, 2H), 1.87 (quint, J = 8 




3a4/3b4 – 1H NMR (Acetone-d6 400 MHz): 7.23 (m, 3H), 7.10 (m, 2H), 6.95 (m, 2H), 
6.88 (d, J = 8 Hz, 2H), 6.78 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.51 (d, J = 8 Hz, 2H), 4.81 (s, 
2H), 3.03 (s, 1H). 
3c4/3d4 – 1H NMR (Acetone-d6 400 MHz): 7.86 (s, 1H), 7.54 (m, 3H), 6.88 (d, J = 8 Hz, 
2H), 6.78 (d, J = 8 Hz, 2H), 4.82 (s, 2H), 3.04 (s, 1H). 
3e4/3f4 – 1H NMR (Acetone-d6 400 MHz): 7.61 (d, J = 8 Hz, 1H), 7.05 (d, J = 8 Hz, 2H), 
6.89 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.80 (d J = 8 Hz, 1H), 6.78 (d, J = 8 Hz, 2H), 4.82 (s, 
2H), 3.04 (s, 1H), 2.30 (s, 3H).  
3g4 – 1H NMR (Acetone-d6 400 MHz): 7.64 (d, J = 4 Hz, 1H), 7.29 (m, 3H), 7.17 (dd, J = 
8 Hz, 1.92 Hz, 2H), 7.02 (d, J = 8 Hz, 2H), 6.90 (d, J = 2.44 Hz, 1H), 6.65 (d, J = 8 Hz, 
2H), 4.79 (s, 2H), 3.09 (s, 1H). 
3a5 – 1H NMR (Acetone-d6 400 MHz): 8.37 (s, 1H), 7.39 (m, 6H), 7.29 (s, 1H), 7.22 (m, 
4H), 7.11 (s, 1H), 7.04 (m, 4H), 6.97 (m, 7H), 6.88 (dd, J = 8 Hz, 2.4 Hz, 1H), 5.29 (s, 
2H), 4.61 (t, 2H), 4.16 (t, 2H), 2.35 (quint, J = 8 Hz, 2H). 
3b5 – 1H NMR (Acetone-d6 400 MHz): 8.35 (s, 1H), 7.37 (m, 6H), 7.26 (s, 1H), 7.15 (m, 
4H), 7.08 (s, 1H), 7.04 (m, 4H), 6.91 (m, 4H), 6.87 (s, 1H), 6.54 (dd, J = 8 Hz, 2.36 Hz, 
1H), 5.29 (s, 2H), 4.50 (t, J = 8 Hz, 2H), 4.15 (t, J = 8 Hz, 2H), 2.05 (quint, J = 8 Hz, 2H), 
1.78 (quint, J = 8 Hz, 2H). 
3c5 – 1H NMR (Acetone-d6 400 MHz): 8.35 (s, 1H), 8.08 (s, 2H), 7.68 (m, 2H), 7.58 (d, J 
= 8 Hz, 4H), 7.18 (s, 1H), 7.05 (m, 3H), 6.84 (d, J = 8 Hz, 2H), 5.29 (s, 2H), 4.61 (t, J = 8 




3d5 – 1H NMR (Acetone-d6 400 MHz): 8.33 (s, 1H), 8.07 (s, 2H), 7.68 (m, 2H), 7.58 (d, J 
= 8 Hz, 4H), 7.18 (s, 1H), 7.04 (m, 2H), 6.85 (d, J = 8 Hz, 4H), 5.29 (s, 2H), 4.50 (t, J = 8 
Hz, 2H), 4.13 (t, J = 8 Hz, 2H), 2.06 (quint, J = 8 Hz, 2H), 1.77 (quint, J = 8 Hz, 2H). 
3e5 – 1H NMR (Acetone-d6 400 MHz): 8.37 (s, 1H), 8.00 (s, 2H), 7.57 (t, J = 8 Hz, 2H), 
7.04 (s, 1H), 7.02 (d, J = 8 Hz, 4H), 6.92 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.89 (m, 2H), 6.74 
(d, J = 8 Hz, 4H), 5.21 (s, 2H), 4.58 (t, J = 8 Hz, 2H), 4.08 (t, J = 8 Hz, 2H), 2.35 (quint, J 
= 8 Hz, 2H), 2.16 (s, 6H). 
3f5 – 1H NMR (Acetone-d6 400 MHz): 8.33 (s, 1H), 7.96 (s, 2H), 7.75 (t, J = 8 Hz, 2H), 
7.17 (s, 1H), 7.11 (d, J = 8 Hz, 4H), 7.07 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.99 (m, 2H), 6.84 
(d, J = 8 Hz, 4H), 5.30 (s, 2H), 4.51 (t, J = 8 Hz, 2H), 4.14 (t, J = 8 Hz, 2H), 2.25 (s, 6H), 
2.04 (quint, J = 8 Hz, 2H), 1.77 (quint, J = 8 Hz, 2H). 
3g5 – 1H NMR (Acetone-d6 400 MHz): 8.24 (s, 1H), 8.03 (s, 1H), 7.42 (m, 6H), 7.23 (m, 
4H), 7.09 (m, 3H), 7.01 (m, 4H), 6.90 (m, 5H), 5.27 (s, 2H), 4.47 (t, J = 8 Hz, 2H), 4.13 (t, 
J = 8 Hz, 2H), 1.99 (quint, J = 8 Hz, 2H), 1.70 (quint, J = 8 Hz, 2H). 
3i1/3j1 – 1H NMR (Acetone-d6 400 MHz): 7.24 (m, 3H), 7.09 (dd, J = 8 Hz, 1.8 Hz, 2H), 
6.84 (d, J = 8 Hz, 1H), 6.69 (s, 1H), 6.63 (dd, J = 8 Hz, 1.8 Hz, 1H), 6.58 (s, 1H), 6.45 (d, 
J = 8 Hz, 1H), 6.32 (dd, J = 8 Hz, 2 Hz, 1H). 
3i2/3j2 – 1H NMR (DMSO-d6 400 MHz): 7.49 (m, 11H), 7.33 (m, 3H), 7.20 (m, 2H), 6.90 





3i3/3j3 – 1H NMR (CDCl3-d1 400 MHz): 7.42 (m, 4H), 7.31 (m, 6H), 7.22 (m, 3H), 7.03 
(3H), 6.82 (s, 1H), 6.66 (m, 4H), 3.99 (t, J = 8Hz, 2H), 3.55 (t, J = 8 Hz, 2H), 1.97 (m, 
4H). 
3j4 – 1H NMR (DMSO-d6 400 MHz): 7.49 (m, 11H), 7.33 (m, 3H), 7.20 (m, 2H), 6.90 (d, 
J = 8 Hz, 1H), 6.83 (m, 3H), 6.75 (dd, J = 8 Hz, 2.4 Hz, 1H), 6.61 (dd, J = 8H, 2.4 Hz, 
1H), 5.04 (s, 2H), 3.59 (s, 1H). 
3i5/3j5 – 1H NMR (CDCl3-d1 400 MHz): 7.33 (m, 3H), 7.14 (m, 3H), 6.93 (s, 1H), 6.79 
(dd, J = 8 Hz, 2.4 Hz, 1H), 6.73 (s 1H), 6.57 (d, J = 8 Hz, 1H), 6.39 (dd, J = 8 Hz, 2.4 Hz, 
1H), 4.16 (t, J = 8 Hz, 2H), 3.67 (t, J = 8 Hz, 2H), 2.03 (m, 4H). 
3i6/3j6 – 1H NMR (Acetone-d6 400 MHz): 7.39 (m, 3H), 7.24 (m, 2H), 7.04 (d, J = 8Hz, 
1H), 6.98 (s, 1H), 6.86 (dd, J = 8 Hz, 2.4 Hz, 1H), 6.74 (s, 1H), 6.61 (d, J = 8 Hz, 1H), 
6.47 (dd, J = 8 Hz, 2.4 Hz, 1H), 4.22 (t, J = 8 Hz, 2H), 3.49 (t, J = 8 Hz, 2H), 1.98 (quint, J 
= 8 Hz, 2H), 1.86 (quint, J = 8 Hz, 2H). IR (neat): 2109 cm-1 and 2115 cm-1. 
3i7 – 1H NMR (DMSO-d6 400 MHz): 8.16 (s, 1H), 7.93 (s, 1 H), 7.34 (m, 8H), 7.16 (m, 
2H), 7.10 (m, 2H), 7.02 (m, 2H), 6.84 (m, 5H,), 6.54 (dd, J = 8 Hz, 2.4 Hz, 1H), 5.00 (s, 
2H), 4.40 (t, J = 8 Hz, 2H), 4.06 (t, J = 8 Hz, 2H), 1.95 (quint, J = 8 Hz, 2H), 1.67 (quint, J 
= 8 Hz, 2H). 
3j7 – 1H NMR (Acetone-d6 400 MHz): 7.91 (s, 1H), 7.64 (s, 1H), 7.30 (m, 8H), 7.08 (m, 
4H), 6.89 (s, 1H), 6.86 (s, 1H), 6.81 (s, 1H), 6.75 (d, J = 8 Hz, 2H), 6.70 (dd, J = 8 Hz, 2.4 
Hz, 1H), 6.59 (s, 1H), 6.46 (d, J = 8 Hz, 1H), 6.32 (dd, J = 8 Hz, 2.4 Hz, 1H), 4.99 ( s, 2H), 





1a – Sodium 6-chloro-7-methyl-2-oxo-2H-chromen-4-yl sulfate – 1H NMR (DMSO-d6 
400 MHz): 7.72 (s, 1H), 7.63 (s, 1H), 6.28 (s, 1H), 2.76 (s, 3H). 13C NMR (DMSO-d6, 100 
MHz): 161.35, 159.75, 151.46, 128.79, 122.15, 118.89, 114.85, 96.21, 52.79, 19.86. MS 
(ESI) calculated for C10H6ClNaO6S [(M-Na)]-, m/z 289.6519, found [(M-Na)]-, m/z 289.43. 
1b – Sodium 3-chloro-4-methyl-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6 
400 MHz): 7.81-7.79 (d, J = 8 Hz, 1H), 7.25-7.23 (d, J = 8 Hz, 2H), 2.57 (s, 3H). 13C NMR 
(DMSO-d6, 100 MHz): 156.74, 156.37, 151.67, 148.71, 126.38, 117.11, 116.78, 114.36, 
106.58, 16.08. MS (ESI) calculated for C10H6ClNaO6S [(M-Na)]-, m/z 289.6518, found 
[(M-Na)]-, m/z 289.39. 
1c – Sodium 6-chloro-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6 400 MHz): 
7.99-7.97 (d, J = 8 Hz, 1H), 7.87 (s, 1H), 7.59 (s, 1H), 6.43-6.41 (d, J = 8 Hz, 1H). 13C 
NMR (DMSO-d6, 100 MHz): 159.71, 152.74, 151.98, 143.13, 128.31, 119.64, 114.68, 
114.41, 107.76. MS (ESI) calculated for C9H4ClNaO6S [(M-Na)]-, m/z 275.6248, found 
[(M-Na)]-, m/z 275.37. 
1d – Sodium 6-chloro-4-methyl-2-oxo-2H-chromen-7-yl sulfate– 1H NMR (DMSO-d6 
400 MHz): 7.84 (s, 1H), 7.59 (s, 1H), 6.32 (s, 1H), 2.43 (s, 3H). 13C NMR (DMSO-d6, 100 
MHz): 159.62,152.52, 152.11, 151.97, 125.60, 119.66, 115.31, 112.92, 107.73, 18.04. MS 
(ESI) calculated for C10H6ClO6S [(M-Na)]-, m/z 289.6620, found [(M-Na)]-, m/z 289.39. 
2a – Sodium 6-chloro-3-(3,4-dimethoxyphenyl)-4-methyl-2-oxo-2H-chromen-7-yl 
sulfate – 1H NMR (DMSO-d6, 400 MHz): 7.81 (s, 1H), 7.53 (s, 1H), 6.97-6.94 (d, J = 12 
Hz 1H), 6.85 (s, 1H), 6.78-6.75 (d, J = 12 Hz, 1H), 3.73 (s, 3H), 3.67 (s, 3H), 2.20 (s, 3H). 




122.68, 119.67, 115.87, 114.05, 111.49, 107.46, 55.63, 55.53, 16.47. MS (ESI) calculated 
for C18H14ClNaO8S [(M-Na)]-, m/z 425.8018, found [(M-Na)]-, m/z 425.52. 
2b – Sodium 3-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6, 
400 MHz): 8.00 (s, 1H), 7.63-7.61 (d, J = 8 Hz, 1H), 7.51-7.37 (m, 4H), 7.22 (s, 1H), 7.14-
7.12 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100M Hz): 159.00, 157.05, 154.21, 142.96, 
134.26, 132.86, 131.82, 130.14, 129.26, 129.11, 127.19, 123.65, 116.82, 113.92. MS (ESI) 
calculated for C15H8ClNaO6S [(M-Na)]-, m/z 351.7228, found [(M-Na)]-, m/z 351.42. 
2c – Sodium 6-chloro-4-methyl-2-oxo-3-phenyl-2H-chromen-7-yl sulfate – 1H NMR 
(DMSO-d6, 400 MHz): 7.83 (s, 1H), 7.55 (s, 1H), 7.41-7.32 (m, 3H), 7.26-7.23 (d, J = 8 
Hz, 2H), 2.17 (s, 3H). 13C NMR (DMSO-d6, 100M Hz): 159.71, 151.75, 151.18, 
147.13,134.46, 130.19,130.12, 128.09, 127.87, 126.06, 124.92, 119.76, 115.77, 107.53, 
16.39. MS (ESI) calculated for C16H10ClNaO6S [(M-Na)]-, m/z 365.7498, found [(M-Na)]-, 
m/z 365.48. 
2d – Sodium 3-(2-chlorophenyl)-2-oxo-4-phenyl-2H-chromen-7-yl sulfate – 1H NMR 
(DMSO-d6, 400 MHz): 7.38-7.11 (m, 12H), 7.00-6.98 (d, J = 8 Hz, 1H). 13C NMR 
(DMSO-d6, 100M Hz): 161.49, 159.42, 156.92, 154.68, 153.58, 133.80, 133.54, 132.65, 
132.51, 129.58, 128.82, 128.64, 128.49, 128.30, 127.99, 127.20, 126.62, 116.87, 113.42, 
106.96, 102.33. MS (ESI) calculated for C21H12ClNaO6S [(M-Na)]-, m/z 427.8208, found 
[(M-Na)]-, m/z 427.53. 
2e – Sodium 3-(3-chlorophenyl)-2-oxo-4-phenyl-2H-chromen-7-yl sulfate – 1H NMR 
(DMSO-d6, 400 MHz): 7.32-7.25 (m, 4H), 7.18-7.11 (m, 5H), 7.03-7.01 (dd, J = 8 Hz, 




156.83, 153.39, 151.66, 151.23, 136.60, 134.13, 132.00, 130.39, 129.37, 129.22, 128.96, 
128.38, 128.23, 127.89, 127.19, 122.85, 116.62, 115.08, 106.80. MS (ESI) calculated for 
C21H12ClNaO6S [(M-Na)]-, m/z 427.8208, found [(M-Na)]-, m/z 427.54. 
2f – Sodium 3-(3-chlorophenyl)-4-methyl-2-oxo-2H-chromen-7-yl sulfate – 1H NMR 
(DMSO-d6, 400 MHz): 7.80-7.78 (d, J = 8 Hz, 1H), 7.52-7.43 (m, 3H), 7.31-7.29 (m, 1H), 
7.26-7.21 (m, 2H), 2.26 (s, 3H). 13C NMR (DMSO-d6, 100M Hz): 13C NMR (DMSO-d6, 
100M Hz): 159.89, 156.59, 152.83, 148.59, 139.05, 136.87, 132.71, 130.00, 129.06, 
127.79, 126.50, 122.71, 116.40, 114.96, 106.48, 16.42. MS (ESI) calculated for 
C16H10ClNaO6S [(M-Na)]-, m/z 365.7498, found [(M-Na)]-, m/z 365.48. 
2g – Sodium 3-(4-chlorophenyl)-4-methyl-2-oxo-2H-chromen-6-yl sulfate – 1H NMR 
(DMSO-d6, 400 MHz): 7.52-7.51 (d, J = 4 Hz, 1H), 7.47-7.45 (d, J = 8 Hz, 2H), 7.42-7.39 
(dd, J = 8 Hz, 1H), 7.32-7.29 (d, J = 8 Hz, 3H), 2.16 (s, 3H). 13C NMR (DMSO-d6, 100M 
Hz): 159.79, 149.83, 148.02, 147.97, 133.49, 132.69, 132.31, 132.09, 128.16, 125.19, 
124.77, 120.06, 116.74, 116.63, 116.57, 16.44. MS (ESI) calculated for C16H10ClNaO6S 
[(M-Na)]-, m/z 365.7498, found [(M-Na)]-, m/z 365.49. 
2h – Sodium 3-(2-chlorophenyl)-4-methyl-2-oxo-2H-chromen-7-yl sulfate – 1H NMR 
(DMSO-d6, 400 MHz): 7.74-7.72 (d, J = 8 Hz, 1H), 7.54-7.51 (m, 1H), 7.41-7.32 (m, 3H), 
7.20-7.15 (m, 2H), 2.09 (s, 3H). 13C NMR (DMSO-d6, 100M Hz): 159.10, 156.75, 153.02, 
149.62, 133.63, 133.29, 132.04, 130.03, 129.23, 127.34, 126.51, 121.85, 116.55, 114.62, 
106.64, 16.05. MS (ESI) calculated for C16H10ClNaO6S [(M-Na)]-, m/z 365.7498, found 





2i – Sodium 3-(2,4-dichlorophenyl)-4-methyl-2-oxo-2H-chromen-7-yl sulfate – 1H 
NMR (DMSO-d6, 400 MHz): 7.72 (s, 1H), 7.54-7.33 (m, 5H), 2.09 (s, 3H). 13C NMR 
(DMSO-d6, 100 MHz): 158.97, 156.96, 153.08, 150.10, 134.48, 133.76, 133.43, 132.75, 
128.83, 127.60, 126.57, 120.77, 116.58, 114.49, 106.63, 16.07. MS (ESI) calculated for 
C16H9Cl2NaO6S [(M-Na)]-, m/z 400.1918, found [(M-Na)]-, m/z 399.46. 
2j – Sodium 3-(2,4-dichlorophenyl)-4-methyl-2-oxo-2H-chromen-6-yl sulfate – 1H 
NMR (DMSO-d6, 400 MHz): 7.72 (s, 1H), 7.54-7.33 (m, 5H), 2.08 (s, 3H). 13C NMR 
(DMSO-d6, 100 MHz): 158.79, 154.01, 150.00, 149.72, 148.25, 134.28, 133.88, 133.24, 
132.65, 128.85, 127.64, 125.32, 123.17, 119.53, 116.81, 16.10. MS (ESI) calculated for 
C16H9Cl2NaO6S [(M-Na)]-, m/z 400.1918, found [(M-Na)]-, m/z 399.47. 
2k – Sodium 3-(2,4-dichlorophenyl)-2-oxo-4-phenyl-2H-chromen-7-yl sulfate – 1H 
NMR (DMSO-d6, 400 MHz): 7.32–7.25 (m, 4H), 7.18–7.12 (m, 5H), 7.03–7.01 (m, 2H), 
6.91-6.89 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 177.67, 170.10, 160.22, 
156.83, 153.39, 151.66, 151.23, 136.60, 134.13, 132.00, 130.39, 129.37, 129.22, 128.96, 
128.23, 127.89, 127.19, 122.85, 116.62, 115.08, 106.80. MS (ESI) calculated for 
C21H11Cl2NaO6S [(M-Na)]-, m/z 462.2628, found [(M-Na)]-, m/z 461.07. 
2l – Sodium 3-(4-chlorophenyl)-2-oxo-4-phenyl-2H-chromen-7-yl sulfate – 1H NMR 
(DMSO-d6, 400 MHz): 7.31-7.26 (m, 4H), 7.17-7.08 (m, 7H), 7.03-7.00 (d, J = 12 Hz, 
1H), 6.91-6.88 (d, J = 12 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 161.23, 160.47, 
159.94, 154.41, 151.94, 134.40, 133.53, 132.55, 132.52, 132.47, 131.78, 128.97, 128.76, 
128.28, 128.22, 127.48, 127.43, 121.15, 113.27, 112.31, 102.20. MS (ESI) calculated for 




2m – Sodium 3-(2,4-dichlorophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR 
(DMSO-d6, 400 MHz): 8.02 (s, 1H), 7.68 (s, 1H), 7.63-7.61 (d, J = 8 Hz, 1H), 7.48 (s, 1H), 
7.47 (s, 1H), 7.22 (s, 1H), 7.15-7.12 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 
158.88, 157.14, 154.25, 143.36, 133.96, 133.91, 133.25, 133.14, 129.26, 128.81, 127.42, 
122.53, 116.86, 113.84, 106.55. MS (ESI) calculated for C15H7Cl2NaO6S [(M-Na)]-, m/z 
386.1648, found [(M-Na)]-, m/z 385.44. 
2n – Sodium 3-(4-bromophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6, 
400 MHz): 8.20 (s, 1H), 7.65-7.57 (m, 5H), 7.19 (s, 1H), 7.13-7.10 (d, J = 8 Hz, 1H). 13C 
NMR (DMSO-d6, 100 MHz): 159.66, 156.87, 153.86, 140.92, 134.08, 131.12, 130.43, 
129.15, 122.95, 121.57, 116.76, 114.50, 106.28, 104.80, 99.49. MS (ESI) calculated for 
C15H8BrNaO6S [(M-Na)]-, m/z 396.1768, found [(M-Na)]-, m/z 397.38. 
2o – Sodium 3-(4-bromophenyl)-2-oxo-4-phenyl-2H-chromen-7-yl sulfate – 1H NMR 
(DMSO-d6 400 MHz): 7.40-7.36 (m, 6H), 7.23-7.21 (d, J = 8 Hz, 2H), 7.12-7.08 (m, 3H), 
6.98-6.96 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 179.59, 160.26, 156.73, 
153.33, 151.40, 144.49, 134.22, 133.79, 133.00, 132.79, 130.40, 129.00, 128.37, 128.27, 
127.84, 123.08, 120.61, 116.60, 115.13, 106.79, 90.08. MS (ESI) calculated for 
C21H12BrNaO6S [(M-Na)]-, m/z 472.2748, found [(M-Na)]-, m/z 471.56. 
2p – Sodium 4-(4-chlorobenzyl)-2-oxo-3-phenyl-2H-chromen-7-yl sulfate – 1H NMR 
(DMSO-d6 400 MHz): 7.42-7.39 (d, J = 12 Hz, 1H), 7.36-7.28 (m, 3H), 7.26-7.18 (m, 5H), 
7.11-7.09 (d, J = 8 Hz, 2H), 6.99-6.96 (dd, J = 10, 4 Hz, 1H), 3.97 (s, 2H). 13C NMR 
(DMSO-d6, 100 MHz): 173.47, 160.75, 160.43, 154.47, 148.44, 137.10, 134.73, 134.62, 




99.38, 44.22, 33.95. MS (ESI) calculated for C22H14ClNaO6S [(M-Na)]-, m/z 441.8478, 
found [(M-Na)]-, m/z 441.63. 
2q – Sodium 3-(4-bromophenyl)-4-methyl-2-oxo-2H-chromen-7-yl sulfate – 1H NMR 
(DMSO-d6 400 MHz): 7.80-7.78 (d, J = 8 Hz, 1H), 7.67-7.65 (d, J = 8 Hz, 2H), 7.32-7.30 
(d, J = 8 Hz, 2H), 7.25-7.22 (m, 2H), 2.26 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): 
159.89, 156.58, 155.99, 152.81, 148.33, 134.00, 132.52, 131.06, 126.44, 122.89, 121.16, 
116.39, 115.01, 106.48, 101.41, 16.40. MS (ESI) calculated for C16H10BrNaO6S [(M-Na)]-, 
m/z 410.2038, found [(M-Na)]-, m/z 409.45. 
2r – Sodium 3-(3-bromophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6 
400 MHz): 8.31 (s, 1H), 7.96 (s, 1H), 7.77-7.75 (d, J = 8 Hz, 1H), 7.72-7.70 (d, J = 8 Hz, 
1H), 7.62-7.60 (d, J = 8 Hz, 1H), 7.46-7.42 (t, J = 8 Hz, 1H), 7.27 (s, 1H), 7.21-7.19 (d, J = 
8 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 159.65, 157.05, 153.95, 141.49, 137.70, 
137.21, 130.93, 130.88, 130.30, 129.25, 127.40, 122.53, 121.41, 116.79, 114.43, 106.28. 
MS (ESI) calculated for C15H8BrNaO6S [(M-Na)]-, m/z 396.1768, found [(M-Na)]-, m/z 
397.42. 
2s – Sodium 3-(3-chlorophenyl)-4-methyl-2-oxo-2H-chromen-6-yl sulfate – 1H NMR 
(DMSO-d6 400 MHz): 7.61-7.59 (m, 1H), 7.50-7.48 (m, 3H), 7.45 (s, 1H), 7.40-7.37 (m, 
1H), 7.33-7.31 (m, 1H). 2.24 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): 159.71, 149.90, 
148.17, 148.05, 136.80, 132.75, 130.02, 129.87, 128.93, 127.92, 125.04, 124.84, 120.01, 
116.73, 116.64, 44.20, 16.44. MS (ESI) calculated for C16H10ClNaO6S [(M-Na)]-, m/z 




2t – Sodium 3-(4-chlorophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6 
400 MHz): 8.27 (s, 1H), 7.79-7.77 (d, J = 8 Hz, 2H), 7.71-7.69 (d, J = 8 Hz, 1H), 7.54-7.52 
(d, J = 8 Hz, 2H), 7.27 (s, 1H), 7.21-7.19 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100 
MHz): 167.40, 159.72, 156.85, 153.86, 140.95, 133.70, 132.94, 130.14, 129.15, 128.19, 
122.90, 116.76, 114.50, 106.28, 44.21. MS (ESI) calculated for C15H8ClNaO6S [(M-Na)]-, 
m/z 351.7228, found [(M-Na)]-, m/z 351.46. 
2u – Sodium 3-(3-chlorophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6 
400 MHz): 8.33 (s, 1H), 7.83 (s, 1H), 7.73-7.69 (m, 2H), 7.53-7.49 (m, 2H), 7.28 (s, 1H), 
7.22-7.20 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 159.65, 157.00, 153.93, 
141.50, 136.94, 132.87, 131.07, 130.04, 129.26, 128.06, 127.01, 122.59, 116.77, 114.44, 
106.26. MS (ESI) calculated for C15H8ClNaO6S [(M-Na)]-, m/z 351.7228, found [(M-Na)]-, 
m/z 351.46. 
2v – Sodium 4-(6-bromo-4-methyl-2-oxo-2H-chromen-3-yl)phenyl sulfate – 1H NMR 
(DMSO-d6 400 MHz): 7.94 (s, 1H), 7.73 (dd, J = 8 Hz, 1H), 7.36 (d, J = 8 Hz, 1H), 7.17 
(m, 4H), 2.22 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): 159.46, 153.39, 151.06, 146.67, 
133.93, 130.64, 128.48, 128.14, 126.97, 122.18, 119.88, 119.83, 118.45, 116.31, 26.17, 
16.49. MS (ESI) calculated for C16H10BrNaO6S [(M-Na)]-, m/z 410.2038, found [(M-Na)]-, 
m/z 409.49. 
2w – Sodium 2-hydroxy-4-(2-oxo-4-phenyl-7-(sulfonatooxy)-2H-chromen-3-yl)phenyl 
sulfate – 1H NMR (DMSO-d6 400 MHz): 7.38-7.31 (m, 5H), 7.20 (d, J = 8 Hz, 2H), 7.07 
(dd, J = 8 Hz, 2.32 Hz, 1H), 6.93 (d, J = 8 Hz, 1H), 6.64 (dd, J = 8 Hz, 2.16 Hz, 1H). 13C 




129.02, 128.97, 128.20, 128.13, 127.76, 127.47, 124.48, 123.98, 122.72, 118.27, 116.40, 
115.30, 106.67, 99.49. MS (ESI) calculated for C21H12Na2O11S2 [(M-2Na)]-, m/z 504.4155, 
found [(M-2Na)]2-, m/z 252.51. 
2x – Sodium 4-(6,8-dichloro-2-oxo-4-phenyl-2H-chromen-3-yl)phenyl sulfate – 1H 
NMR (DMSO-d6 400 MHz): 8.02 (d, J = 2.4 Hz, 1H), 7.44-7.37 (m, 3H), 7.25-7.23 (m, 
2H), 7.07 (d, J = 8 Hz, 2H), 7.00 (d, J = 8 Hz, 2H), 6.86 (d, J = 8 Hz, 1H). 13C NMR 
(DMSO-d6, 100 MHz):  160.44, 154.36, 150.33, 148.27, 134.89, 132.31, 132.21, 131.93, 
130.36, 130.01, 129.88, 129.83, 129.45, 129.24, 128.95, 126.46, 124.46, 123.26, 122.66, 
120.26, 120.20. MS (ESI) calculated for C21H11Cl2NaO6S [(M-Na)]-, m/z 462.2628, found 
[(M-Na)]-, m/z 461.58. 
2y – Sodium 4-(2-oxo-4-phenyl-7-(sulfonatooxy)-2H-chromen-3-yl)phenyl sulfate – 1H 
NMR (DMSO-d6 400 MHz): 7.40-7.31 (m, 4H), 7.23-7.21 (m, 2H), 7.08-6.93 (m, 6H). 13C 
NMR (DMSO-d6, 100 MHz): 160.62, 156.40, 153.15, 152.58, 150.83, 147.52, 134.60, 
131.12, 129.04, 128.55, 128.23, 128.18, 127.71, 123.88, 118.91, 118.89, 118.82, 116.49, 
115.36, 114.40, 106.74. MS (ESI) calculated for C21H12Na2O10S2 [(M-2Na)]-, m/z 
488.4165, found [(M-2Na)]2-, m/z 244.54. 
3a – Sodium 4-(2-oxo-7-((1-(3-((2-oxo-4-phenyl-3-(4-(sulfonatooxy)phenyl)-2H-
chromen-7-yl)oxy)propyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-phenyl-2H-chromen-3-
yl)phenyl sulfate – 1H NMR (DMSO-d6 400 MHz): 8.37 (s, 1H), 7.40-7.32 (m, 6H), 7.29 
(s, 1H), 7.22-7.19 (m, 4H), 7.11 (s, 1H), 7.04-7.01 (m, 4H), 6.97-6.93 (m, 7H), 6.88 (dd, J 
= 8 Hz, 2.4 Hz, 1H), 5.29 (s, 2H), 4.61 (t, 2H), 4.16 (t, 2H), 2.35 (quint, J = 8 Hz, 2H). 13C 




150.96, 150.94, 147.96, 143.19, 141.93, 134.61, 131.14, 129.02, 128.50, 128.38, 128.36, 
128.24, 128.19, 127.46, 125.00, 123.60, 123.13, 123.02, 122.63, 118.84, 114.19, 113.92, 
113.81, 112.85, 112.65, 102.77, 101.47, 101.18, 99.50, 67.38, 65.51, 65.49, 59.27, 52.77, 
50.97, 48.67, 46.63, 46.59, 42.40, 29.22, 9.92. MS (ESI) calculated for C48H33N3Na2O14S2 
[(M-2Na)]-, m/z 939.8985, found [(M-2Na)]2-, m/z 470.45. 
3b – Sodium 4-(2-oxo-7-((1-(4-((2-oxo-4-phenyl-3-(4-(sulfonatooxy)phenyl)-2H-
chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-phenyl-2H-chromen-3-
yl)phenyl sulfate – 1H NMR (DMSO-d6 400 MHz): 8.35 (s, 1H), 7.40-7.31 (m, 6H), 7.29 
(s, 1H), 7.21-7.19 (m, 4H), 7.11 (s, 1H), 7.04-7.01 (m, 4H), 6.97-6.94 (m, 4H), 6.92 (s, 
1H), 6.90 (dd, J = 8 Hz, 2.36 Hz, 1H), 5.29 (s, 2H), 4.50 (t, J = 8 Hz, 2H), 4.15 (t, J = 8 
Hz, 2H), 2.05 (quint, J = 8 Hz, 2H), 1.78 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6, 100 
MHz): 203.94, 196.89, 195.80, 175.54, 166.72, 165.45, 161.34, 161.31, 160.73, 157.49, 
155.67, 154.06, 152.59, 141.90, 140.87, 139.56, 134.65, 134.61, 131.14, 129.52, 129.22, 
129.15, 129.12, 129.03, 128.61, 128.52, 128.50, 128.45, 128.36, 128.31, 128.24, 124.82, 
123.13, 120.66, 118.93, 118.83, 113.93, 112.68, 101.52, 101.12, 94.16, 88.00, 67.65, 
61.78, 52.77, 51.47, 49.08, 26.41, 7.31. MS (ESI) calculated for C49H35N3Na2O14S2 [(M-
2Na)]-, m/z 953.9255, found [(M-2Na)]2-, m/z 477.49. 
3c – Sodium 4-(2-oxo-7-((1-(3-((2-oxo-3-(4-(sulfonatooxy)phenyl)-2H-chromen-7-
yl)oxy)propyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-3-yl)phenyl sulfate – 1H 
NMR (DMSO-d6 400 MHz): 8.38 (s, 1H), 8.18 (s, 2H), 7.72-7.62 (m, 6H), 7.25-7.22 (m, 
5H), 7.05-7.04 (m, 2H), 6.99 (dd, J = 8 Hz, 2.4 Hz, 1H), 5.30 (s, 2H), 4.62 (t, J = 8 Hz, 




175.55, 159.13, 144.57, 139.90, 139.49, 136.17, 135.28, 132.43, 131.38, 128.92, 128.85, 
126.18, 123.16, 122.63, 119.91, 117.12, 116.36, 115.79, 110.72, 109.93, 108.24, 103.12, 
102.74, 88.62, 79.35, 78.57, 72.02, 71.32, 66.46, 56.09, 47.12, 42.14, 40.72, 37.56, 13.22, 
10.00. MS (ESI) calculated for C36H25N3Na2O14S2 [(M-2Na)]-, m/z 787.7025, found [(M-
2Na)]2-, m/z 394.24. 
3d – Sodium 4-(2-oxo-7-((1-(4-((2-oxo-3-(4-(sulfonatooxy)phenyl)-2H-chromen-7-
yl)oxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-3-yl)phenyl sulfate – 1H 
NMR (DMSO-d6 400 MHz): 8.35 (s, 1H), 8.18 (s, 2H), 7.71-7.62 (m, 6H), 7.25-7.22 (m, 
5H), 7.04-6.97 (m, 3H), 5.29 (s, 2H), 4.51 (t, J = 8 Hz, 2H), 4.16 (t, J = 8 Hz, 2H), 2.06 
(quint, J = 8 Hz, 2H), 1.79 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6, 100 MHz): 181.55, 
175.12, 174.05, 168.82, 160.00, 154.61, 154.52, 145.95, 141.93, 141.60, 139.90, 129.56, 
129.39, 128.85, 124.83, 123.15, 122.93, 119.91, 113.39, 113.10, 112.90, 105.82, 101.07, 
100.68, 94.85, 67.61, 61.76, 57.57, 49.07, 45.69, 44.08, 26.43, 25.47, 18.59, 13.88, 7.98, 
3.25. MS (ESI) calculated for C37H27N3Na2O14S2 [(M-2Na)]-, m/z 801.7295, found [(M-
2Na)]2-, m/z 401.27. 
3e – Sodium 4-(4-methyl-7-((1-(3-((4-methyl-2-oxo-3-(4-(sulfonatooxy)phenyl)-2H-
chromen-7-yl)oxy)propyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-oxo-2H-chromen-3-
yl)phenyl sulfate – 1H NMR (DMSO-d6 400 MHz): 8.38 (s, 1H), 7.79 (d, J = 8 Hz, 1H) 
7.76 (d, J = 8 Hz, 1H), 7.26-7.20 (m, 8H), 7.09-6.97 (m, 4H), 5.31 (s, 2H), 4.63 (t, J = 8 
Hz, 2H), 4.17 (t, J = 8 Hz, 2H), 2.27 (s, 6H), 2.40 (quint, J = 8 Hz, 2H). 13C NMR 
(DMSO-d6, 100 MHz): 161.19, 160.63, 160.22, 153.66, 153.58, 153.06, 147.91, 147.87, 




112.68, 112.48, 101.33, 100.93, 84.69, 67.56, 61.73, 56.57, 52.78, 49.09, 44.34, 36.61, 
26.59, 26.44, 25.48, 16.44, 13.45, 10.45, 3.42. MS (ESI) calculated for C38H29N3Na2O14S2 
[(M-2Na)]-, m/z 815.7565, found [(M-2Na)]2-, m/z 408.71. 
3f – Sodium 4-(4-methyl-7-((1-(4-((4-methyl-2-oxo-3-(4-(sulfonatooxy)phenyl)-2H-
chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-oxo-2H-chromen-3-
yl)phenyl sulfate – 1H NMR (DMSO-d6 400 MHz): 8.36 (s, 1H), 7.79 (m, 2H), 7.22-7.19 
(m, 9H), 7.09-6.98 (m, 3H), 5.30 (s, 2H), 4.52 (t, J = 8 Hz, 2H), 4.16 (t, J = 8 Hz, 2H), 
2.27 (s, 6H), 2.07 (quint, J = 8 Hz, 2H), 1.79 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6, 
100 MHz): 168.27, 166.21, 161.19, 160.63, 160.22, 153.66, 153.58, 153.06, 147.91, 
147.87, 141.98, 130.79, 129.05, 127.00, 126.96, 124.80, 123.09, 122.90, 119.84, 113.84, 
113.57, 112.68, 112.48, 101.33, 100.93, 84.69, 82.62, 67.56, 61.73, 56.57, 52.78, 49.09, 
44.34, 26.59, 26.44, 25.48, 16.44, 13.45, 3.42. MS (ESI) calculated for C39H31N3Na2O14S2 
[(M-2Na)]-, m/z 829.7835, found [(M-2Na)]2-, m/z 415.29. 
3g – Sodium 4-(7-((1-(4-((3-(2,4-dichlorophenyl)-2-oxo-4-phenyl-2H-chromen-7-
yl)oxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-oxo-4-phenyl-2H-chromen-3-yl)phenyl 
sulfate – 1H NMR (DMSO-d6 400 MHz): 8.24 (s, 1H), 8.03 (s, 1H), 7.41-7.34 (m, 6H), 
7.24-7.18 (m, 4H), 7.10-7.08 (m, 3H), 7.03-6.94 (m, 4H), 6.91-6.86 (m, 5H), 5.07 (s, 2H), 
4.46 (t, J = 8 Hz, 2H), 4.11 (t, J = 8 Hz, 2H), 1.99 (quint, J = 8 Hz, 2H), 1.71 (quint, J = 8 
Hz, 2H). 13C NMR (DMSO-d6, 100 MHz): 185.99, 161.31, 160.64, 159.15, 154.45, 
154.14, 150.97, 148.97, 146.95, 142.47, 140.96, 134.63, 133.65, 131.67, 131.45, 131.12, 
130.60, 130.11, 129.14, 129.07, 129.02, 128.63, 128.49, 128.33, 128.23, 127.96, 125.11, 




68.03, 67.65, 61.02, 56.52, 49.03, 47.23, 45.67, 26.37, 25.45, 16.06, 5.86. MS (ESI) 
calculated for C49H34Cl2N3NaO10S [(M-Na)]-, m/z 927.7718, found [(M-Na)]-, m/z 928.83. 
3i – Sodium 4-(7-(4-(4-((4-(6,8-dichloro-2-oxo-4-phenyl-2H-chromen-3-
yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)butoxy)-2-oxo-4-phenyl-2H-chromen-3-yl)-
1,2-phenylene bis(sulfate) – 1H NMR (DMSO-d6 400 MHz): 8.23 (s, 1H), 8.01 (s, 1H), 
7.42 (m, 8H), 7.23 (d, J = 8 Hz, 2H), 7.17 (d, J = 8 Hz, 2H), 7.09 (d, J = 8 Hz, 2H), 6.91 
(m, 5H), 6.59 (dd, J = 8 Hz, 2.4 Hz, 1H), 5.07 (s, 2H), 4.47 (t, J = 8 Hz, 2H), 4.13 (t, J = 8 
Hz, 2H), 2.07 (quint, J = 8 Hz, 2H), 1.73 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6, 100 
MHz): 161.26, 160.48, 159.14, 157.45, 154.15, 150.91, 148.95, 146.94, 143.24, 142.52, 
142.45, 134.47, 133.65, 131.66, 130.59, 129.07, 128.94, 128.63, 128.49, 128.36, 128.20, 
128.05, 127.96, 125.88, 125.11, 124.48, 124.39, 123.07, 122.70, 121.35, 118.29, 113.77, 
113.59, 112.58, 101.09, 67.63, 61.04, 49.03, 26.40, 25.46. MS (ESI) calculated for 
C49H33Cl2N3Na2O14S2 [(M-Na)]-, m/z 1045.82, found [(M-SO3Na)]-, 942.13 m/z. 
3j – Sodium 4-(7-((1-(4-((3-(3,4-bis(sulfonatooxy)phenyl)-2-oxo-4-phenyl-2H-
chromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-oxo-4-phenyl-2H-chromen-
3-yl)-1,2-phenylene bis(sulfate) – 1H NMR (DMSO-d6 400 MHz): 8.33 (s, 1H), 7.38 (m, 
13H), 6.96 (m, 5H), 6.74 (m, 3H), 5.33 (s, 2H), 4.49 (t, J = 8 Hz, 2H), 4.13 (t, J = 8 Hz, 
2H), 2.03 (quint, J = 8 Hz, 2H), 1.76 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6 100 
MHz): 203.94, 196.89, 195.80, 175.54, 166.72, 165.45, 161.34, 161.31, 160.73, 157.49, 
155.67, 154.06, 152.59, 141.90, 140.87, 139.56, 134.65, 134.61, 131.14, 129.52, 129.22, 
129.15, 129.12, 129.03, 128.61, 128.52, 128.50, 128.45, 128.36, 128.31, 128.24, 124.82, 




61.78, 52.77, 51.47, 49.08, 26.41, 25.43. MS (ESI) calculated for C49H33N3Na4O22S4 [(M-









CHAPTER 3 Evaluation of Inhibition and Thrombin-CSAM Binding Mechanism 
 
 
Many glycosaminoglycans exist as highly negatively charged ligands, which 
typically interact with the surface of proteins through electrostatic forces by pairing with 
positively charged residues on the surface of said protein (lysine, arginine, and histidine 
residues). These interactions commonly occur at allosteric (distal) sites on the protein 
inducing some type of conformational change of the protein. The general theory behind 
how these interactions take place is the polyelectrolyte theory, which explains that the 
binding is actually an entropic event143. In this theory, we assume that sodium cations are 
bound to the sulfate groups in a manner to stabilize the large, negative charge density; 
which is thermodynamically unfavorable143. In the event the GAG’s sulfate comes into 
contact with a protein’s positively charged surface, for example an arginine, the sodium 
ion is displaced and the arginine’s positive charge stabilizes the sulfate’s negative charge; 
providing a more favorable interaction. Although these types of binding are generally 
homologous interactions (i.e., Na+ v. R-NH4+), the sulfates present on GAGs have been 
shown to prefer the guanidinium group of the arginine residues over the ammonium group 
of lysine (Arg > Lys > His)143. This lays towards the specificity GAGs possess for their 




GAG recognition and specificity relies on many other factors. First, spacing of Arg 
and Lys residues is essential for proper binding and decreases the possibility of non-
specific interactions143. This is also done by the protein surface displaying other residues. 
For example, thrombin’s exosite 2 contains hydrophobic patches around key residues, as 
well as strategically placed serines, glutamines, and asparagines for enhancement of 
binding.  Another considerable aspect is the topography of the protein’s surface, by which 
the GAG interacts with. For instance, heparin interacts with both thrombin and 
antithrombin; this facilitates the inactivation of thrombin by antithrombin through a 
heparin-induced, pseudo-intramolecular reaction. This is attained by thrombin having a 
lower binding affinity to heparin than antithrombin. Thrombin’s binding affinity (KD) for 
heparin is 6-10 µM144, while antithrombin’s binding affinity is ~10 nM95. This 1000-fold 
difference in affinities, allows tight binding of antithrombin to heparin, while thrombin is 
moves toward the antithrombin reactive loop. This information shows why heparin acts in 
an indirect manner. Thus, the binding of heparin to thrombin does not cause a 
dysfunctional conformational change of thrombin’s orthosteric (active) site. Many studies 
have shown that thrombin’s allosteric (or exo-) sites and the active site are interconnected; 
thus binding at one site induces a change to the subsequent sites145, but not seen with 
heparin binding to thrombin113.  
Taking into consideration the combination of thermodynamic effects of 
polyelectrolytes, additional hydrophilic or hydrophobic interactions, and allosteric effects, 
compounds can be derived to specifically bind to thrombin’s exosites. The coumarin-based 




selectively target thrombin, at a specific exosite. Weighing into the conformational 
changes they induce, could alter the ability for thrombin to hydrolyze thrombin’s 
substrates. Additionally, using minimal sulfates while increasing the hydrophobicity of the 
CSAMs eliminates the polyelectrolyte phenomenon, effectively using the sulfate as a 
steering group and increases the necessity for other binding examples. 
3.1. Dose-Dependent Inhibition 
 Thrombin is the major regulatory serine protease within the coagulation cascade. 
Its mechanism within the active site utilizes a catalytic triad composed of histidine 57, 
aspartate 102, and serine 195, in collaboration with a water molecule to hydrolyze the 
carboxy-side of the arginine or lysine residues13,109. This mechanism allows for a much 
simpler approach to probing the active site’s function of an activated thrombin. By 
obtaining synthetic peptides containing p-nitroanilide groups on the carboxy-side of the 
arginine’s, when thrombin hydrolyzes the substrate, p-nitroaniline is released and can be 
monitored at 405 nm. This technique has been used extensively for thrombin, as well as 
other serine proteases like factor Xa and factor XIa118,120,122,124–127,129,146.  
The first generation library of CSAMs was initially screened against thrombin, 
factor Xa and factor XIa, which are considered major targets for anticoagulation. The 
experiments tested CSAMs at a high concentration of 250 µM in duplicates. Depending on 
the enzyme present in the well being screened, appropriate chromogenic substrates were 
used; H-D-cyclohexylalanyl-Ala-Arg-p-nitroanilide for thrombin, methoxycarbonyl-D-
cyclohexylglycyl-Gly-Arg-p-nitroanilide for factor Xa, and L-pyroGlu-Pro-Arg-p-




 For thrombin, the experiments were carried out in 180 µL of buffer (20 mM Tris-
HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH = 7.4) at 25 °C, 5 µL of 240 nM 
thrombin and 10 µL of CSAM (or vehicle, DMSO) were incubated for 10 minutes. Then, 
with the addition of 5 µL of substrate (2 mM), the initial rates obtained from p-nitroaniline 
production were monitored over a period of 60 seconds on the Flexstation III plate reader. 
For factor Xa, 180 µL of buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% 
PEG 8000, 0.02% Tween 80, pH 7.4) was added to each well followed by 5 µL of 43.5 nM 
enzyme and 10 µL of CSAM or vehicle. After a 10 min incubation, 5 µL of 5 mM 
substrate was added to each well simultaneously and allowed to react for 300 seconds at 37 
ºC. Lastly for factor XIa screens, 85 µL of buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% 
PEG 8000, 0.02% Tween 80, pH 7.4) was added to each well, followed by 7 µL of 15.3 
nM enzyme and 3 µL of CSAM or vehicle and incubated for 10 min at 37 ºC. After the 
incubation period, 5 µL of 6.9 mM S-2366 was and allowed to react for 300 seconds at 37 
ºC. Any sample that showed ≥20% reduction in initial rate compared to vehicle was 
considered a “hit”. A total of eleven compounds produced hits, ten were identified for 




These eleven CSAMs were then tested in a dose-response manner to assess the 
half-maximal inhibitory concentration (IC50), efficacy of inhibition (ΔY), and Hill slope 
(HS) against their respected enzymes, calculated through non-linear regression analysis 
𝑌 = 𝑌0 +
𝑌𝑀−𝑌0
1+10(log⁡[𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟]0−𝑙𝑜𝑔⁡𝐼𝐶50)×𝐻𝑆
  (Equation 1). Similar to the protocol above, serial 
dilutions of stock CSAM in DMSO were prepared (0.04 - 5 mM) giving way to 
concentrations ranging from 0.002 - 250 µM in the wells. The experimental data produced 
dose-response curves calculating the fractional activity (Y) at each concentration of the 
inhibitors tested against each protease; see Table 1. 
The analysis provided extremely interesting data. The compounds against factor Xa 
were very mild in potency, having all IC50s ≥ 13 µM, and were not very attractive to 
pursue further (Table 1). For factor XIa, the CSAMs behaved similarly to SAMs 
previously synthesized and tested127,129. The IC50s for monomers were relatively high, 220 




compounds to induce inhibition of factor XIa. The dimeric CSAMs ranged in IC50s from 
97 – 31 µM, of which 3g was the most potent SAM identified to date (Table 1). Similarly 
to previous SAMs tested127,129,146, the CSAMs showed high Hill slopes owing to the 
cooperativity of the dimeric factor XIa, but all possessed ΔY > 80%. 
In the case of thrombin, the active CSAMs ranged in IC50s from 0.2 – 58 µM, 
describing the most potent SAMs to date (Figure 10). More strikingly however, was the 
efficacies of inhibition. The ΔYs ranged from 22 – 73%, suggesting that the CSAM 
scaffold inherently induces 
partial inhibition. The 
exception to this was the 
compound 3h, which is 3g 
without the sulfate, or 
known as 3g5 as depicted by 
the NMR data. This could 
mean that the binding of 
CSAM to thrombin, induces 
a slight conformational 
change to the orthosteric site, allowing it to remain partially active. This also suggests that 
the sulfate is indeed required for proper binding of the CSAM to thrombin.  
3.1.1 Structure-Activity Relationships 
In order to fully understand what was causing the active CSAMs to inhibit 




identify the compound’s structural groups necessary for activity by comparing against 
various structural differences at that position on the molecule, which is then compared to 
the activity it induces on the target. First, looking at the monomeric sulfated coumarins, 
only three were active toward thrombin (2e, 2k and 2p). These three possessed bulky 
phenyl (or 4-chlorobenzyl) groups at the 4-position. Also, the monomers all contained 
chloro groups, either on the 3-(phenyl) or 4-(benzyl) moiety, suggesting that significant 
hydrophobic interactions are at play inhibiting thrombin. It is worth noting that not all 
compounds with bulky moieties at the 4-position inhibited thrombin. Additionally, 
compounds containing the sulfate at the 7-position were favored over the 6-position, or at 
the 4-(4’-hydroxyphenyl) position. Increasing the sulfate count as in 2w or 2y was not 
favorable for inhibition of thrombin. 
In contrast, all dimeric CSAMs displayed good inhibition potencies (IC50 < 20 
µM). Multiple variations were involved with the dimers, including chain length, linker 
position, number of sulfates, and 4-position moieties. First linker length varied between 3 
and 4 carbons, which did not alter the inhibition significantly. Linker position gave way to 
either alkylation at the 7-position yielding head-to-head or 7-7’ dimers, and one head-to-
tail or 7-4’ dimer. Dimers 3a – 3f were 7-7’ dimers consisting of a total of two sulfates, 
one at each 4-(4’-hydroxyphenyl) position, while 3g, the 7-4’ dimer contained one sulfate 
at the 4-(4’-hydroxylphenyl) position. Lastly, the 4-position varied by phenyl, methyl, and 
hydrogen. The original observation that the 4-phenyl group was more potent held true, and 




3g contained all the structural elements of the most active dimers and monomers including 
a sulfated 4-(4’-hydroxyphenyl), 4-position phenyl, and aryl chloride substituents.  
3.2 Michaelis-Menten Kinetics 
 The inhibition profiles of CSAMs show interesting results when compared to other 
compounds against the same proteases. For thrombin, the molecule 3g presents a 
nanomolar IC50 while allowing the enzyme to remain active. Likewise, 3g also is shown to 
be the most potent sulfated allosteric modulator of FXIa to date127,129. Thus, it is of high 
priority to understand the binding mechanism of 3g and its represented library. Typically 
to achieve this, Michaelis-Menten kinetic studies are performed to observe the enzyme’s 
catalytic rate to hydrolyze various concentrations of a substrate and applying the 
parameters to the equation: 𝑣0 =
𝑉𝑀𝐴𝑋[𝑆]
[𝑆]+𝐾𝑀
 (Equation 2). This can be performed in the 
absence or presence of an inhibitor. As the concentration of the inhibitor increases from the 
control, there can be decreases in the VMAX (maximum velocity or = kcat[E]0; kcat is the 
catalytic rate and [E]0 is the initial enzyme concentration), the KM (Michaelis constant or 
the substrate concentration at ½ VMAX), or both. Decreases in the KM represent competitive 
inhibition, decreases in the VMAX represent non-competitive inhibition, and decreases in 
both represent un-competitive inhibition.  
 Considering 3g was the most potent compound against thrombin and factor XIa, we 
chose it to represent the CSAM library and test its kinetics, respectively. In a similar 




NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, 
pH = 7.4) was incubated with 5 µL of 240 
nM thrombin and 10 µL of vehicle, 0.5, 
3.74, or 50 µM of 3g (0.025, 0.187, 2.5 
µM in the well) for 10 minutes at 25 °C. 
After the incubation period, 5 µL of 
Spectrozyme TH dilutions ranging from 
0.019 – 10 mM were added and the initial 
rate of hydrolysis was monitored at 405 
nm for p-nitroaniline production at a 
constant 25 °C. The slopes generated from 
the Flexstation III were inputted into 
SigmaPlot and applied to equation 2. The data revealed that as the concentration of 3g 
increased from 0 to 2.5 µM, the KM remained within the measured range for thrombin 
activity uninhibited as shown in Figure 11. However, the increase in 3g did cause the 
VMAX to decrease in a concentration dependent manner, shown in Figure 11. This supports 
a non-competitive mechanism of binding, suggesting allostery.  
 Likewise, with factor XIa, 85 µL of factor XIa buffer (50 mM Tris-HCl, 150 mM 
NaCl, 0.1% PEG 8000, 0.02% Tween 80, pH 7.4) was incubated with 7 µL of 15.3 nM 
enzyme and 3 µL of vehicle, 7.5, 15, 30, or 45 µM for 10 minutes at 37 ºC. After the 




405 nm for 300 seconds at a constant 
temperature of 37 °C. The slopes 
generated by the Flexstation III were 
applied to equation 2 in SigmaPlot. The 
data from this showed a non-competitive 
mechanism of binding as well. The KM 
remained within standard deviation of 
uninhibited factor XIa. Although, the 
VMAX decreased in a concentration 
dependent manner. Comparing the 
kinetics of 3g with thrombin and factor 
XIa, both indeed maintain a non-
competitive mechanism, however, at 
saturation of 3g against thrombin, the rate 
of hydrolysis does not become diminished beyond ~50%. The same cannot be said for 
factor XIa, because as the concentration of 3g reaches saturation, the rate of hydrolysis 
continues to become abolished. This further supports the phenomenon of allosteric, partial 
inhibition. 
3.3 Exosite Competition 
 As mentioned earlier, thrombin possesses two distinct allosteric sites called exosite 
1 and exosite 2. These exosites are selective to a number of different ligands. Exosite 1 




thrombomodulin, hirudin, and heparin cofactor II109. Conversely, exosite 2 binds 
exclusively with heparin/heparin sulfate, chondroitin sulfate of thrombomodulin, 
glycoprotein 1bα, and γ’-fibrinogen109. It is safe to assume that because of these sudden, 
yet significant differences in structural features, synthetic compounds can selectively target 
one exosite over the other.  
 To assess whether 3g binds to exosite 1 or 2, competition studies are performed to 
investigate such a phenomenon. For exosite 1, hirudin peptide (HirP, [5F]-Hir-(54-65)-
(SO3-)) is a truncated, fluoresceinylated version of the anticoagulant hirudin, which is 
found in the salivary glands of leeches147. The HirP does not possess the portion of the 
peptide that interacts and inactivates thrombin’s active site, thus can be used to probe 
exosite 1. Likewise, unfractionated heparin (UFH) was used for probing exosite 2 
interactions. As mentioned previously, UFH does not interfere with thrombin’s ability to 
hydrolyze substrate. The experiments utilized the calculated KD of HirP or UFH for 
thrombin and appropriate concentrations are used to show absence of competitor, the KD 
concentration, and two-fold the KD concentration. If there is a change in the dose-response 
curves, showing an increased IC50, the competitor is competing with 3g at that exosite.  
 For exosite 1 competition studies, appropriate volumes (175 or 170 µL) of buffer 
(20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH = 7.4) were 
incubated with 5 µL of 240 nM thrombin, 10 µL of DMSO or varying concentrations of 3g 




of 500 mM HirP were added. After 
ten minutes of incubation at 25 °C, 
5 µL of Spectrozyme TH (2 mM) 
was added to the reaction and 
monitored for 60 seconds at 405 
nm. Slopes generated from the 
Flexstation III were input into 
SigmaPlot using Equation 1.  
 Similarly for exosite 2, 
adjusted volumes (177 or 174 µL) 
of buffer (20 mM Tris-HCl, 100 
mM NaCl, 2.5 mM CaCl2, 0.1% 
PEG 8000, pH = 7.4) were 
incubated with 5 µL of 240 nM of 
thrombin, 10 µL of DMSO or 
varying concentrations of 3g (50 – 
0.2 µM) giving 2.5 – 0.001 µM, and 3 µL of vehicle, 3 µL of 761 µM, or 6 µL of 761 µM 
UFH were added. After the ten-minute incubation, 5 µL of Spectrozyme TH was added 
and monitored for initial rate of hydrolysis (60 seconds) at 405 nm. The slopes generated 
from the Flexstation III were input into SigmaPlot using Equation 1.  
Hirudin peptide’s binding affinity for thrombin has been determined to be 12.5 nM, 




response profiles generated did not 
seem to differ significantly, nor did 
the IC50 generated (Table 2 and 
Figure 13A). However in the 
presence of HirP, the IC50 of 3g 
increased by 50% (from 236 nM to 
327 and 330 nM). This 
phenomenon led us to believe that 
the interactions at exosite 1 caused 
a slight conformational change to exosite 2, resulting in the decreased potency of 3g to 
exosite 2. For this to hold true, there must be competition at exosite 2 with UFH. Analysis 
of the dose-response profiles of UFH (at 0, 11.4, and 22.8 µM) showed concentration-
dependent increases of the IC50 from 170 nM at 0 µM UFH, to 285 nM and 577 nM for 
11.4 and 22.8 µM, respectively (Table 2 and Figure 13B). An interesting observation of 
the dose-response profiles of exosite 2 competition was that as the concentration of UFH 
increased, the Hill slope also increased. As increased Hill slopes generally mean enhancing 
or inducing cooperativity of ligand binding to protein148, this same phenomenon may be 
occurring to the system considering 3g has a 100-fold higher binding affinity than UFH (as 




) (Equation 3; Table 2) showed that the 3g did not compete 




UFH for exosite 2. This supports exosite 2 as the primary binding site of 3g and that it 
indeed binds in an allosteric region of thrombin. 
3.4 Mutant Studies 
 Considering the general binding region of 3g was identified as exosite 2, further 
investigation into the specific residues involved with binding was essential. Typically, 
mutation studies such as alanine scans, give pertinent information regarding what single 
residues are responsible for binding by replacing them with an alanine residue. Our 
previous work involving exosite 2 binders have led us to using mutants that have arginines 
and lysines of exosite 2 mutated to alanines124,125,128. The information obtained from dose-
response profiles generally show a 2 to 10-fold decrease in potency when the arginine or 
lysine involved in binding the sulfate(s) of SAMs is mutated. These residues can be 
mapped out to assist in the identification of the specific binding pocket. A few difficulties 
are observed with this technique however, especially with 3g considering it only contains 
one sulfate. First, mutating surface arginines and lysines may affect the folding of 
thrombin or changes in structure and conformation. This must be taken into account 
because thrombin’s activity is so highly influenced by small changes on the surface, it may 
cause alterations in activity and binding. Second, usually compounds tested using this 
method contain multiple sulfates at different positions. This gives way to sulfate-R/K 
interaction mapping. With 3g possessing one sulfate, we may be only able to identify one 
residue responsible for binding; unless the R/K mutation influences a favorable hydrogen 
bonding of ligand to another residue, thus increasing the potency of 3g. Lastly, mutants of 




thrombin. The lack of glycosylation has been shown to cause improper quaternary (4°) 
folding of proteins and change thermodynamic properties necessary for ideal function and 
propensity149. This may affect thrombin in the same manner.  
 To obtain useful data from the thrombin mutants, dose-response profiles generated 
from incubation with dilutions of 3g in the presence of recombinant wild type thrombin 
were compared against the mutants K236A, K235A, R233A, R175A, R173A, K169A, 
R165A, R126A, R101A, R97A, and R93A (K240A was found to be completely inactive 
and removed from the experimental data). The mutants were kindly provided by the Rezaie 
laboratory (St. Louis University), where their individual optical densities (ODs) were 
reported. Prior to performing the hydrolysis assays, the concentrations of the obtained 
mutants were determined from their ODs and used accordingly. Similar to the previous 
dose-response experiments, 180 µL of buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM 
CaCl2, 0.1% PEG 8000, pH 7.4) was incubated at 25 °C with 5 µL of 240 nM recombinant 
thrombins (determined from OD) and 10µL of DMSO or 3g (0.04 - 5 mM). After ten 
minutes, 5 µL of 2 mM Spectrozyme TH was added and monitored at 405 nm for 60 
seconds at a constant 25 °C. 
 As shown in Figure 14, the wild type thrombin results in an IC50 ~400 nM; about 




this is most likely due to decreased 
activity and incomplete quaternary 
conformation from lacking 
glycosylation, we used this as our 
control IC50. The subsequent 
thrombin mutants showed varying 
effects resulting from 3g interactions 
(Table 3). Most notably was the lack 
of statistically significant increases of IC50 with a single residue; going against what was 
originally predicted to be observed. What we instead observed for R101A and R93A, was 
a 2.3-fold increase in potency, yielding an IC50 of 170 nM. We could only make the 
rationale that the mutation and loss of the 
arginine(s) at those positions resulted in 
increasing the binding affinity of 3g to 
thrombin, by most likely inducing a more 
favorable interaction or conformation.  
3.5 Computational Docking 
 In lieu of the mutant studies not 
identifying a specific residue responsible 
for binding the sulfate of 3g, we took to 
using computational docking and scoring 




from the mutants’ data. Our lab has previously used docking functions to aid with 
identification of allosteric binding sites for glycosaminoglycans, their derivatives, and 
GAG mimetics150. Typically two major scoring functions are used, GoldScore and 
ChemPLP, which cluster and rank the best binding pose over a number of iterations. 
ChemPLP was used first to rank and score the docking poses and GoldScore was 
subsequently used to rescore the docking poses. Using the algorithms in this manner 
inserts a checks and balance system. ChemPLP is much more efficient at analyzing 
hydrophobic and salt interactions, while GoldScore is more efficient at hydrophilic 
interactions. Thus because 3g contains mainly hydrophobic with the highly likelihood of 
an electrostatic interaction, ChemPLP was chosen as the first filter. 
 To assess 3g as a ligand for thrombin, it was first drawn in SYBYL-X, a molecular 
modeling and docking software. To the structure energy minimization was executed to 
give the optimal conformation and torsion angles of the rotatable bonds in the structure. 
Then, the x-ray crystal structure of thrombin (3EQ0) bound to a hirudin variant at exosite 1 
and the active site was uploaded into SYBYL-X from the Protein Data Bank. The crystal 
structure’s ligands such as water, sodium, and the hirudin variant were removed from the 
structure and side chains were minimized to their lowest energies. The remaining outlier 
rotamers not visible in the original crystal structure, were added minimized and fixed. 
Once completed, the file containing the minimized thrombin and 3g were transferred to the 





 To perform the initial wild type thrombin docking, a centroid was set in the middle 
of exosite 2 with a radius of 20 Å. Upon 3g docking, 300 generic algorithm (GA) iterations 
were performed in triplicate and binding poses were clustered with an RMSD ≤ 2.5 Å to 
categorize into tight clusters. The initial ranking and scoring was performed using 
ChemPLP and was rescored with GoldScore. Subsequently, each alanine mutation was 
installed into the thrombin structure individually and the methyl group of the alanine was 
used as the centroid of the 20 Å radius. Likewise, 3g was docked into these individual 
mutated structures using the parameters as described above. Figure 15 shows the top 
scored poses for each set of runs for wild type and the individual mutations. 
 Analysis of the docking poses show several interesting aspects. To examine the 
relevance of exosite 2 binding, we aligned the crystal structure 1XMN, which shows 
thrombin bound to heparin with the minimized 3EQ0 crystal structure to define the heparin 
binding pocket Figure 15A. Applying the poses of 3g predicted to bind to thrombin 
showed that 3g binds in the same binding pocket as heparin. This was regarded as a 
positive observation, because experimental evidence shows 3g binding at the heparin 
binding site. Upon further investigation, it seems that phenyl O-sulfate of 3g may be 
binding in a pocket made up of R126 and R233. This influence of two arginines binding 
one sulfate, may explain why mutations at these residues do not alter the IC50s observed in 




(R126 or R233), simply 
forms a stronger electrostatic 
interaction with the 
remaining arginine available; 
instead of sharing a partial 
charge by the two arginines. 
To confirm this 
experimentally however, a 
double mutation (R126A and 
R233A) would have to be 
obtained and the dose-
response profile would need 
to be evaluated. It is 
important to note that when 
3g lacks a sulfate and is the 
hydroxyl, no inhibition is 
observed. This suggests that 
the sulfate is indeed essential 
for binding and inducing 
inhibition of thrombin. 
 Further insight into the 




was obtained by investigating the individual mutations of exosite 2 itself; most notably, the 
R93A and R101A mutations. Structurally, these two residues are adjacent to one another 
and tend to show similar effects to how 3g binds when they are individually mutated. For 
both mutations versus the wild type, the docking showed the triazole ring shifting to a 
more favorable position, where the amines can act as hydrogen bond acceptors for K240 
and K236. These interactions are posed as too far away (> 4 Å) for the wild type docking, 
but still may be involved depending on the rotamers of K240 and K236 (Figure 15B and 
C). 
 Additionally, the unique feature of 3g is that it contains a very hydrophobic tail 
with two aryl chlorides in addition to the necessity of the 4-phenyl on the coumarin cores; 
suggested to be important for high affinity binding. In the docked poses it shows that both 
4-phenyls are set in hydrophobic pockets where π-π and cation-π interactions can have 
much greater influence over the compounds that contained the methyl or hydrogen groups 
at the 4-position. In reference to the dichloro-tail, it appears to show halogen bonding with 
the ammonium group of K87 at an acceptable angle (observed θ = 125-155°; reported θ = 
165-180° for R-Cl---NR3) and distance (observed distance ~ 3.2 Å; reported distance 3.27 
Å) (Figure 15B and C). All of the tail end docked poses, with the exception of R175A, are 
relatively conserved to the K87 ammonium group. It is important to note that with regard 
to the halogen bonding angle to the ammonium group, the K87 side chain rotamer is fixed 
and under no constriction would most likely have a more acceptable angle (closer to θ = 
165-180°). This collective information strongly suggests the necessity of the dichloro 




competition studies and clarifies the results of the mutant studies performed. The data 
obtained suggest viable poses and binding partners of 3g to thrombin’s exosite 2.  
3.6 Thermodynamic Binding Affinities 
 According to our IC50 data, 3g binds quite tightly to have such high potency for an 
allosteric interaction with an enzyme. To obtain more applicable information of its binding 
characteristics, we obtained the binding affinities through fluorescence changes as a ligand 
is titrated into the system, taking into account dilution factors. The characteristic loss or 
gain in fluorescence intensity as the ligand concentration increases, results directly from 
the ligand binding to thrombin. This loss or gain of fluorescence can be then used to 
calculate the binding affinity (KD) using the quadratic equation 
 (Equation 4) because the free 
enzyme (initial enzyme) concentration is known.  
 The binding affinity of 3g was therefore determined by first, addition of 180 μL of 
buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH 7.4) to a 
quartz cuvette and placed inside the fluorometer to measure background fluorescence. 
Fluorescence intensities were monitored by excitation at 490 nm and emission at 525 nm 
using slit widths of 0.5 mm throughout the experiments. Then 20 μL of 2 μM fluorescein-
labeled (f-FPRck-) human α-thrombin (f-TH) was added to the cuvette, mixed, and placed 













titration of 1 μL additions of 3g, which 
was monitored after each addition, until 
the intensity began to remain unchanged 
with excess 3g. The KD of the 3g–
thrombin complex was calculated using 
Equation 4, in which ∆F is the change 
in fluorescence from the formation of 
the 3g–thrombin complex with each 
addition of 3g. F0 is the initial 
fluorescence of f-TH with buffer, 
∆FMAX represents the maximum 
observed change in fluorescence due to 
3g saturation of f-TH, and [Th]0 is the 
initial concentration of f-TH unbound. 
The binding was assumed to possess a stoichiometry of 1:1. The data obtained from the 
fluorescence studies was input into SigmaPlot, using Equation 4. The studies revealed that 
3g has a binding affinity for thrombin of 143 ± 12 nM, with a ΔFMAX of ~28%, as seen in 
Figure 16A. This thermodynamic affinity is comparable and is within the deviation of the 
IC50 (187 ± 40 nM). 
 With this information in hand along with the docking results, we wanted to 
investigate whether addition of a sulfate at the 3-(3’-hydroxylphenyl) position would incur 




contained two arginines. As synthesized and described in Chapter 2, Section 1, the 
compound 3i contained the 3-(3’,4’-di-O-phenylsulfate). To assess the binding affinity of 
3i, the same experiment as stated above was implemented, but instead of titrating in 3g, 3i 
was used instead. The results we observed were to our surprise that, 3i showed a > 15-fold 
loss in affinity (KD = 2171 nM; ΔFMAX = ~57%) (Figure 16B). This detrimental loss in 
affinity suggested that the meta-sulfate adjacent to the para-sulfate was most likely 
causing steric clash or hindrance with the binding pocket. This further supported the 
likelihood of the phenyl sulfate of 3g binding within the pocket made up of R126 and 
R233, because the bisulfate is too bulky to make a proper fit.  
3.7 Allostery-Induced Dysfunction of Thrombin’s Orthosteric Site 
 Understanding the mechanism behind binding and the location of CSAMs binding 
to thrombin is an essential aspect of drug discovery. One elusive detail missing from these 
GAG mimetics was how the CSAMs were inducing allosteric, partial inhibition of 
thrombin. We knew that proteins, like receptors, had the ability to adopt ligand-induced 
conformations that allowed the receptor to not produce a signal at maximal efficiency. The 
ligand can bind to an allosteric site or to the agonist’s binding site and induce the change 
from there134,136. Likewise, ligands can also induce a type of partial inhibition on soluble, 
smaller, dimeric enzymes like phosphodiesterase 4137, or hemoglobin, a tetrameric protein 
when CO competes with O2 for the heme151.   
A significant difference in those systems compared to thrombin is that it is not only 
a conformationally flexible protease, but is also monomeric. This dramatically complicates 




bind natural substrate is viewed as a cooperative effect. For example with hemoglobin, one 
molecule of oxygen binds to one of the four subunits of the tetramer at slow relative rate. 
This induces a conformational change, and subsequent oxygen molecules can then bind at 
a faster rate; causing a conformational change every time152. For thrombin however, it does 
not contain multiple domains or even a dimeric structure. Therefore, comprehending on a 
structural level how CSAMs induce submaximal enzymatic activity, without 
crystallographic information, casts doubt on the phenomenon. Thus strong experimental 
information to support such a claim is desired. The other option is that CSAMs induce 
dynamic allostery, which alters the free energy of thrombin’s conformational space 
through enthalpic and entropic changes. Distinguishing between the two type of allostery 
would greatly assist in understanding the mechanism of the observed partial inhibition. 
3.7.1 Collisional Fluorescence Quenching 
 There are limited techniques available to probe conformational change of a protein 
without the use of NMR or x-ray crystallography, that do not require expensive 
technologies (i.e. surface plasmon resonance or mass spectroscopy)153–155. To overcome 
this hurdle, we implemented a system where an active site fluorophore-bound thrombin 
(fTH) could be utilized as an internal probe. The system would work as such, because 
when the chloromethylketone of f-FPRck covalently binds to thrombin’s active site serine 
(Ser195), the arginine lays within the S1 pocket, proline within the S2 pocket, 
phenylalanine within the S3 pocket, and the fluorophore (in this case fluorescein) lays 
within the S4 pocket of thrombin’s active site. Under normal and uninhibited dynamic 




fluorescein molecule resides in the pocket, it would be available to collisional quenching 
agents156. In this case, two collisional quenching agents were sampled, acrylamide and NaI, 
however the iodide quencher gave more significant quenching and was used throughout 
the experiments157. The basis of the experiments was that if 3g or another SAM were 
causing full or partial inhibition, then there would be noticeable differences in the two 
SAMs versus the uninhibited thrombin. This is due to the conformational change in and 
around the active site, which would cause changes to the iodide’s ability to access the 
fluorophore. This could be measured using the Stern-Volmer equation  
(Equation 5), where the change in fluorescence intensity versus the concentration of 
collisional quencher is linearized; then the slopes of each experiment could be compared.  
 To perform the initial uninhibited experiments, 180 µL of buffer (20 mM Tris-HCl, 
100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH 7.4) was added to a clean quartz 
cuvette and the background fluorescence was measured (constant λEX = 490 nm, λEM = 525 
nm, 0.5 mm slit widths). To this, 20 µL of 2 µM fTH was added and its basal fluorescence 
𝐹𝑜
𝐹




intensity was measured. Then, 1 µL of 10 
M NaI was added, mixed, and measured 
for intensity. This we repeated five times 
until equilibrium was reached and no 
more loss in fluorescence was observed. 
For quenching in the presence of 
inhibitors (3g and benzofuran trimer 
(BT)), we chose to keep the 
concentration of the inhibitors at 90% 
saturation (3g = 1 µM for 90% and BT = 
2.5 µM for 90%), due to the compounds 
precipitating at high concentrations. The 
3g experiments were carried out using 
177.5 µL of buffer (20 mM Tris-HCl, 
100 mM NaCl, 2.5 mM CaCl2, 0.1% 
PEG 8000, pH 7.4) in a quartz cuvette, 
monitored the same as above. Then 20 
µL of 2 µM fTH was added and a reading was taken for the initial fluorescence. Following 
2.5 µL of 80 µM 3g, the solution was mixed, incubated at room temperature for 5 minutes, 
and measured for fluorescence intensity. Lastly, the 1 µL increments of 10 M NaI were 
added and measured individually six times. Similarly for BT (with the exception of 




observe the changes in fluorescence intensity (Figure 17A). The intensities measured were 
input into an Excel file and dilution factors were taken into account to receive accurate 
quenching agent concentrations. The data was then applied to Equation 5, where the term 
KSV represents the Stern-Volmer constant, which portrays the slope of the linear 
relationship, [Q] is the quencher concentration, F0 is the initial fluorescence and F is the 
fluorescence intensity at a particular [Q]. 
 Analysis of the data revealed that fTH in the absence of inhibitor produced a KSV of 
2.37 ± 0.14 M-1, corresponding to saturated quenching of the fluorescein. However in the 
presence of 3g, the KSV reduced to 1.19 ± 0.06 M-1, see Figure 17B. Such a significant 
decrease suggests that 3g induces a conformational change of the protein’s region 
surrounding the fluorescein in the S4 pocket. Likewise, fTH in the presence of BT showed 
a more significant reduction in the KSV (0.69 ± 0.02 M-1). This result suggests that BT 
induces a larger conformational change to the surround residues around S4. In comparison 
to the control (absence of inhibitor) to 3g and BT, the 3g’s KSV is 50% of the uninhibited, 
while the BT’s KSV is 71% of the uninhibited. If this corresponds to the ΔY values 
generated through dose-response profiles, the ΔY of 3g (47%) compares very well with the 
percentage of KSV (%KSV) observed in the quenching studies. The comparison of BT’s ΔY 
(79%) also matches well with the %KSV of 71%. These results signify that differential 
conformational changes can be achieved with small molecule, allosteric modulators of 
thrombin, and the extent of the changes depends on the ligand used for inhibition. 




 The results discussed above show definitive examples that there is indeed a 
modulation of conformational changes to thrombin’s structure, using different exosite 2 
targeted ligands; resulting in reduced catalytic efficiency (kcat/KM). However to be 
thorough and subject this theory to scrutiny, we chose to develop a label-free assay to 
investigate the change to thrombin’s active site induced by 3g using an endogenous 
biomolecule known to exclusively interact with thrombin’s active site. This assay utilized 
antithrombin III (AT), an endogenous serpin, known to contain an inactivation loop that 
covalently inactivates thrombin’s active site serine92,96. The methodology includes using 
excess AT in the presence of thrombin over a period of 6 half-lives, to obtain the kinetic 
rate of inactivation. If the presence of increased concentrations of 3g (from 0 to near 
saturation) show a decrease in the rate compared to an uninhibited system, then 3g is truly 
causing allosteric dysfunction of the catalytic triad residues, and embellishes on the 
biophysical mechanism of how 3g is partially inhibiting thrombin. It is of importance to 
note that the antithrombin reaction is uncatalyzed, meaning unfractionated heparin was not 
used within the experiment. We eliminated the use of UFH because in the presence of 
heparin, antithrombin inactivation of thrombin is accelerated by ~4000-fold. This would 
render us unable to perform this type of experiment because the reaction kinetics would be 
too fast to observe.  
Initial experiments using the uninhibited system contained a fixed concentration of 
6 nM of α-thrombin incubated with 0 mM 3g (vehicle = DMSO) in buffer (20 mM Tris-
HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH 7.2) for 10 minutes at 25 °C. The 




time point (t = 0 seconds), an aliquot of sample was mixed with 2 mM Spectrozyme TH 
and monitored on the Flexstation for 60 seconds at 405 nm. The Spectrozyme was used to 
quantify the amount of active thrombin available, and the t = 0-time point would be used to 
normalize the data. Subsequent time points were taken at 240, 480, 960, 1920, 3840, and 
7680 seconds by removing aliquots of the reaction and mixing with Spectrozyme TH. 
Similarly, the inhibited system containing either 75, 225, or 675 nM of 3g were 
investigated using the same time points and procedure for monitoring.  
Analysis of the raw data involved first inputting the slopes obtained from the 
Flexstation into an Excel spread sheet, taking averages of the individual experiments for 
each concentration of 3g used. To normalize the data, each averaged slope at its respected 
time point was divided into the zero-time point, where t0s/t0s = %normalized 0s, t240s/t0s = 
%normalized 240s, etc. The measured activity from the beginning of the experiment to the last 
time point was input into the standard exponential decay equation [𝐴] = [𝐴]0𝑒
−𝑘𝑜𝑏𝑠𝑡 
(Equation 6) assuming pseudo-first order rate constant, the observed rate (kobs), at each 
concentration of 3g. The intrinsic second-order rate constant of antithrombin inhibition of 
thrombin (kint) was calculated by inputting the kobs from Equation 6 into 𝑘𝑖𝑛𝑡 = 𝑘𝑜𝑏𝑠[𝐴𝑇]0, 
Equation 7. The intrinsic rate constant (kint) was then plotted against the % concentration of 
thrombin–3g complex, obtained from quadratic equation 8, 
, to derive the linear 
relationship of the different kints of antithrombin inhibition of thrombin–3g complex. 











varying 3g levels discussed above. The comparison of the decay profiles using the control 
versus the 3g experiments, show a concentration dependent reduction in the rate of 
antithrombin inactivation. This suggested that in the presence of 3g, thrombin’s active site 
is protected from antithrombin’s inactivation loop. However, to understand if thrombin 
remains active, even at 100% 3g saturation, the derived intrinsic rate constant must be used 
to compare in an expected linear manner against the calculated thrombin-3g concentration; 
which we derived with Equation 8. Figure 18B showed that kint versus the concentration of 
thrombin-3g complex as a percent, 
would be expected to remain 33 ± 12% 
active at saturation. The ability of 
thrombin to remain active at 3g 
saturation compares relatively well with 
the ΔY observed from dose-response 
profiles (ΔY = 47%), as well as the 
reduction of quenching (%KSV = 50%). This observation fully supports the hypothesis that 
an intermediate conformational change of thrombin’s active site induced by the allosteric 
effector 3g can cause alteration in the catalytic efficiency and by the same principle, to 
thrombin’s ability to cleave substrate. We propose that the inability of antithrombin to 
interact and inhibit thrombin in the presence of 3g is directly caused by this conformational 
change of the active site (described in Figure 19).  
To further validate this, several experiments were performed to assess 3g’s effect 




itself. This ensured that effects observed in the inactivation assay are due solely to 3g’s 
interaction with thrombin. The primary experiment was a dose-response inhibition, similar 
to the ones described in Section 1 of this chapter. In brief, 6 nM of thrombin, various 3g 
concentrations, and 100 nM of antithrombin were incubated together in thrombin buffer 
(20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH = 7.4) over the 
course of five minutes at 25 °C. Then Spectrozyme TH was added to the solution and 
monitored for p-nitroaniline release at 405 nm. The linear slopes of the residual thrombin 
activity for each concentration of 3g were input into SigmaPlot and applied to Equation 1. 
As seen in comparative Figure 18E, the IC50s between the (-) AT and (+) AT show no 
significant difference, suggesting that the presence of AT does not affect 3g’s ability to 
inhibit thrombin.  
We then wanted to establish whether 3g was binding to antithrombin. For this we 
used a fluorometric thermodynamic binding assay similar to the one used in Section 6. 
There was however a significant difference in that the antithrombin did not possess a 
labeled fluorophore. We turned to use of 1-anilinonapthalene-8-sulfonic acid (ANS) which 
non-covalently binds to protein surface, causing an increase in the basal fluorescence 
emission of the molecule (λEX = 405 nm and λEM = 532 nm). Then once the saturation of 
ANS to antithrombin is established, a subsequent titration of ligand is added stepwise and 
if the molecule is binding, the intensity will decrease. Once ligand binding saturation is 
reached, the decreases in fluorescence will cease. Thus, 1 µM of AT was incubated in 
thrombin buffer in a quartz cuvette and monitored at the wavelengths described above. To 




individually measured. To remove background fluorescence, the same procedure was done 
in the absence of AT. Once the background was subtracted from the AT sample, it was 
plotted as ΔF/ΔF0 versus concentration of ANS (corrected for dilution) (figure not shown). 
This displayed what seemed like a biphasic curve, suggesting a high and low affinity 
binding site. Focusing on the high affinity site, the calculated concentration of ANS needed 
for the displacement assay was 35 µM. 
With this information, the displacement assay was constructed using in the quartz 
cuvette, thrombin buffer, 1 µM of AT, and 35 µM of ANS. The fluorescence intensities 
were taken at each addition of volume and the titration of 3g began using 7 x 1 µL 
increments of 8 µM 3g, followed by 3 x 1 µL of 16 µM 3g. Again dilution factors were 
taken into consideration and the readings of ΔF/F0 versus the concentration of 3g was input 
into Equation 4. The calculated KD from the experiment showed that 3g’s binding affinity 
to antithrombin was 74 nM and the ΔFMAX was 17 % (Figure 18C). That is 2-fold higher 
affinity than 3g for thrombin. This was worrisome, so one last experiment was developed 
to resolve the potential issue. 
Through our previous studies on 3g with factor Xa, we knew that 3g’s IC50 for FXa 
was ~160 µM, well beyond the KD’s of thrombin and antithrombin. Additionally, 
antithrombin inactivates FXa using the same mechanism as it does for thrombin. Thus, we 
developed a FXa inactivation assay to probe whether the binding of 3g to antithrombin 
affected the rate of inactivation of FXa. The assay was set up the same as above, where 
instead of using FXa was incubated in the presence of excess AT and vehicle (DMSO) or 




inactivation of thrombin was seen at the same concentration and we know 3g will not 
inhibit FXa at this concentration. The reaction was initiated by incubating 1.1 nM of FXa 
with 100 nM of AT with vehicle or 3g. A total of ten time points between 0 and 12600 
seconds were taken by aliquoting a volume of reaction and measuring activity with 
Spectrozyme Xa. The two sets of raw data were input into SigmaPlot and assessed using 
Equation 6. The results shown in Figure 18D, reveal no observable change in the kobs for 0 
or 220 nM of 3g.  
The results taken herein overwhelming support the theory that 3g was in fact 
inducing direct, allosteric, partial inhibition of thrombin. 3g acts by causing dysfunction of 
thrombin’s active site where it remains active against small chromogenic substrate, even at 
saturated inhibitor concentration. Although experimental results suggest 3g also binds 
tightly with antithrombin, there is no evidence that the binding caused a disruption of 
antithrombin’s inactivation loop. Most likely, 3g binds to a distal location on antithrombin 
that does not cause any significant structural changes that would render the inactivation 

















CHAPTER 4 Endogenous Substrate Hydrolysis: Examination of Inhibition in vitro, ex 




The notion of using thrombin as a key target for anticoagulant therapy arises from 
experimental evidence that the alteration of its activity leads to a range of different effects 
downstream in the system. It has been shown that thrombin’s reactive specificity is 
contingent on its binding partner109,158,159. In the example of thrombomodulin (TM), 
thrombin bound to thrombomodulin loses the ability to hydrolyze fibrinogen, but increases 
the kcat/KM by ~1000-fold for hydrolysis of protein C160. This phenomenon is theorized to 
occur for several reasons. First, thrombomodulin binding to exosite 1 and to some extent 
exosite 2 (through interaction with chondroitin sulfate present on 20-35% of TM) may act 
as a supplementary exosite for protein C to bind and alter conformation to favorably bind 
within thrombin’s active site161,162. Another theory is that TM binding alters thrombin’s 
active site to favor protein C hydrolysis and not fibrinogen163,164. Additionally, it has been 
suggested that TM may conformationally alter the sodium binding site on thrombin, which 
in turn reduces the cationic effects seen by the activation peptide of protein and thus 
influences a favorable conformation for protein C to be hydrolyzed160. These effects may 




This notable, induced change to the kcat/KM, which results in the lower activation 
energy for protein C in the presence of TM was partially the driving force behind the 
development of NSGMs and the CSAM library itself. We have shown that 3g induced a 
reduction in the catalytic efficiency of thrombin for small substrate, but up until this point, 
we have not investigated whether the same type of partial inhibition is carried through for 
the endogenous substrates of thrombin. These substrates of particular interest include 
fibrinogen, factor XI, protein C, and factor XIII. Therefore, we began studies into the 
understanding of the mechanism of 3g-induced partial inhibition of thrombin as it pertains 
to endogenous substrates.  
4.1 In vitro Fibrinogenolysis 
 The major substrate for thrombin and the protein responsible for fibrin clots, 
fibrinogen exists as a soluble, free-flowing 340 kDa protein in plasma at concentrations of 
2-4 g/L165. It is a dimeric protein consisting of three pairs of nonidentical subunits (Aα, Bβ, 
and γ). Upon hydrolysis by thrombin, insoluble fibrin monomers are produced and are 
subsequently crosslinked through a transglutamination reaction by factor XIIIa. The 
crosslinked fibrin forms a mesh with platelets, trapping red and white blood cells, forming 
a thrombus or occlusion within a blood vessel. As previously mentioned, current therapies 
that target thrombin result in the absence of fibrin production, which can have detrimental 
effects on a patient74,85,102. With 3g showing partial inhibition of thrombin against small 
substrate, it created curiosity to whether the same phenomenon would occur against 




more sensitive regulation of thrombosis, without abolishing thrombin’s innate activity 
towards the substrate.    
 To investigate this property of sensitizing thrombin to fibrinogen by 3g, a 
transmittance assay was performed in triplicates to examine the amount of fibrin clot 
formed in the presence of inhibitor. Human fibrinogen was purchased from Haematologic 
Technologies Inc. (Essex Junction, CT) and used in place of Spectrozyme TH as 
thrombin’s substrate. In brief, 85 µL of buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM 
CaCl2, 0.1% PEG 8000, pH = 7.4), 5 µL of 120 nM thrombin, and 5 µL of varying 
concentrations of 3g (0.002-250 µM) were mixed in wells of a 96-well plate. Once 
thoroughly mixed, 5 µL of 5.3 mg/mL of fibrinogen was added to each well 
simultaneously and placed in the Flexstation. To assess transmittance, the plate reader was 
set to scan the wells at 600 nm for the first 100 seconds after the addition of fibrinogen. 
The slopes generated are directly related to the amount of fibrin clot formed in each well, 
thus the amount of light transmitted through the well during clot formation, assessing 
thrombin’s rate of activity toward fibrinogen. The slopes and corresponding concentrations 





 Much to our surprise, the dose-
response profiles (Figure 20A) 
generated from the experiments 
showed that 3g indeed inhibited 
thrombin from hydrolyzing 
fibrinogen, but full, not partial 
inhibition was observed (ΔY = 
94%). Additionally, the IC50 
increased 2.3-fold to 514 nM, 
which was a peculiar event 
considering the thrombin 
concentration was kept at 6 nM 
throughout all experiments 
performed, as used previously. 
After investigation of the 
literature, a few explanations could be drawn about why there may be loss of partial 
inhibition and loss of potency. About 7% of human fibrinogen contain an additional 20 
amino acid sequence called γ’-fibrinogen, caused by an alternative mRNA processing 
event in the γ-chain167, as well as significant posttranslational modifications168. This results 
in a sequence which contains a tyrosine sulfate and binds with thrombin’s exosite 2 with a 
KD of ~0.18 µM and ~0.63 µM168–170, respectively. This γ’-chain may be interacting with 




A recombinant γ’-peptide with phosphorylated tyrosines (PEHPAETE-Y(PO3-)-
DSL-Y(PO3-)- PEDDL, replacing the tyrosine sulfates, was obtained from Dr. Farrell at 
Oregon Health and Science University, as a free flowing powder. We performed 
competition studies using 0, 0.65, and 2 µM of γ’-chain (γ’fibP) using the same protocol as 
in Chapter 3 Section 3, however the results were inconclusive and showed no competition. 
We then looked at the γ’fibP itself and calculated the molar extinction coefficient at a 
wavelength of 280 nm (ε280) for tyrosine and tryptophans present on the peptide. Assuming 
the sample was pure, the γ’fibP powder was weighed, and calculated to make an 80 µM 




transferred to a quartz cuvette and placed inside a UV spectrophotometer to observe the 
absorption at 280 nm. The absorption revealed that compared to a calculated 80 µM, the 
concentration in the sample was 70% lower than that according to the Beer’s Law (A = 
εLc; where A is absorbance, ε is the molar extinction coefficient, L is the pathlength of the 
cell, and c is concentration of solution).  
Subsequently, the same solution was injected into the UPLC-MS to analyze the 
contents and to verify the peptide was in the sample. The analysis showed that at a 
retention time of 3 minutes, two major peaks corresponding to 1191.2 m/z and 1173.1 m/z, 
respectively (as seen in Figure 21) were present. After examining the MS data in 
conjunction with the chromatograph, we determined that the sample actually contained 
~1:1 mixture of N-acetylated (2322.15 Da) and N-free (2280.12 Da) γ’fibP. This was 
confirmed by integrating the chromatograph peaks and taking the percentage of the N-
acetylated peak corresponding to 1191.2 m/z, which related to the doubly charged species 
with hexylamine, [M+C6H13N]2+ and comparing it against the second peak corresponding 
to the N-free γ’fibP, 1173.1 m/z, relating to the doubly charged species with sodium 
[M+Na]2+. Both peptides are considered to be in their protonated forms, and the MS was in 
positive mode, so only one counter ion was observed for each. 
After confirming the sample did contain variants of γ’fibP, we adjusted the stock 
volumes to use in the competition assay to again use 0, 0.65, and 2 µM and repeated the 
assay; assuming the KD = 0.63 µM as described in literature for the peptide. In this 
instance, the comparison of IC50s generated from the dose-response profiles with γ’fibP 




increased using Dixon-Webb analysis. However the system does not seem to behave as a 
truly ideal competitor, as expected for a competitor of exosite 2, because there remains a 
significant difference in the observed versus predicted IC50s. Considering the trend seen in 
Figure 20B, it can be suggested that the 1:1 mixture of N-acetylated and free-NH2 γ’fibP 
causes a slight difference in binding and thus are competitors of 3g against thrombin. 
With this information, we then used the average of 7% to calculate the theoretical 
amount of γ’-fibrinogen present in the original 5.3 mg/mL (15.59 µM) fibrinogen sample 
for the fibrinogenolysis assay. The concentration of γ’-fibrinogen expected to be present 
was 0.0546 µM in each well. The IC50 generated from the fibrinogenolysis (514 nM) was 
input into the Dixon-Webb analysis (Equation 3) using a KD of 0.2 µM, corresponding to 
the literature169. This result showed a predicted IC50 of 655 nM compared to the 514 nM 
reported by the assay (Figure 20B). Although not absolutely convincing, the analysis 
suggests that the natural γ’-fibrinogen may be competing with 3g at exosite 2. We do know 
the exact concentration of γ’-fibrinogen present in the sample considering the 
concentration varies by source, but this is a relative estimate and the results support 
competition.  
These data give support for the reasoning of the 2.3-fold loss in potency of 3g for 
thrombin using fibrinogen as the substrate, but does not account for the loss of partial 
inhibition. This explanation requires a more theoretical approach. Considering the exosites 
and active site are interconnected145, the major binding of fibrinogen to exosite 1, coupled 
with 3g binding, may cause an overall structural change. so that the subsequent 




site; but at lower potency because the conformation of exosite 2 is not favorable for 3g. A 
similar event was seen in the HirP competition studies, where the IC50 increased by ~50%, 
but did not go beyond that; even as the concentration of HirP increased. The 
conformational changes resulting from the HirP at exosite 1, while 3g was binding to 
exosite 2, supports an altered binding site for 3g. Although we did not see a loss of partial 
inhibition, the sheer size difference between a small peptide and a 340 kDa protein binding 
to thrombin at both exosites, may cause enough conformational changes to completely lose 
partial inhibition.  
4.2 In vitro Protein C Activation 
Another protease within the web of coagulation, protein C in its activated form is a 
natural anticoagulant found endogenously in the plasma of mammals. The purpose of 
activated protein C (aPC), is to inactivate the cofactors for factor IXa and factor Xa, factors 
VIIIa and Va respectively; through a proteolytic event. The inactivation of these result in a 
vast reduction in the rate of IXa and Xa’s activity; therefore causing a significant loss of 
thrombin production in vivo. As mentioned, thrombin is the protease responsible for 
activation of protein C through a hydrolysis reaction with its cofactor thrombomodulin. 
Upon thrombin binding to thrombomodulin, it is believed that the complex facilitates first 
binding with protein C through a supplementary exosite on thrombomodulin, then inducing 
a conformational change of protein C. There are also arguments as to whether 
thrombomodulin induces allosteric changes to the active site of thrombin upon binding. 
According to work done by Fruentes-Prior, P. and Bode, W. et al., the binding of 




active site, as shown by high resolution crystal structures; thereby suggesting the thrombin-
TM complex’s activity is solely due to conformational changes of protein C caused by 
TM171. Opposition to that theory from Koeppe, J. R. and Komive, E. A et al., suggests that 
the binding of TM to thrombin causes a long-range tightening of the loop on thrombin 
containing residues 126-132, which in turn alters substrate specificity164. This theory was 
supported by 1H/2H exchange studies, fluorescent probing of the active site, and 
crystallography.  
Once in the activated form, aPC utilizes a cofactor, protein S, to facilitate and 
accelerate the inactivation of factor Va172. The aPC-protein S complex also overcomes a 
biochemical hurdle by increasing the rate of hydrolyzing Arg506 of factor Va by ~20-
fold173, as well as thwarting the innate protection of FVa’s Arg506 by FXa when in 
complex173. Due to aPC’s important role as an in vivo anticoagulant, there is an absolute 
necessity to understand how 3g affects not only activated protein C itself, but to discover 
whether 3g has any effect on the thrombin-TM complex as it activates protein C. 
To probe this system, activated protein C was obtained from Haematologic 
Technologies Inc. (Essex Junction, CT) and used in a chromogenic substrate hydrolysis 




8000, pH 7.2), 5 µL of 500 nM of 
activated protein C was incubated 
with 5 µL of varying concentrate ions 
of 3g or vehicle (DMSO) for 10 
minutes. Then, 5 µL of 6.9 mM S-
2366 was added and monitored at 405 
nm for 300 seconds. The slopes 
generated from the Flexstation were 
input into SigmaPlot and applied to 
Equation 1 for IC50, ΔY, and HS.  
The dose-response profile generated showed that 3g does not inhibit aPC 
significantly, with an IC50 of 346 µM. This aids in confirming 3g’s selectivity towards 
thrombin, but also that the activated protein C produced in the following coupled 
experiment, would not interfere with the readings obtained. From here we devised a 
coupled thrombin-protein assay, where a fixed concentration of thrombin (6 nM) would be 
incubated with trabbit-derived thrombomodulin (10 nM) in the presence of a range of 3g 
concentrations (0.002-250 µM) or vehicle. To the incubated solution, excess protein C 
(400 nM) would be added and the solution would react for 10 minutes. To quench the 
reaction, argatroban (800 nM) in a buffer containing 0.02% tween 80 would be added to 
inhibit thrombin fully and break up any aggregates. After the quenching, chromogenic 
substrate (S-2336) for protein C would be added and monitored at 405 nm for production 




Completion of these experiments yielded some interesting results. First the 
experiments containing 0 nM thrombomodulin (TM) did not show any response with the 
addition of S-2366, signifying that 3g in the presence of thrombin, without TM does not 
activate protein C. We anticipated this result, as the activation of protein C requires TM, 
but we did not know if 3g would also induce activation of protein C. However, as the 
concentration of TM increased to 10 nM, we saw a dose-dependent inhibition of thrombin-
TM activation of protein C having IC50 of 1.65 µM. Under normal conditions, the 
thrombin-TM complex would activate protein C without issue, as seen at low 
concentrations of 3g (Figure 22). However in a dose-dependent manner with 3g, the 
thrombin-TM complex was inhibited, not allowing for protein C to become activated. This 
posed an interesting problem in terms of this scaffold becoming a viable drug candidate. If 
3g was inducing inhibition of protein C activation in the presence of thrombin and TM, 
then it would be inhibiting a pathway crucial for the homeostasis of coagulation. 
On the other hand, if one looks at these results from a biophysical standpoint, the 
dose-dependent inhibition of thrombin-TM complex demonstrates several things. It first 
validates the potential for a small molecule to induce significant alteration to a protease 
complex through allostery. Although the partial inhibition as seen with small substrate was 
not carried through to this substrate, the 3g still has a significant impact on the complex. 
The 3g-thrombin-TM complex formed in the assays reversed the innate mechanism of 
thrombin-TM significantly. This suggests that 3g significantly altered the active site of 




inhibitor reversing protein C activation is the first of its kind and has not been reported in 
literature to our knowledge.  
4.3 In vitro Factor XIIIa Activation 
The general trend seen with thrombin is that it has many endogenous substrates and 
considerably more when bound cofactors. Under normal and thrombotic states, after 
thrombin cleaves fibrinogen into fibrin monomers, it also activates factor XIII (existing in 
either plasma or on platelet surfaces). The activated FXIII (FXIIIa) is a transglutaminase, 
which exists in vivo as a zymogen (FXIII). The plasma zymogen (320 kDa) is a tetramer in 
the absence of calcium and consists of two non-identical pairs of α and β subunits (α2β2)62. 
Upon the activation of FXIII, thrombin hydrolyzes the bond between the Arg36 and Gly37 
of the α subunits and releases a two signal peptides per tetramer. This forms the activated 
intermediate FXIIIa (α2’β2), which after binding to calcium causes dissociation of the β 
subunits from the α. The FXIIIa now possesses the ability to cross-link the fibrin 
monomers through a transglutamination reaction174. This cross-linking accelerates the 
build-up of a thrombus by forming the platelet-fibrin mesh. In an up-regulated thrombotic 
event, this reaction continues, which eventually can lead to a blockage or a distal 
embolism. However, absence of FXIIIa activity causes severe bleeding complications175. 
Because of this, thrombin-3g interaction in the presence of FXIII zymogen was studied to 
assess whether 3g would induce full, partial, or no inhibition of FXIII activation.  
The method of validation utilized SDS-PAGE to observe the activation of FXIII by 
thrombin through monitoring the α and β subunit migration on gradient 4-15% gels. Under 




distinguishable bands on the gel (Figure 23A). When the α subunit is activated by 
thrombin, the α2 band loses ~ 8 kDa from the activation peptide cleavage and migrates 
down towards the β subunit. This distinct band shift in migration can used to analyze 
activity of thrombin in the presence and absence of 3g.  
To first understand the kinetics of 1 NIH unit of thrombin (7.8 nM) against 200 nM 
of FXIII, the reaction was carried out in 200 µL containing the 7.8 nM thrombin and 200 
nM FXIII from 0-30 minutes, and 0, 20-60 minutes taking 20 µL aliquots every 2.5 
minutes and 5 minutes, respectively and mixing 1:1 with 2x Laemlli buffer (non-reducing), 
and denaturing the sample at 95 °C for 5 minutes. From each sample, 20 µL was 
transferred into wells of 7.5% Mini-Protean TGX precast 10-well gels (BioRad) and 
electrophoresed using 1x SDS running buffer at a constant 30 mA. After 50 minutes the 
gels were washed with high purity water and SDS was removed from the gels by 
microwaving the gels in water baths three times and each time allowing them to cool down 
for five minutes on an orbital shaker. The water from the baths was discarded and the gels 
were stained using Coomassie brilliant blue G-250. After ~1 hour, the gels were destained 




The first gel showed that after 30 minutes, the appearance of a migratory band 
representing the α2’ subunit was beginning to appear. The second gel, which monitored a 
longer period of time (0, 20-60 minutes), showed that a time-dependent increase of α2’ was 
being produced (see Figure 23A) The reaction was not driven to completion at 60 minutes, 
but the substantial visual amount of α2’ present on the stained gel would allow for a dose-
dependent experiment to be performed using an incubation time of 60 minutes. The 
experiment would show whether thrombin in the presence of 3g would inhibit, reduce or 




In brief, the reaction took place using 600 µL microcentrifuge tubes, solutions of 
200 µL buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH 7.3) 
contained 7.8 nM of thrombin and varying concentrations of 3g (0-250 µM) or vehicle. 
After a five-minute incubation period, FXIII was added to each tube to bring the 
concentration to 200 nM and allowed to react for 60 minutes. Aliquots of the reaction were 
quenched by mixing 20 µL of the sample with 20 µL of 2x Laemlli sample buffer (non-
reducing). Each mixed sample was denatured by incubating at 90 °C for 5 minutes and 
then immediately placed on ice until ready for analysis. For gel electrophoresis, a 4-15% 
Mini-Protean TGX precast 10-well gel (BioRad) was used to which 10 µL of PageRuler 
10-250 kDa (Thermo Scientific) was added to well number 1, while 20 µL of denatured, 
mixed sample was added to the subsequent wells (2-10) in the order of increasing 
concentration (0-250 µM). The chamber and gel cassette were filled with 1x SDS running 
buffer and the gel was run at a constant 30 mA for ~55 minutes. Upon completion, the gel 
was removed from its casing, washed with high purity water, heated by microwave briefly, 
and was placed on an orbital shaker for 5 minutes. The water was discarded, and the 
wash/heating step was repeated twice more. After the last water discard, a solution 
containing Coomassie brilliant blue G-250 dye was added to cover the gel, heated briefly, 
and placed on an orbital shaker for 1 hour. After the hour incubation, the stain was 
removed and high purity was added to destain the gel. The gel was then photographed by 
an Amersham Imager 600 (GE) for further analysis.  
Images of the gel seemed to reveal a dose-dependent inhibition of FXIII activation, 




analysis software (BioRad), intensities of the α2’ band in each well were compared against 
the mean background intensity of the lanes and the α2’ band in the well containing 0 nM 
3g. The values were normalized (Xnorm) using the equation 
𝑋−𝜇
𝑋𝑚𝑎𝑥−𝜇
= 𝑋𝑛𝑜𝑟𝑚, where X is 
the α2’ band intensity of wells containing 3g, Xmax is the α2’ band intensity of the well 
containing 0 nM 3g, and µ is the mean background intensity; also known as the minimum 
X value. The data received was then input into SigmaPlot to calculate the IC50, ΔY, and 
HS, outputting an excited dose-response profile.  
As seen in Figure 23B, there is a concentration dependent inhibition of FXIIIa 
generation in the presence of 3g. The α2’ band shows partial generation at saturating levels 
of 3g indicative of partial activation of FXIIIa by thrombin. The slope generated by 
SigmaPlot from the gel shows an IC50 of 0.87 nM and ΔY of 55%. This is the first example 
of the thrombin-3g complex showing partial inhibition of hydrolysis for an endogenous 
substrate. As exciting as this is, it is important to mention that this is an uncatalyzed 
reaction. In vivo, fibrin acts as cofactor, binding to exosite 1 of thrombin and accelerates 
the hydrolysis of FXIII by 80-fold109. The lack of fibrin at exosite 1 may distort the results 
seen here. The observation that exosite 1 cofactors remove the potential for partial 
inhibition is an important aspect of this work and will need further investigation to 
understand if the partial inhibition is carried through in the presence of fibrin.  
4.4 In vitro Factor XIa Activation 
 Thrombin has the ability to up-regulate itself through auto-activation of the 




uninhibited cascade of reactions ultimately activating thrombin from prothrombin and 
continuing through that feedback loop176. A means to circumvent this phenomenon is to 
inhibit FXIa entirely, because it has been shown to have little bleeding consequences, and 
hemostasis remains largely intact177. Although CSAMs are shown to inhibit FXIa, the most 
potent inhibitor (3g) does so with a 150-fold less potency of FXIa compared to thrombin. 
However, it may stand to reason that 3g’s partial inhibition of thrombin may affect 
activation of FXIa by thrombin. Therefore an assay can be used to probe the activation of 
FXIa by thrombin in the presence of 3g.  
Although this seemed relatively simple, a few caveats were found in the literature. 
The relative rate of thrombin activating FXI is very slow; so slow in fact that rate has been 
shown to be only 2.5 x 102 M-1s-1 when the concentrations of thrombin and FXI are 
1:1178,179. Though, if a polyanionic cofactor is added (i.e., 70-mer polyphosphate or 500 
kDa dextran sulfate) to a reaction where thrombin is 40-fold lower concentration than FXI, 
the rate drastically increases (7.0 x 105 M-1s-1)178,179. An issue with this however, is that 
FXI intrinsically auto activates after 5-10 minutes of incubation with a polyanion179. 
Therefore, if use of a polyanion is necessary, a control to monitor the autoactivation must 
be taken into account. Lastly, considering FXI is a dimer with one active site on each of its 
monomeric subunits, traditional monitoring via chromogenic substrate would not allow for 
us to distinguish between ½ FXIa of full FXIa.  
To circumvent the hurdles with FXI activation, the initial steps taken involved first 
studying the plasma-obtained FXI in the presence of 1 NIH unit of thrombin alone. This 




observing activation of FXI on 
SDS-PAGE. As FXI is activated 
to first ½ FXIa and then FXIa, 
there is a conformational change 
that allows differential 
migration on low percentage 
gels, as seen in Figure 24A. 
Additionally, being ½ FXIa and 
FXI migrate very similarly on 
the gels, active site fluorophore 
implementation was used. 
Fluorescein-labeled FPRck or 
dansyl-EGRck was used to 
enhance sensitivity for visualization of the bands as seen in Figure 24A.  
Two experiments were undertaken to assess the thrombin-3g complex effects on 
FXI. The first was to observe dose-dependence of the uncatalyzed complex on FXI over a 
5-hour period using 1 NIH unit of thrombin and 200 nM of FXI. The second experiment 
looked at the same dose-dependence effects, but using 1 µg/mL of dextran sulfate (DS; 
mol. Wt. 500 kDa) as a the polyanionic cofactor over a 5 and 10-minute period. The 
experiments proceeded by taking a fixed concentrations of thrombin (7.8 nM) in buffer (50 
mM Tris-HCl, 100 mM NaCl, 0.1% PEG 8000, pH 7.4) and incubating with increasing 




°C. For the catalyzed experiment, 5 µL of 20 µg/mL of DS was added to each reaction to 
give 1 µg/mL in each tube. To quench all of the reactions, 3-fold molar equivalence of 
fluorescein-FPRck would be added and allowed to react over 30 minutes at room 
temperature. The tubes were mixed 1:1 with 2x Laemlli buffer (non-reducing) and 20 µL 
of mixed sample were loaded on 7.5% Mini-Protean TGX precast 10-well gel (BioRad) 
and run at 30 mA for 60 minutes using 1x SDS running buffer. The gels were removed of 
SDS by washing and heating with distilled water 3x. The gels were scanned using the 
fluorescent setting of the Amersham 600 gel imager (GE). The gels were then stained with 
coomassie G-250, destained, and imaged with the Amersham 600.  
Upon imaging the uncatalyzed and catalyzed gels, the bands for each individual 
concentration of 3g appeared to not be significantly different from one another. To obtain 
clarification of this, we employed the use of Quantity One gel analysis software (BioRad) 
to analyzed the individual bands, by comparing against the 0 nM 3g and the background. 
First, the uncatalyzed gels showed a dose-dependent decrease in the amount of ½ FXIa 
produced by the reaction. Normalizing the intensities and comparing them versus the 
concentration of 3g showed partial inhibition with an IC50 of 0.782 µM (Figure 24 B and 
C). Alternatively, for the catalyzed gels, partial inhibition was still observed, but with an 
IC50 of 28 µM (Figure 24 B and D). This suggested that the dextran sulfate played a major 
role in competing with 3g for exosite 2 of thrombin and that 3g induced catalytic 
dysfunction to thrombin’s active site resulting partial inhibition. This competition and 
change in IC50 is similar to what is seen in the competition studies with UFH. 




One of the most important aspects involving anticoagulant drug discovery is not 
necessarily understanding the precise target protein or complex, but finding out if the novel 
agent retains its ability to inhibit clot formation in plasma and blood. It is crucial in the 
development process to gather as much information as possible regarding the drug’s 
potency and if there are other proteins within the blood or plasma that it may be binding to. 
In this case, the CSAMs are known to bind thrombin tightly, but it also behaves relatively 
promiscuous with other coagulation proteins. To investigate this further, we used an ex 
vivo assay and human citrated plasma to probe whether the CSAMs act towards the 
intrinsic or extrinsic pathways. This is performed by measuring the activated partial 
thromboplastin time (aPTT) for the intrinsic pathway, and prothrombin time (PT) for the 
extrinsic pathway. In brief, citrated human plasma is used to chelate any calcium ions 
within the plasma, to ensure there is no premature activation of coagulation enzymes. The 
two assays differ in how they are initiated. The aPTT assay incubates with ellagic acid, to 
simulate “contact”-activation. Once the plasma and reagents are incubated and mixed 
properly, a calcium chloride solution is added, which triggers a procoagulant response. 
Alternatively, the PT assay incubates the citrated plasma with thromboplastin-D (tissue 
factor) and is then initiated by addition of calcium. 
To begin, one-stage recalcification assays were performed, using a BBL fibrometer 
(Beton-Dickinson, Sparles, MD). To measure the aPTT, a number of various 3g 
concentrations or vehicle (DMSO) were added to citrated human plasma and aPTT reagent 
(0.2% ellagic acid) which is incubated at 37 ºC for 4 min. Prewarmed 25 mM CaCl2 is 




In the PT assay, 3g or vehicle is added to 
citrated human plasma and incubated at 
37 ºC for 30 sec. After the short 
incubation period, the pre-warmed 
thromboplastin-D solution was added 
and the clotting time is established. The 
concentration required to double the 
clotting time (2xaPTT or 2xPT) was considered the effective concentration in plasma180.  
Results from the plasma studies revealed that 3g targeted the intrinsic pathway, 
having a 2xaPTT of 220 µM compared to the PT having a 2xPT of 660 µM; see Figure 25. 
This ensured that 3g indeed behaved as an anticoagulant, but displayed a 1000-fold loss in 
potency in plasma. In order to evaluate this loss, we looked at the binding of 3g to serum 
albumin, considering that ~55% of plasma consists of albumin and is the likely candidate 
for binding exogenous compounds like drugs181. An intrinsic fluorescence experiment used 
albumin at plasma concentration (45 mg/mL) with titrations of 3g, up to 250 µM. The 
study showed that KD was 184 µM, well above the KD for 3g to thrombin (147 nM). This 
led us to believe that the 3g was not binding to serum albumin. Therefore, the binding must 
be occurring with immunoglobulins in the plasma or with some other serum protein. More 
investigations into the binding partner would need to be established to identify the 
mechanism, but falls out of the scope of these basic ex vivo experiments and more into a 
pharmacokinetic aspect.  




To establish the efficiency of coagulation, fibrin build-up, and clot strength (i.e., 
thrombodynamic properties) in the presence of 3g, thromboelastography (TEG) was used. 
These studies were performed in the laboratory of Dr. Don Brophy (School of Pharmacy, 
VCU). Briefly, the thrombodynamic properties were monitored as a blood sample is 
induced to clot through a recalcification assay. The study was kept at a low-shear 
environment, representing a sluggish venous flow. The properties are expected to 
drastically change when comparing a blood sample with and without an inhibitor. Clot 
formation was monitored via a pin connected to a torsion wire located at the center of a 
cup, where the blood is held. The strength and elasticity of the clot applies a force to the 
pin and changes its rotation, which is subsequently monitored and recorded. The data is 




stability), amplification of clot strength (G), initial reaction time to the start of clotting (R), 
and the angle (α), which is representative of fibrin build-up and cross-linking182. 
The experiments utilized the 2-fold below the aPTT concentration to begin the 
experiment, and increased to the 2xaPTT concentration and increased each subsequent 
concentration by the same factor. The analysis showed an anticoagulant TEG profile 
beginning to take effect at ~3x the 2xaPTT concentration, and equivalent to the 2xPT 
concentration at 627 mg/mL (Figure 26). Clot initiation time was doubled for 0.627 
mg/mL tripled for 0.836 mg/mL and at 1.045 mg/mL was having a 6-fold increase 
compared to the control. Additionally at 1.045 mg/mL of 3g, the maximum amplitude and 




antiplatelet effects (Table 4). However, that is only based off of this empirical evidence 
and was not further investigated due to the extremely high concentration. It is however 
important to note that 3g does behave as an anticoagulant in whole blood, albeit being at a 
substantial dose.  




 A common judgement of the 
efficacy of an anticoagulant is the 
utilization of a mouse tail-bleed 
assay, which is relatively non-
invasive, very simple, and contain a 
considerable amount of 
information183. The experimental 
procedure is rudimentary and straight 
forward. A number of mice are dosed with either controls (positive: argatroban or negative: 
vehicle) or with drug by injection to the tail vein. A short period of time passes, imitating 
an incubation period, and the tip of their tail is cut. Once the initial cut is made, the timer 
starts and continues until a clot has formed. These times are then compared to observe if 
the drug causes any type of excessive bleeding at the concentration dosed.  
 For experiments involving 3g, the CSAM was dissolved in 30% ethanol and diluted 
to 14% to be given as a 2 mg dose/mouse. An injection of the same volume containing 
either 14% ethanol as a negative control or 0.66 µg of argatroban as a positive control were 
used. The single doses were given as bolus injections to the tail vein, and incubated for 5 
minutes prior to the tail cut. The times were recorded for each bleed. Analysis of the 
control bleeds versus the 3g doses showed no significant bleeding for any of the 
experiments. There were no statistically significant changes in 3g from the negative control 
or from the positive control as seen in Figure 27. This indicates that at the dosage in mice, 




of argatroban; which is not surprising being < 5% of patients see adverse bleeding with 
argatroban and only 4 data points were taken for the positive control. To gain more 
confidence in these experiments, higher doses of 3g, as well as argatroban would need be 
done to obtain clinical relevance. An indirect observation was that even at a 2 mg dose, the 
mice seemed unaffected and did not display any acute symptoms even after having an 







CHAPTER 5 Conclusions and Future Work 
 
 
 Exploitation of thrombin’s exosites and inherent plasticity may be a key factor in 
regulation of its endogenous activity and maintaining hemostasis in vivo. Previous studies 
have used similar techniques, which utilize the notion of partial inhibition for alleviation of 
side effects; while still asserting response from the target protein137. The results reported 
herein tie together a number of theories with regard to a new, plausible mechanism for how 
to inhibit thrombin while reducing or eliminating the risk of abnormal bleeding.  The 
potential to remove the risk of bleeding comes from the idea that partial inhibition allows 
for either reduced catalytic efficiency for a specific substrate, or the active site 
conformation may become unfavorable for interaction with certain substrates (i.e., 
inducing previously unobserved selectivity). 
 From a mechanistic point-of-view, a monomeric protease displaying partial 
inhibition suggests that the protease is behaving as an oligomeric protein. This is most 
likely due to the large conformational dynamics inherent to the protease. However, as seen 
in the fluorescence quenching experiments and the antithrombin inactivation, the 
conformation of and around the active site is changing dramatically. Leaving only the 
observation that structural conformational change is being induced, and inhibition is not 




being able to gain access to the fluorescein at the S4 pocket. Additional support for this is 
the significant change observed to thrombin-3g complex’s recognition of protein C when it 
is bound to thrombomodulin. The 3g induced a complete change to thrombin’s recognition 
for protein C from activation under normal conditions, to inhibition of protein C activation 
in the presence of 3g. Similarly, the partial inhibition of FXI and FXIII activation versus 
the full inhibition of fibrinogen cleavage versus recognition of protein C suggests that the 
alteration of thrombin’s structure induced by 3g may cause a meta-stable state of thrombin 
where its activity is suppressed or altered. Therefore, the extent of inhibition may have a 
direct correlation to the cofactors bound to exosite 1 and how that alters the thrombin-3g 
complex. Crystallographic data may be able to clarify the exact mechanism of 3g-induced 
partial inhibition and work on the co-crystal structure is currently underway using 
thrombin-3g and thrombin-TM-3g complexes. 
 From a drug development aspect, 3g is the most potent exosite 2 inhibitor of 
thrombin to date, but does not seem to present a viable route to the clinic; considering its 
loss of potency in plasma and blood, partial inhibition of FXIII activation, inhibition of 
protein C activation, and partial inhibition of FXI activation. The identification of the 
endogenous mechanism by which 3g binds significantly is needed, so further alterations of 
the structure can be performed to regain the nanomolar KD’s seen in vitro. The use of 3g 
does present itself as a valuable tool for probing thrombin and the newly discovered 
possibility to induce allosteric partial inhibition. If a compound could be derived from 3g 
that serves as a partial inhibitor towards fibrinogen or a selective inhibitor to reduce the 




be great clinical potential in that aspect. Maintaining thrombin’s activity towards 
fibrinogen without the side effects of the bleeding in addition to reduction of thrombin 
propagation would make for an ideal anticoagulant. Future work on these compounds of 
the partial inhibition of thrombin is needed to exploit the features mentioned here. 
Additional work into how 3g affects FV and FVIII activation is crucial in this. Ultimately 
obtaining structural information through NMR or x-ray crystallography is of key 









(1)  López-Otín, C.; Matrisian, L. M. Nat. Rev. Cancer 2007, 7 (10), 800–808. 
(2)  Lopez-Otin, C.; Bond, J. S. J. Biol. Chem. 2008, 283 (45), 30433–30437. 
(3)  Koblinski, J. E.; Ahram, M.; Sloane, B. F. Clinica Chimica Acta. 2000, 113–135. 
(4)  van Kempen, L. C. L.; de Visser, K. E.; Coussens, L. M. Eur. J. Cancer 2006, 42 (6), 728–
734. 
(5)  Quirós, P. M.; Langer, T.; López-Otín, C. Nat. Rev. Mol. Cell Biol. 2015, 16 (6), 345–359. 
(6)  Desk, R.; Williams, L. Biochemistry 2006, 114 (10), 1070–1077. 
(7)  Rawlings, N. D.; Barrett, A. J. In Handbook of Proteolytic Enzymes: Second Edition; 2004, 
1, 231–268. 
(8)  Fukasawa, K. M.; Hata, T.; Ono, Y.; Hirose, J.; Fukasawa, K. M.; Hata, T.; Ono, Y.; 
Hirose, J. J. Amino Acids 2011, 1–7. 
(9)  Cerdii-Costa, N.; Gomis-Rooth, F. X. Protein Science. 2014, 123–144. 
(10)  Hooper, N. M. FEBS Letters. 1994, 1–6. 
(11)  Wu, S.; Zhang, C.; Xu, D.; Guo, H. J. Phys. Chem. B 2010, 114 (28), 9259–9267. 
(12)  Blow, D. M. Trends in Biochemical Sciences. 1997, 405–408. 
(13)  Hedstrom, L. Chem. Rev. 2002, 102 (12), 4501–4524. 
(14)  Derewenda, Z. S.; Derewenda, U.; Kobos, P. M. J. Mol. Biol. 1994, 241 (1), 83–93. 
(15)  Henderson, R. J. Mol. Biol. 1970, 54 (2), 341–354. 
(16)  Turk, B.; Turk, D.; Turk, V. Biochim. Biophys. Acta. 2000, 98–111. 




Naeem, A.; Patel, H.; Thomas, E. W.; Sreedharan, S. K.; Verma, C.; Brocklehurst, K. 
Biochemistry 1997, 36 (33), 9968–9982. 
(18)  Barrett, A. J.; Rawlings, N. D. Biol. Chem. 2001, 727–733. 
(19)  Peräkylä, M.; Rouvinen, J. Chem. - A Eur. J. 1996, 2 (12), 1548–1551. 
(20)  Seemüller, E.; Lupas, A.; Stock, D.; Löwe, J.; Huber, R.; Baumeister, W. Science 1995, 
268 (5210), 579–582. 
(21)  Brannigan, J.; Dodson, G.; Duggleby, H. J.; Moody, P. C.; Smith, J. L.; Tomchick, D. R.; 
Murzin,  a G. Nature 1995, 378 (6555), 416–419. 
(22)  Coates, L.; Erskine, P. T.; Mall, S.; Gill, R.; Wood, S. P.; Myles, D. A. A.; Cooper, J. B. 
Eur. Biophys. J. 2006, 559–566. 
(23)  Coates, L.; Tuan, H.-F.; Tomanicek, S.; Kovalevsky, A.; Mustyakimov, M.; Erskine, P.; 
Cooper, J. J. Am. Chem. Soc. 2008, 130 (23), 7235–7237. 
(24)  Coates, L.; Erskine, P. T.; Wood, S. P.; Myles, D. A. A.; Cooper, J. B. Biochemistry 2001, 
40 (44), 13149–13157. 
(25)  Cooper, J. B. Curr. Drug Targets 2002, 3 (2), 155–173. 
(26)  Blankenship, E.; Vukoti, K.; Miyagi, M.; Lodowski, D. T. Acta Crystallogr. Sect. D Biol. 
Crystallogr. 2014, 70 (3), 833–840. 
(27)  Bone, R.; Silen, J. L.; Agard, D. A. Nature 1989, 339 (6221), 191–195. 
(28)  Davis, J. H.; Agard, D. A. Biochemistry 1998, 37 (21), 7696–7707. 
(29)  Bone, R.; Fujishige, A.; Kettner, C. A.; Agard, D. A. Biochemistry 1991, 30 (43), 10388–
10398. 




(31)  Liu, S. Q., et al. Pesticides in the modern world. 2011, 16, 333-376. 
(32)  Hansen, G.; Gielen-Haertwig, H.; Reinemer, P.; Schomburg, D.; Harrenga, A.; Niefind, K. 
J. Mol. Biol. 2011, 409 (5), 681–691. 
(33)  Ain, Q. U.; Méndez-Lucio, O.; Ciriano, I. C.; Malliavin, T.; van Westen, G. J. P. Integr. 
Biol. 2014, 6 (11), 1023–1033. 
(34)  Dorovska, V. N.; Varfolomeyev, S. D.; Kazanskaya, N. F.; Klyosov, A. A.; Martinek, K. 
FEBS Lett. 1972, 23 (1), 122–124. 
(35)  Cottrell, G. S.; Turner, A. J. Handbook of Proteolytic Enzymes. 2013. 
(36)  Olsen, J. V.; Ong, S.-E.; Mann, M. Mol. Cell. Proteomics 2004, 3 (6), 608–614. 
(37)  Gallwitz, M.; Enoksson, M.; Thorpe, M.; Hellman, L. PLoS One 2012, 7 (2), e31756. 
(38)  Backes, B. J.; Harris, J. L.; Leonetti, F.; Craik, C. S.; Ellman, J. A. Nat. Biotechnol. 2000, 
18 (2), 187–193. 
(39)  Newell-Caito, J. L.; Griffiths, A. E.; Fay, P. J. Biochemistry 2012, 51 (16), 3451–3459. 
(40)  Prandoni, P. European Journal of Internal Medicine. 2009, 660–661. 
(41)  Goldhaber, S. Z.; Bounameaux, H. In The Lancet 2012, 379, 1835–1846. 
(42)  Prandoni, P.; Bilora, F.; Marchiori, A.; Bernardi, E.; Petrobelli, F.; Lensing, A. W.; Prins, 
M. H.; Girolami, A. N. Engl. J. Med. 2003, 348 (15), 1435–1441. 
(43)  Eliasson, Å.; Bergqvist, D.; Björck, M.; Acosta, S.; Sternby, N. H.; Ögren, M. J. Thromb. 
Haemost. 2006, 4 (9), 1897–1902. 
(44)  Hong, C.; Zhu, F.; Du, D.; Pilgram, T. K.; Sicard, G. A.; Bae, K. T. Atherosclerosis 2005, 
183 (1), 169–174. 




(46)  Previtali, E.; Bucciarelli, P.; Passamonti, S. M.; Martinelli, I. Blood Transfus. 2011, 9 (2), 
120–138. 
(47)  Wolberg, A. S.; Mackman, N. Arterioscler. Thromb. Vasc. Biol. 2009, 29 (3), 296–297. 
(48)  Sen, S.; Oppenheimer, S. M.; Lima, J.; Cohen, B. Stroke. 2002, 33 (4), 930–935. 
(49)  Mozaffarian, D.; Benjamin, E. J.; Go, A. S.; Arnett, D. K. Circulation 2015, 131 (4), e29–
e39. 
(50)  Finegold, J. A.; Asaria, P.; Francis, D. P. Int. J. Cardiol. 2013, 168 (2), 934–945. 
(51)  Gryglewski, R. J.; Chlopicki, S.; Uracz, W.; Marcinkiewicz, E. Med Sci Monit 2001, 7 (1), 
1–16. 
(52)  Monroe, D. M.; Hoffman, M. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006, 
41–48. 
(53)  Heemskerk, J. W. M.; Bevers, E. M.; Lindhout, T. Thromb. Haemost. 2002, 88 (2), 186–
193. 
(54)  Palta, S.; Saroa, R.; Palta, A. Indian Journal of Anaesthesia. 2014, 515–523. 
(55)  Renn, T.; Schmaier, A. H.; Nickel, K. F.; Blombock, M.; Maas, C. Blood.  2012, 4296–
4303. 
(56)  Cochrane, C. G.; Revak, S. D.; Wuepper, K. D. J. Exp. Med. 1973, 138 (6), 1564–1583. 
(57)  Gailani, D.; Renné, T. Arterioscl. Thromb. Vascul. Biol. 2007, 2507–2513. 
(58)  Mann, K. G. In Thromb. Haemost. 1999, 382, 165–174. 
(59)  Furie, B.; Furie, B. C. N. Engl. J. Med. 1992, 326 (12), 800–806. 





(61)  Di Cera, E. J. Thromb. Haemost. 2007, 196–202. 
(62)  Ariëns, R. A. S.; Lai, T.-S.; Weisel, J. W.; Greenberg, C. S.;. Blood.  2002, 100 (3), 743–
754. 
(63)  De Candia, E.; Hall, S. W.; Rutella, S.; Landolfi, R.; Andrews, R. K.; De Cristofaro, R. J. 
Biol. Chem. 2001, 276 (7), 4692–4698. 
(64)  Coughlin, S. R. Nature 2000, 407 (6801), 258–264. 
(65)  Choi, S. H.; Smith, S. A.; Morrissey, J. H. Blood 2011, 118 (26), 6963–6970. 
(66)  Yun, T. H.; Baglia, F. A.; Myles, T.; Navaneetham, D.; Lopez, J. A.; Walsh, P. N.; Leung, 
L. L. K. J. Biol. Chem. 2003, 278 (48), 48112–48119. 
(67)  Lipets, E. N.; Ataullakhanov, F. I.; Sinauridze, E.; Panteleev, M.; et al. Thromb. J. 2015, 
13 (1), 4. 
(68)  Major, D. A.; Sane, D. C.; Herrington, D. M. Am Hear. J 2000, 140 (2), 189–195. 
(69)  Rosendaal, F. R.; Reitsma, P. H. Journal of Thrombosis and Haemostasis. 2009, 301–304. 
(70)  Poort, S. R.; Rosendaal, F. R.; Reitsma, P. H.; Bertina, R. M. Blood. 1996, 88 (10), 3698–
3703. 
(71)  Bell, R. G.; Sadowski, J. A.; Matschiner, J. T. Biochemistry 1972, 11 (10), 1959–1961. 
(72)  Stenfio, J.; Suttie, J. W. Ann. Res. Biochem. 1977, 46, 157–172. 
(73)  Helgeland, L. Biochem. Educ. 1980, 8 (3), 66–69. 
(74)  Wysowski, D. K.; Nourjah, P.; Swartz, L. Arch Intern Med 2007, 167 (13), 1414–1419. 
(75)  Warkentin, T. E.; Crowther, M. A. Can. J. Anesth. 2002, 49 (6), S11–S25. 
(76)  Lee, C. J.; Ansell, J. E. British Journal of Clinical Pharmacology. 2011, 581–592. 




(78)  Lunven, C.; Gauffeny, C.; Lecoffre, C.; O’Brien, D. P.; Roome, N. O.; Berry, C. N. 
Thromb. Haemost. 1996, 75 (1), 154–160. 
(79)  Wienen, W.; Stassen, J. M.; Priepke, H.; Ries, U. J.; Hauel, N. Thromb. Haemost. 2007, 98 
(2), 333–338. 
(80)  Huttunen, K. M.; Raunio, H.; Rautio, J. Pharmacol. Rev. 2011, 63 (3), 750–771. 
(81)  Grütter, M. G.; Priestle, J. P.; Rahuel, J.; Grossenbacher, H.; Bode, W.; Hofsteenge, J.; 
Stone, S. R. EMBO J. 1990, 9 (8), 2361–2365. 
(82)  Ringwala, S. M.; DiBattiste, P. M.; Schneider, D. J. J. Thromb. Thrombolysis 2012, 34 (3), 
291–296. 
(83)  Agrawal, R.; Jain, P.; Dikshit, S. N. Curr Drug Targets 2012, 13 (6), 863–875. 
(84)  Harder, S. Thromb. J. 2014, 12 (1), 22. 
(85)  Crowther, M. A.; Warkentin, T. E. Blood 2008, 111 (10), 4871–4879. 
(86)  Schiele, F.; Van Ryn, J.; Canada, K.; Newsome, C.; Sepulveda, E.; Park, J.; Nar, H.; 
Litzenburger, T. Blood 2013, 121 (18), 3554–3562. 
(87)  Imamura, A.; Ando, H.; Korogi, S.; Tanabe, G.; Muraoka, O.; Ishida, H.; Kiso, M. 
Essentials Glycobiol. 2009, 784. 
(88)  Sakko, A. J.; Butler, M. S.; Byers, S.; Reinboth, B. J.; Stahl, J.; Kench, J. G.; Horvath, L. 
G.; Sutherland, R. L.; Stricker, P. D.; Henshall, S. M.; Marshall, V. R.; Tilley, W. D.; 
Horsfall, D. J.; Ricciardelli, C. Cancer Epidemiol. Biomarkers Prev. 2008, 17 (9), 2488–
2497. 
(89)  Funderburgh, J. L. IUBMB Life 2002, 54 (4), 187–194. 




207 (207), 159–176. 
(91)  Liu, J.; Pedersen, L. C. Appl. Microbiol. Biotechnol. 2007, 263–272. 
(92)  Huntington, J. A. J. Thromb.Haemost. 2013, 254–264. 
(93)  Griffith, M. J. J. Biol. Chem. 1979, 254 (23), 12044–12049. 
(94)  Baglin, T. P.; Carrell, R. W.; Church, F. C.; Esmon, C. T.; Huntington, J. A. Proc. Natl. 
Acad. Sci. U. S. A. 2002, 99 (17), 11079–11084. 
(95)  Olson, S. T.; Björk, I.; Sheffer, R.; Craig, P. A.; Shore, J. D.; Choay, J. J. Biol. Chem. 
1992, 267 (18), 12528–12538. 
(96)  Desai, U. R.; Petitou, M.; Björk, I.; Olson, S. T. J. Biol. Chem. 1998, 273 (13), 7478–7487. 
(97)  Liu, H.; Zhang, Z.; Linhardt, R. J. Nat. Prod. Rep. 2009, 26 (3), 313–321. 
(98)  Hirsh, J. Circulation 1998, 13 (15), 1575–1582. 
(99)  Xu, Y.; Masuko, S.; Takieddin, M.; Xu, H.; Liu, R.; Jing, J.; Mousa, S. A.; Linhardt, R. J.; 
Liu, J. Science (80-. ). 2011, 334 (6055), 498–501. 
(100)  Bauer, K. A.; Hawkins, D. W.; Peters, P. C.; Petitou, M.; Herbert, J.-M.; van Boeckel, C. a 
a; Meuleman, D. G. Cardiovasc. Drug Rev. 2002, 20 (1), 37–52. 
(101)  Franchini, M.; Chong, B.; Jang, I.-K.; Hursting, H.; Warkentin, T. et al. Thromb. J. 2005, 3 
(1), 14. 
(102)  Levi, M.; Eerenberg, E.; Kamphuisen, P. W. J. Thromb. Haemost. 2011, 1705–1712. 
(103)  Guo, J.; Zhou, H.-X. Chem. Rev. 2016, 116 (11), 6503-6515. 
(104)  Monod, J.; Wyman, J.; Changeux, J. P. J. Mol. Biol. 1965, 12 (1), 88–118. 
(105)  Mihailescu, M. R.; Russu, I. M. Proc. Natl. Acad. Sci. U. S. A. 2001, 98 (7), 3773–3777. 




(107)  Cooper, A.; Dryden, D. T. F. Eur. Biophys. J. 1984, 11 (2), 103–109. 
(108)  Nussinov, R.; Tsai, C. J. Curr. Opin. Struct. Biol. 2015, 30, 17–24. 
(109)  Huntington, J. A. J. Thromb. Haemost. 2005, 3, 1861–1872. 
(110)  Lechtenberg, B. C.; Freund, S. M. V; Huntington, J. A. Biol. Chem. 2012, 393, 889–898. 
(111)  Pechik, I.; Madrazo, J.; Mosesson, M. W.; Hernandez, I.; Gilliland, G. L.; Medved, L. 
Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (9), 2718–2723. 
(112)  Huntington, J. A. Biochimica et Biophysica Acta. 2012, 246–252. 
(113)  Carter, W. J.; Cama, E.; Huntington, J. A. J. Biol. Chem. 2005, 280 (4), 2745–2749. 
(114)  Henry, B. L.; Desai, U. R. Thromb. Res. 2014, 134 (5), 1123–1129. 
(115)  Pineda, A. O.; Chen, Z. W.; Marino, F.; Mathews, F. S.; Mosesson, M. W.; Di Cera, E. 
Biophys. Chem. 2007, 125 (2-3), 556–559. 
(116)  Dumas, J. J.; Kumar, R.; Seehra, J.; Somers, W. S.; Mosyak, L. Science 2003, 301 (5630), 
222–226. 
(117)  Di Cera, E.; Guinto, E. R.; Vindigni, A.; Dang, Q. D.; Ayala, Y. M.; Wuyi, M.; Tulinsky, 
A. J. Biol. Chem. 1995, 270 (38), 22089–22092. 
(118)  Henry, B. L.; Aziz, M. A.; Zhou, Q.; Desai, U. R. Thromb. Haemost. 2010, 103 (3), 507–
515. 
(119)  Henry, B. L.; Connell, J.; Liang, A.; Krishnasamy, C.; Desai, U. R. J. Biol. Chem. 2009, 
284 (31), 20897–20908. 
(120)  Henry, B. L.; Thakkar, J. N.; Liang, A.; Desai, U. R. Biochem. Biophys. Res. Commun. 
2012, 417 (1), 382–386. 




413 (2), 348–352. 
(122)  Mehta, A. Y.; Thakkar, J. N.; Mohammed, B. M.; Martin, E. J.; Brophy, D. F.; Kishimoto, 
T.; Desai, U. R. J. Med. Chem. 2014, 57 (7), 3030–3039. 
(123)  Mehta, A. Y.; Mohammed, B. M.; Martin, E. J.; Brophy, D. F.; Gailani, D.; Desai, U. R. J. 
Thromb. Haemost. 2016, 14 (4), 828–838. 
(124)  Sidhu, P. S.; Liang, A.; Mehta, A. Y.; Abdel Aziz, M. H.; Zhou, Q.; Desai, U. R. J. Med. 
Chem. 2011, 54 (15), 5522–5531. 
(125)  Sidhu, P. S.; Abdel Aziz, M. H.; Sarkar, A.; Mehta, A. Y.; Zhou, Q.; Desai, U. R. J. Med. 
Chem. 2013, 56 (12), 5059–5070. 
(126)  Verghese, J.; Liang, A.; Sidhu, P. P. S.; Hindle, M.; Zhou, Q.; Desai, U. R. Bioorganic 
Med. Chem. Lett. 2009, 19 (15), 4126–4129. 
(127)  Karuturi, R.; Al-Horani, R. A.; Mehta, S. C.; Gailani, D.; Desai, U. R. J. Med. Chem. 2013, 
56 (6), 2415–2428. 
(128)  Abdel Aziz, M. H.; Sidhu, P. S.; Liang, A.; Kim, J. Y.; Mosier, P. D.; Zhou, Q.; Farrell, D. 
H.; Desai, U. R. J. Med. Chem. 2012, 55 (15), 6888–6897. 
(129)  Argade, M. D.; Mehta, A. Y.; Sarkar, A.; Desai, U. R. J. Med. Chem. 2014, 57 (8), 3559–
3569. 
(130)  Al-Horani, R. A.; Liang, A.; Desai, U. R. J. Med. Chem. 2011, 54 (17), 6125–6138. 
(131)  Lane, D. A.; Philippou, H.; Huntington, J. A. Blood. 2005, 2605–2612. 
(132)  Adams, T. E.; Huntington, J. A. Arterioscl. Thromb. Vascul. Biol. 2006,  1738–1745. 
(133)  Dai, J.; Zhou, H. X. Structure 2015, 23 (1), 228–236. 




(135)  Christopoulos, A. Nat Rev Drug Discov 2002, 1 (3), 198–210. 
(136)  Sharma, S.; Rodriguez, A. L.; Conn, P. J.; Lindsley, C. W. Bioorganic Med. Chem. Lett. 
2008, 18 (14), 4098–4101. 
(137)  Burgin, A. B.; Magnusson, O. T.; Singh, J.; Witte, P.; Staker, B. L.; Bjornsson, J. M.; 
Thorsteinsdottir, M.; Hrafnsdottir, S.; Hagen, T.; Kiselyov, A. S.; Stewart, L. J.; Gurney, 
M. E. Nat. Biotechnol. 2010, 28 (1), 63–70. 
(138)  Al-Horani, R. A.; Karuturi, R.; White, D. T.; Desai, U. R. Molecules 2015, 20 (1), 608–
624. 
(139)  Patel, N. J.; Karuturi, R.; Al-Horani, R. A.; Baranwal, S.; Patel, J.; Desai, U. R.; Patel, B. 
B. ACS Chem. Biol. 2014, 9 (8), 1826–1833. 
(140)  Al-Horani, R. A.; Desai, U. R. Tetrahedron. 2010, 2907–2918. 
(141)  Raghuraman, A.; Riaz, M.; Hindle, M.; Desai, U. R. Tetrahedron Lett. 2007, 48 (38), 
6754–6758. 
(142)  Rostovtsev, V. V; Green, L. G.; Fokin, V. V; Sharpless, K. B. Angew. Chemie - Int. Ed. 
2002, 41 (14), 2596–2599. 
(143)  Hileman, R. E.; Fromm, J. R.; Weiler, J. M.; Linhardt, R. J. BioEssays. 1998,  156–167. 
(144)  Olson, S. T.; Halvorson, H. R.; Bjork, I. J. Biol. Chem. 1991, 266 (10), 6342–6352. 
(145)  Petrera, N. S.; Stafford, A. R.; Leslie, B. A.; Kretz, C. A.; Fredenburgh, J. C.; Weitz, J. I. J. 
Biol. Chem. 2009, 284 (38), 25620–25629. 
(146)  Al-Horani, R. A.; Ponnusamy, P.; Mehta, A. Y.; Gailani, D.; Desai, U. R. J. Med. Chem. 
2013, 56 (3), 867–878. 




Pozo-Hernandez, C.; Isabel Terleira-Fernandez, A.; Vargas-Castrillon, E. Curr. Drug 
Discov. Technol. 2012, 9 (2), 22. 
(148)  Mammen, M.; Choi, S.-K.; Whitesides, G. M. Angew. Chem. Int. Ed. 1998, 37 (20), 2754–
2794. 
(149)  Shental-Bechor, D.; Levy, Y. Proc. Natl. Acad. Sci. 2008, 105 (24), 8256–8261. 
(150)  Sankaranarayanan, N. V.; Sarkar, A.; Desai, U. R.; Mosier, P. D. Methods Mol. Biol. 2015, 
1229, 289–314. 
(151)  Ruiz-Larrea, M. B. Biochem. Mol. Biol. Educ. 2002, 30 (4), 235–238. 
(152)  Lee, A. W.; Karplus, M. Proc. Natl. Acad. Sci. U. S. A. 1983, 80 (December), 7055–7059. 
(153)  Palmer, A. G. Curr. Op. Struct. Biol. 1997, 732–737. 
(154)  S. Boussaad; J. Pean, A.; Tao*, N. J. Anal. Chem. 2000, 72 (1), 222–226. 
(155)  Chowdhury, S. K.; Katta, V.; Chait, B. T. J. Am. Chem. Soc. 1990, No. 112, 9013–9015. 
(156)  Keizer, J. J. Am. Chem. Soc. 1983, 105 (6), 1494–1498. 
(157)  Phillips, S. R.; Wilson, L. J.; Borkman, R. F. Curr Eye Res 1986, 5 (0271-3683), 611–619. 
(158)  Adams, T. E.; Huntington, J. A. Arterioscler. Thromb. Vasc. Biol. 2006, 26 (8), 1738–
1745. 
(159)  Lane, D. a; Philippou, H.; Huntington, J. a. Bloodjournal 2008, 106 (8), 2605–2612. 
(160)  Xu, H.; Bush, L. A.; Pineda, A. O.; Caccia, S.; Di Cera, E. J. Biol. Chem. 2005, 280 (9), 
7956–7961. 
(161)  Ye, J.; Esmon, C. T.; Johnson, A. E. J. Biol. Chem. 1993, 268 (4), 2373–2379. 
(162)  Fuentes-Prior, P.; Iwanaga, Y.; Huber, R.; Pagila, R.; Rumennik, G.; Seto, M.; Morser, J.; 




(163)  Yang, L.; Manithody, C.; Walston, T. D.; Cooper, S. T.; Rezaie, A. R. J. Biol. Chem. 2003, 
278 (39), 37465–37470. 
(164)  Koeppe, J. R.; Seitova, A.; Mather, T.; Komives, E. A. Biochemistry 2005, 44 (45), 
14784–14791. 
(165)  Tennent, G. A.; Brennan, S. O.; Stangou, A. J.; O’Grady, J.; Hawkins, P. N.; Pepys, M. B. 
Blood 2007, 109 (5), 1971–1974. 
(166)  Ariëns, R. A. S.; Lai, T.-S.; Weisel, J. W.; Greenberg, C. S. et al. Blood 2002, 100 (3), 
743–754. 
(167)  Farrell, D. H. Blood 2014, 124 (9), 1389–1390. 
(168)  Farrell, D. H. Clinical Chemistry and Laboratory Medicine. 2012, 1903–1909. 
(169)  Meh, D. A.; Siebenlist, K. R.; Mosesson, M. W. J. Biol. Chem. 1996, 271 (38), 23121–
23125. 
(170)  Lovely, R. S.; Moaddel, M.; Farrell, D. H. J. Thromb. Haemost. 2003, 1 (1), 124–131. 
(171)  Fuentes-Prior, P.; Iwanaga, Y.; Huber, R.; Pagila, R.; Rumennik, G.; Seto, M.; Morser, J.; 
Light, D. R.; Bode, W. Nature 2000, 404 (March), 518–525. 
(172)  Kalafatis, M.; Rand, M. D.; Mann, K. G. J. Biol. Chem. 1994, 269 (50), 31869–31880. 
(173)  Rosing, J.; Hoekema, L.; Nicolaes, G. A. F.; Thomassen, M. C. L. G. D.; Hemker, H. C.; 
Varadi, K.; Schwarz, H. P.; Tans, G. J. Biol. Chem. 1995, 270 (46), 27852–27858. 
(174)  Hornyak, T. J.; Bishop, P. D.; Shafer, J. A. Biochemistry 1989, 28, 7326–7332. 
(175)  Hsieh, L.; Nugent, D. Haemophilia 2008, 14 (6), 1190–1200. 
(176)  Kravtsov, D. V; Matafonov, A.; Tucker, E. I.; Sun, M. F.; Walsh, P. N.; Gruber, A.; 




(177)  Guoguen, P.; Galinat, H.; Blouch, M. T.; Bridey, F.; Duchemin, J.; Le Gal, G.; Abgrall, J. 
F.; Pan-Petesch, B. Br. J. Haematol. 2012, 156 (2), 245–251. 
(178)  Matafonov, A.; Sarilla, S.; Sun, M. F.; Sheehan, J. P.; Serebrov, V.; Verhamme, I. M.; 
Gailani, D. Blood 2011, 118 (2), 437–445. 
(179)  Geng, Y.; Verhamme, I. M.; Smith, S. B.; Sun, M. F.; Matafonov, A.; Cheng, Q.; Smith, S. 
A.; Morrissey, J. H.; Gailani, D. Blood.  2013, 121 (19), 3962–3969. 
(180)  Kershaw, G.; Orellana, D. Semin. Thromb. Hemost. 2013, 39 (3), 283–290. 
(181)  Arroyo, V. Hepatology. Wiley Subscription Services, Inc., A Wiley Company August 
2009, 355–357. 
(182)  Bolliger, D.; Seeberger, M. D.; Tanaka, K. A. Transfusion Medicine Reviews.  2012,  1–13. 
(183)  Greene, T. K.; Schiviz, A.; Hoellriegl, W.; Poncz, M.; Muchitsch, E. J. Thromb. Haemost. 









 Ultra-Pressure liquid chromatography (UPLC) coupled to a low-resolution mass 
spectrometer (MS) produced the following spectra. The spectra are labeled on the right for 
the name of the compound with UPLC or TIC, representing the chromatograph and total-
ion count, respectively. The solvent system contained 0.01% formic acid with a gradient of 






















































 The following 1H-NMR and 13C-NMR graphs are taken from a Bruker 400 MHz 
NMR, processed to show the integrations of each peak relevant the compound named on 
the upper-right. Full characterization is found in Chapter 2, Section 2. Unlabeled peaks are 
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